<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C - Hauser, G - 2014 | Cochrane Library</title> <meta content="Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C - Hauser, G - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005441.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C - Hauser, G - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005441.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005441.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C" name="citation_title"/> <meta content="Goran Hauser" name="citation_author"/> <meta content="ghauser@medri.hr" name="citation_author_email"/> <meta content="Tahany Awad" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Jesper Brok" name="citation_author"/> <meta content="Rigshospitalet" name="citation_author_institution"/> <meta content="Kristian Thorlund" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Davor Štimac" name="citation_author"/> <meta content="Clinical Hospital Centre Rijeka" name="citation_author_institution"/> <meta content="Mahasen Mabrouk" name="citation_author"/> <meta content="Faculty of Medicine, Cairo University" name="citation_author_institution"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Lise Lotte Gluud" name="citation_author"/> <meta content="Copenhagen University Hospital Hvidovre" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD005441.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/02/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005441.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005441.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005441.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amantadine [therapeutic use]; Antiviral Agents [*therapeutic use]; Drug Therapy, Combination [methods]; Hepatitis C, Chronic [*drug therapy, mortality]; Interferon alpha‐2; Interferon‐alpha [*therapeutic use]; Interferons [*therapeutic use]; Polyethylene Glycols [*therapeutic use]; Randomized Controlled Trials as Topic; Recombinant Proteins [therapeutic use]; Ribavirin [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005441.pub3&amp;doi=10.1002/14651858.CD005441.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="PSzzz2OT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005441\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005441\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","hr","pl","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005441.pub3",title:"Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C",firstPublishedDate:"Feb 28, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato‐Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005441.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005441.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005441.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005441.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005441.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005441.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005441.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005441.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005441.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005441.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>878 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005441.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-sec-0074"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-sec-0068"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/appendices#CD005441-sec-0079"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/table_n/CD005441StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/table_n/CD005441StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/information#CD005441-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Goran Hauser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/information#CD005441-cr-0003">Tahany Awad</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/information#CD005441-cr-0004">Jesper Brok</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/information#CD005441-cr-0005">Kristian Thorlund</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/information#CD005441-cr-0006">Davor Štimac</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/information#CD005441-cr-0007">Mahasen Mabrouk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/information#CD005441-cr-0008">Christian Gluud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005441.pub3/information#CD005441-cr-0009">Lise Lotte Gluud</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/information/en#CD005441-sec-0082">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 February 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005441.pub3">https://doi.org/10.1002/14651858.CD005441.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005441-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005441-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005441-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005441-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005441-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005441-abs-0001" lang="en"> <section id="CD005441-sec-0001"> <h3 class="title" id="CD005441-sec-0001">Background</h3> <p>Pegylated interferon (peginterferon) plus ribavirin is the recommended treatment for patients with chronic hepatitis C, but systematic assessment of the effect of this treatment compared with interferon plus ribavirin is needed. </p> </section> <section id="CD005441-sec-0002"> <h3 class="title" id="CD005441-sec-0002">Objectives</h3> <p>To systematically evaluate the benefits and harms of peginterferon plus ribavirin versus interferon plus ribavirin for patients with chronic hepatitis C. </p> </section> <section id="CD005441-sec-0003"> <h3 class="title" id="CD005441-sec-0003">Search methods</h3> <p>We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Science Citation Index‐Expanded, and LILACS. We also searched conference abstracts, journals, and grey literature. The last searches were conducted in September 2013. </p> </section> <section id="CD005441-sec-0004"> <h3 class="title" id="CD005441-sec-0004">Selection criteria</h3> <p>We included randomised clinical trials comparing peginterferon plus ribavirin versus interferon plus ribavirin with or without co‐intervention(s) (e.g., other antiviral drugs) for chronic hepatitis C. Quasi‐randomised and observational studies retrieved through the searches for randomised clinical trials were also considered for reports of harms. Our primary outcomes were liver‐related morbidity, all‐cause mortality, serious adverse events, adverse events leading to treatment discontinuation, other adverse events, and quality of life. Our secondary outcome was sustained virological response in serum, that is, undetectable hepatitis C virus RNA in serum by sensitive tests six months after the end of treatment. </p> </section> <section id="CD005441-sec-0005"> <h3 class="title" id="CD005441-sec-0005">Data collection and analysis</h3> <p>Two review authors independently used a standardised data collection form. We meta‐analysed data with both fixed‐effect and random‐effects models. For each outcome, we calculated the odds ratio (OR) (for liver‐related morbidity or all‐cause mortality) or the risk ratio (RR) along with 95% confidence interval (CI) based on intention‐to‐treat analysis. We used domains of the trials to assess the risk of systematic errors (bias) and trial sequential analyses to assess the risk of random errors (play of chance). </p> <p>For each outcome, we calculated the RR with 95% CI based on intention‐to‐treat analysis. Effects of interventions on outcomes were assessed according to GRADE. </p> </section> <section id="CD005441-sec-0006"> <h3 class="title" id="CD005441-sec-0006">Main results</h3> <p>We included 27 randomised trials with 5938 participants. All trials had high risk of bias. We considered that the risk of bias did not impact on the quality of evidence for liver‐related mortality and adverse event outcomes, but it did for virological response. All trials compared peginterferon alpha‐2a or peginterferon alpha‐2b plus ribavirin versus interferon plus ribavirin for participants with chronic hepatitis C. Three trials administered co‐interventions (amantadine hydrochloride 200 mg daily to both intervention groups), and 24 trials were conducted without co‐interventions. The effect observed between the two intervention groups regarding liver‐related morbidity plus all‐cause mortality (5/907 (0.55%) versus 4/882 (0.45%) was imprecise: OR 1.14 ( 95% CI 0.38 to 3.42; five trials; low quality of evidence), as was the risk of adverse events leading to treatment discontinuation (332/2692 (12.3%) versus 409/2176 (18.8%); RR 0.86, 95% CI 0.68 to 1.09; 15 trials; low quality of evidence) or regarding adverse events leading to treatment discontinuation (332/2692 (12.3%) versus 409/2176 (18.8%); RR 0.86, 95% CI 0.66 to 1.12; 17 trials; low quality of evidence). However, peginterferon plus ribavirin versus interferon plus ribavirin significantly increased the risk of neutropenia (332/2202 (15.1%) versus 117/1653 (7.1%); RR 2.15, 95% CI 1.76 to 2.61; 13 trials), thrombocytopenia (65/1113 (5.8%) versus 23/1082 (2.1%); RR 2.63, 95% CI 1.68 to 4.11; 10 trials), arthralgia (517/1740 (29.7%) versus 282/1194 (23.6%); RR 1.19, 95% CI 1.05 to 1.35; four trials), injection site reaction (627/1168 (53.7%) versus 186/649 (28.7%); RR 1.71, 95% CI 1.50 to 1.93; four trials), and nausea (606/1784 (34.0%) versus 354/1239 (28.6%); RR 1.13, 95% CI 1.01 to 1.26; four trials). The most frequent adverse event was fatigue, which occurred in 57% of participants (2024/3608). No significant difference was noted between peginterferon plus ribavirin versus interferon plus ribavirin in terms of fatigue (1177/2062 (57.1%) versus 847/1546 (54.8%); RR 1.01, 95% CI 0.96 to 1.07; 12 trials). No significant differences were reported between the two treatment groups regarding anaemia, headache, rigours, myalgia, pyrexia, weight loss, asthenia, depression, insomnia, irritability, alopecia, pruritus, skin rash, thyroid malfunction, decreased appetite, or diarrhoea. We were unable to identify any data on quality of life. Peginterferon plus ribavirin versus interferon plus ribavirin seemed to significantly increase the number of participants achieving sustained virological response (1673/3300 participants (50.7%) versus 1081/2804 patients (36.7%); RR 1.39, 95% CI 1.25 to 1.56; I<sup>2</sup> = 64%; 27 trials; very low quality of evidence). However, the risk of bias in the 13/27 (48.1%) trials reporting on this outcome was high and was considered only 'lower' in the remainder. Because the conventional meta‐analysis did not reach its required information size (n = 14,486 participants), we used trial sequential analysis to control for risks of random errors. Again, in this analysis, the estimated effect was statistically significant in favour of peginterferon. Subgroup analyses according to risk of bias, viral genotype, baseline viral load, past treatment history, and type of intervention yielded similarly significant results favouring peginterferon over interferon on the outcome of sustained virological response. </p> </section> <section id="CD005441-sec-0007"> <h3 class="title" id="CD005441-sec-0007">Authors' conclusions</h3> <p>Peginterferon plus ribavirin versus interferon plus ribavirin seems to significantly increase the proportion of patients with sustained virological response, as well as the risk of certain adverse events. However, we have insufficient evidence to recommend or reject peginterferon plus ribavirin for liver‐related morbidity plus all‐cause mortality compared with interferon plus ribavirin. The clinical consequences of achieved sustained virological response are unknown, as sustained virological response is still an unvalidated surrogate outcome. We found no evidence of the potential benefits on quality of life in patients with achieved sustained virological response. Further high‐quality research is likely to have an important impact on our confidence in the estimate of patient‐relevant outcomes and is likely to change our estimates.There is very low quality evidence that peginterferon plus ribavirin increases the proportion of patients with sustained virological response in comparison with interferon plus ribavirin. There is evidence that it also increases the risk of certain adverse events. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005441-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005441-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005441-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005441-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005441-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD005441-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005441-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD005441-abs-0007">Polski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005441-abs-0004" lang="en"> <h3>Peginterferon plus ribavirin is more effective than interferon plus ribavirin in clearing hepatitis C virus </h3> <p><b><i>Importance of the review/background on the condition</i> </b> </p> <p>Hepatitis C is a disease of the liver caused by the hepatitis C virus. Globally, an estimated 170 million people are chronically infected with the hepatitis C virus. Chronic hepatitis C can cause liver damage in the form of inflammation and scarring of the liver (cirrhosis). Liver damage can lead to liver failure and other complications, including liver cancer. The goal of treatment of chronic hepatitis C is to prevent complications of hepatitis C infection; this could possibly be achieved by clearing the virus from the blood of the patient (sustained virological response, that is, undetectable hepatitis C virus RNA in serum by sensitivity testing six months after the end of treatment). However, we still need to understand whether the sustained virological response outcome induced by antiviral treatment has any association with patient‐relevant and clinically relevant outcomes. A combination of weekly injections of peginterferon and oral ribavirin represents the current standard of care. </p> <p><b><i>Main findings of the review</i> </b> </p> <p>The review identified and included 27 randomised clinical trials comparing peginterferon plus ribavirin versus interferon plus ribavirin in patients with chronic hepatitis C. All trials had high risk of bias, that is, overestimation of benefits and underestimation of harms. If we disregard bias from lack of blinding and industry support, then 14 trials were considered to have a lower risk of bias. All trials were able to inform on clearing virus from blood six months after the end of treatment (sustained virological response). We could not be certain that peginterferon plus ribavirin has an effect on liver‐related morbidity plus all‐cause mortality when compared with interferon plus ribavirin. Because so few events occurred, we cannot exclude major beneficial or detrimental effects<i>.</i> This review shows that peginterferon plus ribavirin compared with interferon plus ribavirin significantly increases the number of patients with sustained virological response (50.2% compared with 38.5%), but we do not yet know about any patient‐relevant outcomes. </p> <p><b><i>Adverse effects</i> </b> </p> <p>Peginterferon plus ribavirin compared with interferon plus ribavirin significantly increased the risk of adverse events such as neutropenia (lack of white blood cells in the blood), thrombocytopenia (lack of blood platelets in the blood), arthralgia (joint pain), injection site reaction, and nausea, but adverse events leading to treatment discontinuation remained comparable for both treatments (12.3% versus 18.7%). Data about the influence of treatment on quality of life are insufficient. </p> <p><b><i>Limitations of the review</i> </b> </p> <p>This effect on virological response seems robust to analysis controlling for the risk of random errors ('play of chance'), but it may be due to the fact that all trials were considered at high risk of bias. Furthermore, we still need to have proof that sustained virological response induced by antiviral treatment has any association with patient‐relevant and clinically relevant outcomes. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005441-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005441-sec-0074"></div> <h3 class="title" id="CD005441-sec-0075">Implications for practice</h3> <section id="CD005441-sec-0075"> <p>Moderate evidence shows that pegylated interferon plus ribavirin compared with interferon plus ribavirin increases sustained virological response for patients with chronic hepatitis C, irrespective of genotype, previous antiviral status, or viral load, and with or without amantadine as cointervention. However, evidence is insufficient with regard to the risk of liver‐related morbidity plus all‐cause mortality, adverse events, and quality of life. Therefore, in their best interest, patients must be informed and involved in the decision to treat and with what to treat. Once started, treatment should be monitored carefully to minimise the risk of harm for patients. </p> </section> <h3 class="title" id="CD005441-sec-0076">Implications for research</h3> <section id="CD005441-sec-0076"> <p>We can have very low confidence in the current evidence on treatment benefits measured as sustained virological response; thus, further research may not change our confidence in the estimate of effect. However, we lack knowledge about the clinical consequences of obtaining sustained virological response through antiviral treatment. We have only low confidence in the current evidence on harms measured as morbidity and mortality and adverse events leading to discontinuation; thus, further research is very likely to have an important impact on our confidence in the estimates of effect and is likely to change the estimates. Although we did not find differences regarding adverse events leading to treatment discontinuation between peginterferon plus ribavirin when compared with interferon plus ribavirin, an obvious trend was noted toward more adverse events among patients treated with pegylated interferons. Randomised clinical trials are needed to confirm or refute the effect of peginterferon plus ribavirin treatment in non‐responders and relapsers. Longer follow‐up assessment on existing trials and research on the long‐term association between sustained virological response and liver‐related morbidity and all‐cause mortality seem warranted. Future trials ought to assess quality of life as well. Future trials should be designed according to the SPIRIT guidelines (<a href="./references#CD005441-bbs2-0045" title="ChanAW , TetzlaffJM , GøtzschePC , AltmanDG , MannH , BerlinJA , et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (Clinical Research Ed.)2013;8:346:e7586. ">Chan 2013</a>) and reported according to the CONSORT guidelines (<a href="http://www.consort-statement.org" target="_blank">www.consort‐statement.org</a>) (<a href="./references#CD005441-bbs2-0078" title="MoherD , HopewellS , SchulzKF , MontoriV , GøtzschePC , DevereauxPJ , et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. International Journal of Surgery2012;10:28‐55. ">Moher 2012</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005441-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005441-sec-0022"></div> <div class="table" id="CD005441-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin for chronic hepatitis C</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin for chronic hepatitis C</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic hepatitis C.<br/> <b>Settings:</b> mainly outpatients.<br/> <b>Intervention:</b> peginterferon.<br/> <b>Comparison:</b> non‐pegylated. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Non‐pegylated</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Peginterferon </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Liver‐related morbidity plus all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Five per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Six per 1000</b> <br/> (two to 17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.14</b> <br/> (0.38 to 3.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1789<br/> (five studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events leading to treatment discontinuation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>207 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b> <br/> (141 to 226) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/> (0.68 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4571<br/> (15 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sustained virological response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>386 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>537 per 1000</b> <br/> (482 to 602) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.39</b> <br/> (1.25 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6104<br/> (27 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>4,5</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All trials had high risks of bias.</p> <p>Only an unvalidated surrogate outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Low due to imprecision and indirectness wide confidence interval. The meta‐analysis included only nine events. </p> <p><sup>2</sup>Low due to imprecision and indirectness.The proportions of observed adverse events differ substantially across trials, and the direction of effect is heterogeneous. However, because the event rate is still relatively low across trials, all of the included trials may be subject to considerable random error, thus explaining the apparent heterogeneity in the direction of estimates.<br/> <sup>3</sup>The observed treatment effects differ in both direction and magnitude, but most confidence intervals have considerable overlap. Low due to indirectness. </p> <p><sup>4</sup>Sustained virological response does not seem to be a valid surrogate marker for assessing hepatitis C virus treatment efficacy of interferon treatment. Very low due to high risk of bias in all trials and imprecision and indirectness due to surrogate<br/> <sup>5</sup>Only randomised clinical trials were included. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005441-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005441-sec-0023"></div> <section id="CD005441-sec-0024"> <h3 class="title" id="CD005441-sec-0024">Description of the condition</h3> <p>Globally, an estimated 170 million people are chronically infected with hepatitis C virus, and three to four million persons are infected each year (<a href="./references#CD005441-bbs2-0106" title="World Health Organization (WHO). Global surveillance and control of hepatitis C. Journal of Viral Hepatitis1999;6(1):35‐47. ">WHO 1999</a>). In most patients, hepatitis C infection is asymptomatic in the initial phase. Hepatitis C infection generally is first recognised in the chronic phase (<a href="./references#CD005441-bbs2-0067" title="HodgsonHJF . Viral hepatitis—clinical aspects. In: WarrellDA , CoxTM , FirthJD , BenzEJJr editor(s). Oxford Textbook of Medicine. 4th Edition. Oxford/ New York: Oxford University Press, 2003. ">Hodgson 2003</a>). Around 85% of patients who become infected with hepatitis C fail to clear the virus and become chronic carriers. A number of these individuals are reported to develop cirrhosis over a period of approximately 20 to 25 years (<a href="./references#CD005441-bbs2-0092" title="SeeffLB , HoofnagleJH . National institutes of health consensus development conference: management of hepatitis C: 2002. Hepatology2002; Vol. 36, issue 5 Suppl 1:S1‐S2. [DOI: 10.1002/hep.1840360702] ">Seeff 2002</a>; <a href="./references#CD005441-bbs2-0093" title='SeeffLB . The history of the "natural history" of hepatitis C (1968‐2009). Liver International2009;29(S1):89‐99. '>Seeff 2009</a>). Patients with advanced fibrosis or cirrhosis develop liver complications such as hepatocellular carcinoma at the annual rate of approximately 2% to 4% (<a href="./references#CD005441-bbs2-0040" title="BenvegnuL , AlbertiA . Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus‐related cirrhosis. Antiviral Research2001;52:199‐207. ">Benvegnu 2001</a>; <a href="./references#CD005441-bbs2-0054" title="FattovichG , PantalenaM , ZagniI , RealdiG , SchalmSW , ChristensenE , European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. American Journal of Gastroenterology2002;97(11):288‐95. ">Fattovich 2002</a>). Chronic hepatitis C is the single most common indication for liver transplantation (<a href="./references#CD005441-bbs2-0080" title="United Network for Organ Sharing. Chapter IV; Liver and Intestine Transplantation in the United States, 1998‐2007. optn.transplant.hrsa.gov/ar2008/chapter_iv_AR_cd.htm?cp=5 (accessed 27 May 2013). ">OPTN 2008</a>). Chronic hepatitis C is expected to become a greater burden during the next decades. </p> <p>Hepatitis C virus is an enveloped RNA virus that constitutes the genus <i>Hepacivirus</i> within the <i>Flaviviridae</i> family (<a href="./references#CD005441-bbs2-0103" title="vanRegenmortelMHV , FauquetCM , BishopDHL , CarstensEB , EstesMK , LemonSM , et al. Virus Taxonomy: The Classification and Nomenclature of Viruses. The Seventh Report of the International Committee on Taxonomy of Viruses. San Diego: Academic Press, 2000:599‐621. ">van Regenmortel 2000</a>; <a href="./references#CD005441-bbs2-0081" title="PeninF , DubuissonJ , ReyFA , MoradpourD , PawlotskyJ . Structural biology of hepatitis C virus. Hepatology2004; Vol. 39, issue 1:5‐19. [DOI: 10.1002/hep.20032] ">Penin 2004</a>). Hepatitis C virus is divided into six genotypes, which differ from each other by up to 30% in the nucleotide sequence (<a href="./references#CD005441-bbs2-0086" title="RosenbergS . Recent advances in the molecular biology of hepatitis C virus. Journal of Molecular Biology2001;313:451‐64. ">Rosenberg 2001</a>). Furthermore, hepatitis C virus genotypes differ by geographic region (<a href="./references#CD005441-bbs2-0049" title="DavisGL . Hepatitis C virus genotypes and quasispecies. American Journal of Medicine1999;107(6B):S21‐S26. ">Davis 1999</a>). Although a genotype does not predict the outcome of the infection, it does predict the likelihood of virological response to treatment and in many cases determines the duration of treatment (<a href="./references#CD005441-bbs2-0015" title="ButiM , MedinaM , CasadoMA , WongJB , FosbrookL , EstebanR . A cost‐effectiveness analysis of peginterferon alfa‐2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Alimentary Pharmacology &amp; Therapeutics2003;17:687‐94. CondatB . Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b and ribavirin for the treatment of chronic hepatitis C: A randomized trial. Hepato‐Gastroenterology2002;9(2):141‐2. GishR , BzowejN , BrooksL , BrassC , WengW . Treatment with pegylated interferon alfa‐2b in combination with ribavirin improved health‐related quality of life compared with interferon alfa‐2b plus ribavirin in chronic hepatitis C [AASLD abstract]. Hepatology2002;36(4 Pt 2):582A. JenJ , LaughlinM , ChungC , HeftS , AffrimeMB , GuptaSK , et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic‐pharmacodynamic models. Clinical Pharmacology and Therapeutics2002;72(4):349‐61. MannsMP , McHutchisonJG , GordonS , RustgiV , ShiffmanML , LeeWM , et al. Peginterferon alfa‐2b plus ribavirin compared to interferon alfa‐2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [AASLD abstract]. Hepatology2000;32(4 Pt 2):297A. MannsMP , McHutchisonJG , GordonSC , RustgiVK , ShiffmanM , ReindollarR , et al. Peginterferon alfa‐2a plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001;358:958‐65. McHutchisonJ , MannsM , HarveyJ , AlbrechtJK . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peg‐interferon alfa‐2b plus ribavirin [abstract]. Journal of Hepatology2001;34(1):2‐3. McHutchisonJG , MannsM , PatelK , PoynardT , LindsayKL , TrepoC , et al. Adherence to combination therapy enhances sustained response in genotype‐1‐infected patients with chronic hepatitis C. Gastroenterology2002;123(4):1061‐9. McHutchisonJG , MannsMP , HarveyJ , GaraudJ‐J , AlbrechtJ . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peginterferon alfa 2b plus ribavirin. Hepatology2001;34(4 Pt 2):417A. McHutchisonJG , MannsMP , LingM‐H , AlbrechtJK . Peginterferon alfa‐2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factor for sustained virological response when ribavirin dose is expressed as mg/kg of body weight? [AASLD abstract]. Hepatology2001;34(4 Pt 2):329A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated‐interferon alpfa‐2b and ribavirin combination [AASLD abstract]. Hepatology2002;36(4 Pt 2):351A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa‐2b and ribavirin. Hepatology2003;38(2):481‐92. PoynardT , RatziuV , McHutchisonJ , MannsM , GoodmanZ , ZeuzemS , et al. Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology2003;38(1):75‐85. SiebertU , SroczynskiG , RossolS , WasemJ , Ravens‐SiebererU , KurthBM , et al. Cost effectiveness of peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C. Gut2003;52:425‐32. WongJB , DavisGL , McHutchisonJG , MannsMP , AlbrechtJK . Economic and clinical effects of evaluating rapid viral response to peginterferon alfa‐2b plus ribavirin for the initial treatment of chronic hepatitis C. American Journal of Gastroenterology2003;98(11):2354‐62. ">Manns 2001</a>; <a href="./references#CD005441-bbs2-0009" title="Bosques‐PadillaF , Trejo‐EstradaR , Campollo‐RivasO , Cortez‐HernandezC , Dehesa‐ViolanteM , Maldonado‐GarzaH , et al. Peginterferon alfa‐2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Annals of Hepatology2003;2(3):135‐9. FriedMW , ShiffmanML , ReddyKR , SmithC , MarinosG , GoncalesFLJr , et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine2002;347(13):975‐82. HassaneinT , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. The impact of peginterferon alfa‐2a plus ribavirin combination therapy on health‐related quality of life in chronic hepatitis C. Journal of Hepatology2004;40(4):675‐81. HassaneinTI , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. Treatment with 40 kDa peginterferon alfa‐2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alfa‐2b plus ribavirin [AASLD abstract]. Hepatology2001;34(4 Pt 2):243A. HassaneinTI , CooksleyWGE , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. QOL benefits observed as early as week 2 with peginterferon alfa‐2a (40kD) (Pegasys) in combination with ribavirin (RBV) versus interferon alfa‐2b plus RBV [EASL abstract]. Journal of Hepatology2002;36(1):110. HerrmannE , LeeJ‐H , MarinosG , ModiM , ZeuzemS . Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology2003;37(6):1351‐8. LutchmanG , HoofnagleJH . Viral kinetics in hepatitis C. Hepatology2003;37(6):1257‐9. SullivanSD , CraxiA , AlbertiA , GiulianiG , DeCarliC , WintfeldN , et al. Cost effectiveness of peginterferon alpha‐2a plus ribavirin versus interferon alpha‐2b plus ribavirin as initial therapy for treatment‐naive chronic hepatitis C. Pharmacoeconomics2004;22(4):257‐65. SullivanSD , GreenJ , PatelKK , CraxiA , AlbertiA , GiulianiG , et al. A comparison of cost‐effectiveness of peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (Copegus) vs interferon alfa‐2b plus ribavirin as first treatment of chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):174‐5. SullivanSD , JensenDM , BernsteinDE , HassaneinTI , FosterGR , LeeSS , et al. Cost‐effectiveness of combination peginterferon alpha‐2a and ribavirin compared with interferon alpha‐2b and ribavirin in patients with chronic hepatitis C. American Journal of Gastroenterology2004;99:1490‐6. ZeuzemS , HerrmannE , LeeJ‐H , MarinosG , ModiM , RothWK . Effect of ribavirin on viral kinetics in hepatitis C virus genotype 1 infected patients treated with pegylated interferon alpha2a [AASLD abstract]. Hepatology2001;34(4 Pt 2):558A. ">Fried 2002</a>; <a href="./references#CD005441-bbs2-0062" title="HadziyannisSJ , SetteH , MorganTR , BalanV , DiagoM , MarcellinP , et al. Peginterferon alfa‐2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Annals of Internal Medicine2004;140:346–55. ">Hadziyannis 2004</a>). </p> </section> <section id="CD005441-sec-0025"> <h3 class="title" id="CD005441-sec-0025">Description of the intervention</h3> <p>The goal of treatment of chronic hepatitis C is to prevent complications of hepatitis C infection; this is principally sought by eradication of the infection (<a href="./references#CD005441-bbs2-0056" title="GhanyMG , StraderDB , WrightT , ThomasDL , SeeffLB , American Association for the Study of Liver Disease. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009;49(4):1335‐74. ">Ghany 2009</a>). Accordingly, treatment is aimed at achieving a virological response, defined as the absence of hepatitis C virus RNA in serum by sensitive testssix months after the end of treatment (sustained virological response). It is not known whether this outcome bears any relevance to the patient regarding mortality, morbidity, or quality of life (<a href="./references#CD005441-bbs2-0058" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734‐42. ">Gluud 2007</a>). </p> </section> <section id="CD005441-sec-0026"> <h3 class="title" id="CD005441-sec-0026">How the intervention might work</h3> <p>Interferons work through complicated cellular mechanisms, leading to a reduction of viral load in patients with chronic hepatitis C. Monotherapy with interferon produces sustained virological response in less than 20% of study participants (<a href="./references#CD005441-bbs2-0079" title="MyersRP , RegimbeauC , ThevenotT , LeroyV , MathurinP , OpolonP , et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD000370] ">Myers 2002</a>). The introduction of combination therapy with interferon plus ribavirin was considered a major advance because of its increased effect on sustained virological response. Combination therapy produces sustained virological response in approximately 40% of previously untreated participants, that is, participants who were previously naive to antiviral drugs (<a href="./references#CD005441-bbs2-0044" title="BrokJ , GluudLL , GluudC . Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD005445.pub2] ">Brok 2009a</a>). A combination of weekly subcutaneous injections of long‐acting peginterferon alpha plus oral ribavirin has achieved the highest overall sustained virological response of 56% of participants (<a href="./references#CD005441-bbs2-0056" title="GhanyMG , StraderDB , WrightT , ThomasDL , SeeffLB , American Association for the Study of Liver Disease. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009;49(4):1335‐74. ">Ghany 2009</a>). This represents the current standard of treatment according to the guidelines of the American Association for the Study of Liver Diseases (<a href="./references#CD005441-bbs2-0056" title="GhanyMG , StraderDB , WrightT , ThomasDL , SeeffLB , American Association for the Study of Liver Disease. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009;49(4):1335‐74. ">Ghany 2009</a>) and the European Association for the Study of the Liver (<a href="./references#CD005441-bbs2-0053" title="European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. Journal of Hepatology2011;55:245‐64. ">EASL 2012</a>). </p> <p>Pegylation involves the addition of polyethylene glycol molecules to the interferon molecule, thus altering metabolism, decreasing renal clearance, and increasing the half‐life of the peginterferon molecule in the circulation, thereby necessitating fewer doses (<a href="./references#CD005441-bbs2-0083" title="ReddyKR , WrightTL , PockrosPJ , ShiffmanM , EversonG , ReindollarR , et al. Efficacy and safety of pegylated (40‐kd) interferonalpha‐2a compared with interferon alpha‐2a in noncirrhotic patients with chronic hepatitis C. Hepatology2001;33(2):433–8. ">Reddy 2001</a>). Currently, two licenced products of peginterferon are available: peginterferon alpha‐2a (Pegasys<sup>®</sup>, Roche), which consists of a 40‐kDa branched pegylated chain linked to the interferon molecule (<a href="./references#CD005441-bbs2-0038" title="BailonP , PalleroniA , SchafferCA , SpenceCL , FungW‐J , PorterJE , et al. Rational design of a potent, long‐lasting form of interferon: a 40 kDa branched polyethylene glycol‐conjugated interferon alpha‐2a for the treatment of hepatitis. Bioconjugate Chemistry2001;12(2):195‐202. ">Bailon 2001</a>), and peginterferon alpha‐2b (Peg‐Intron<sup>®</sup>, Merck Corporation), which consists of a 12‐kDa linear pegylated chain linked to the interferon molecule (<a href="./references#CD005441-bbs2-0057" title="GlueP , FangJWS , Rouzier‐PanisR , RaffanelC , SaboR , GuptaSK , et al. Pegylated interferon‐[alpha]2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clinical Pharmacology and Therapeutics2000;68(5):556‐67. ">Glue 2000</a>). The two forms of peginterferon differ substantially in terms of chemical and structural characteristics, as well as pharmacokinetic and pharmacodynamic properties (<a href="./references#CD005441-bbs2-0055" title="FosterGR . Pegylated interferons: chemical and clinical differences. Alimentary Pharmacology &amp; Therapeutics2004;20(8):825‐30. ">Foster 2004</a>; <a href="./references#CD005441-bbs2-0037" title="AwadT , ThorlundK , HauserG , StimacD , MabroukM , GluudC . Peginterferon alpha‐2a is associated with higher sustained virological response than peginterferon alfa‐2b in chronic hepatitis C: systematic review of randomized trials. Hepatology2010;51:1176‐84. [DOI: 10.1002/hep.23504.] ">Awad 2010</a>; <a href="./references#CD005441-bbs2-0063" title="HauserG , AwadT , ThorlundK , ŠtimacD , MabroukM , GluudC . Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C (Review). Cochrane Database of Systematic Reviews2014, Issue 2. ">Hauser 2014</a>). In the present systematic review, we consider peginterferon alpha‐2a and peginterferon alpha‐2b as a single intervention, but in a subgroup analysis, we analyse them separately. </p> </section> <section id="CD005441-sec-0027"> <h3 class="title" id="CD005441-sec-0027">Why it is important to do this review</h3> <p>Previous reviews, including narrative reviews, meta‐analyses, and health technology assessments, have compared pegylated interferon versus interferon given with or without co‐interventions (<a href="./references#CD005441-bbs2-0046" title="ChanderG , SulkowskiMS , JenckesMW , TorbensonMS , HerlongHF , BassEB , et al. Treatment of chronic hepatitis C: a systematic review. Hepatology2002;36(S1):135‐44. ">Chander 2002</a>; <a href="./references#CD005441-bbs2-0109" title="ZamanA , FennertyMB , KeeffeEB . Peginterferon vs. standard interferon in the treatment of chronic hepatitis C. Alimentary Pharmacology &amp; Therapeutics2003;18(7):661‐70. ">Zaman 2003</a>; <a href="./references#CD005441-bbs2-0070" title="KhurooMS , KhurooMS , DahabST . Meta‐analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Alimentary Pharmacology and Therapeutics2004;20(9):931‐8. ">Khuroo 2004</a>; <a href="./references#CD005441-bbs2-0094" title="ShepherdJ , BrodinH , KanFT , CaveCB , WaughNR , PriceA , et al. Clinical‐ and cost‐effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. International Journal of Technology Assessment in Health Care2005;21(1):47‐54. ">Shepherd 2005</a>; <a href="./references#CD005441-bbs2-0095" title="SiebertU , SroczynskiG , German Hepatitis C Model GEHMO Group, HTA Expert Panel on HepatitisC . Effectiveness and cost‐effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. International Journal of Technology Assessment in Health Care2005;21(1):55‐65. ">Siebert 2005</a>). The overall conclusion of these review authors was that the combination of pegylated interferon plus ribavirin was more efficient than interferon plus ribavirin in obtaining sustained virological response. However, these reviews relied on a sparse number of included trials. Intervention research for hepatitis C is high‐paced, and new trials have emerged since these reviews were completed. This Cochrane systematic review aimed to include and critically assess evidence obtained through extensive searches for randomised clinical trials. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005441-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005441-sec-0028"></div> <p>To systematically evaluate the benefits and harms of peginterferon plus ribavirin versus interferon plus ribavirin for patients with chronic hepatitis C. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005441-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005441-sec-0029"></div> <section id="CD005441-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005441-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included randomised clinical trials, irrespective of language, publication status, sample size, or year of publication, for assessment of benefits and harms. We also included for assessment of harms quasi‐randomised studies and observational studies that were identified during our searches for randomised trials. </p> </section> <section id="CD005441-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included patients with chronic hepatitis C. The diagnosis was based on the presence of hepatitis C virus RNA for longer than six months, or the presence of hepatitis C virus RNA plus elevated transaminases in the blood for longer than six months, or histological evidence of chronic hepatitis C. Based on history of previous antiviral treatment, included patients were classified as treatment‐naive (not previously treated with antiviral drugs), relapsers (patients with a transient response to previous treatment), or non‐responders (patients without response to previous treatment). Patients who had undergone liver transplantation and patients with hepatitis B or human immunodeficiency virus coinfection were excluded. </p> </section> <section id="CD005441-sec-0033"> <h4 class="title">Types of interventions</h4> <p>This review included randomised clinical trials comparing peginterferon alpha‐2a or peginterferon alpha‐2b plus ribavirin versus interferon plus ribavirin for participants with chronic hepatitis C. Trials were included regardless of the type, the dose, or the duration of the interventions. Cointerventions were permitted if they were received by and applied equally to all intervention groups. </p> </section> <section id="CD005441-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD005441-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD005441-list-0001"> <li> <p>Liver‐related morbidity plus all‐cause mortality: number of participants who developed cirrhosis, ascites, variceal bleeding, hepatic encephalopathy, or hepatocellular carcinoma, or who died. </p> </li> <li> <p>Adverse events leading to treatment discontinuation.</p> <ul id="CD005441-list-0002"> <li> <p>Numbers and types of adverse events, defined as participants with any untoward medical occurrence not necessarily having a causal relationship to the treatment. We reported separately on adverse events that led to treatment discontinuation and those that did not lead to treatment discontinuation. We defined a serious adverse event according to the guidelines of the International Conference on Harmonisation (<a href="./references#CD005441-bbs2-0069" title="International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines. Vol. 1, PA 19063‐2043, USA: Barnett International/PAREXEL, 1997. ">ICH‐GCP 1997</a>) as any event that leads to death, is life threatening, requires in‐patient hospitalisation or prolongation of existing hospitalisation, or results in persistent or significant disability, as well as any important medical event that may have jeopardised the participant or required an intervention to prevent it. All other adverse events were considered non‐serious. </p> </li> <li> <p>Other adverse events: haematological effects, fatigue, flu‐like symptoms, psychiatric symptoms, dermatological symptoms, thyroid malfunction, gastrointestinal symptoms (other than liver related). </p> </li> </ul> </li> <li> <p>Quality of life.</p> </li> </ul> </p> </section> <section id="CD005441-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD005441-list-0003"> <li> <p>Sustained virological response: number of participants with undetectable hepatitis C virus RNA in serum by sensitive tests six months after the end of treatment. </p> </li> </ul> </p> </section> </section> </section> <section id="CD005441-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005441-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register (<a href="./references#CD005441-bbs2-0059" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 12. Art. No.: LIVER. ">Gluud 2013</a>)<i>,</i> the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Science Citation Index‐Expanded (<a href="./references#CD005441-bbs2-0087" title="RoyleP , MilneR . Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care2003;19(4):591‐603. ">Royle 2003</a>), and LILACS, using the search strategies and time spans given in <a href="./appendices#CD005441-sec-0080">Appendix 1</a>. The searches were conducted until September 2013. </p> </section> <section id="CD005441-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We identified further trials by searching national and topic‐specific databases, bibliographies, conference abstracts, journals, and grey literature. Furthermore, we reviewed the reference lists of the included trials and contacted the principal authors of the identified trials. </p> </section> </section> <section id="CD005441-sec-0040"> <h3 class="title" id="CD005441-sec-0040">Data collection and analysis</h3> <p>We performed the review and meta‐analyses according to the recommendations of The Cochrane Collaboration (<a href="./references#CD005441-bbs2-0065" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>) and the Cochrane Hepato‐Biliary Group Module (<a href="./references#CD005441-bbs2-0059" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 12. Art. No.: LIVER. ">Gluud 2013</a>). The analyses were performed using Review Manager 5.2 (<a href="./references#CD005441-bbs2-0084" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>) and Trial Sequential Analysis version 0.9 (<a href="./references#CD005441-bbs2-0048" title="Copenhagen Trial Unit. TSA—Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 28 May 2013). ">CTU 2011</a>; <a href="./references#CD005441-bbs2-0102" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual forTrial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 23 April 2013). ">Thorlund 2011</a>). </p> <section id="CD005441-sec-0041"> <h4 class="title">Selection of studies</h4> <p>We listed the identified trials, and two of the review authors (GH and TA) independently assessed their fulfilment of the inclusion criteria. We listed the excluded trials along with the reasons for exclusion. Disagreements were resolved by discussion and were arbitrated with a third review author (CG). </p> </section> <section id="CD005441-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>A standardised template or data collection form was used to extract data regarding source identification, eligibility, methods, participants, interventions, outcomes, and results obtained from published reports or by contact with the study authors. Two review authors (GH and TA) extracted all the data independently. Disagreements were resolved by discussion and were arbitrated with a third review author (CG). Any further information required of the original authors was requested by written correspondence, and any relevant information obtained in this manner was included in the review. </p> </section> <section id="CD005441-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Methodological quality was defined as the level of confidence that the design and the report of the randomised clinical trial would restrict bias in the comparison of interventions (<a href="./references#CD005441-bbs2-0077" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352:609‐13. ">Moher 1998</a>). According to empirical evidence (<a href="./references#CD005441-bbs2-0091" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a>; <a href="./references#CD005441-bbs2-0077" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352:609‐13. ">Moher 1998</a>; <a href="./references#CD005441-bbs2-0071" title="KjaergardLL , VillumsenJ , GluudC . Reported methodological quality and discrepancies between small and large randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001</a>; <a href="./references#CD005441-bbs2-0108" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanGD , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336:601‐5. ">Wood 2008</a>; <a href="./references#CD005441-bbs2-0076" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>; <a href="./references#CD005441-bbs2-0089" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment2012;16(35):1‐82. ">Savovic 2012</a>; <a href="./references#CD005441-bbs2-0090" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. ">Savovic 2012a</a>), the methodological quality of the trials, hence the risk of bias, was based on the following. </p> <p><b><i>Sequence generation</i> </b> </p> <p> <ul id="CD005441-list-0004"> <li> <p>Low risk of bias: Sequence generation was achieved by using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice are adequate if performed by an independent person not otherwise involved in the trial. </p> </li> <li> <p>Uncertain risk of bias: The method of sequence generation was not specified.</p> </li> <li> <p>High risk of bias: The sequence generation method was not random.</p> </li> </ul> </p> <p><b><i>Allocation concealment</i> </b> </p> <p> <ul id="CD005441-list-0005"> <li> <p>Low risk of bias: The participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (e.g., if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes). </p> </li> <li> <p>Uncertain risk of bias: The method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment. </p> </li> <li> <p>High risk of bias: The allocation sequence was likely to be known to the investigators who assigned the participants. </p> </li> </ul> </p> <p><b><i>Blinding of outcome assessors</i> </b> </p> <p> <ul id="CD005441-list-0006"> <li> <p>Low risk of bias: Blinding was performed adequately, or assessment of outcomes was not likely to be influenced by lack of blinding. </p> </li> <li> <p>Uncertain risk of bias: Information was insufficient to permit assessment of whether blinding was likely to induce bias for the results. </p> </li> <li> <p>High risk of bias: No blinding or incomplete blinding was performed, and assessment of outcomes was likely to be influenced by lack of blinding. </p> </li> </ul> </p> <p><b><i>Incomplete outcome data</i> </b> </p> <p> <ul id="CD005441-list-0007"> <li> <p>Low risk of bias: Missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, were employed in handling missing data. </p> </li> <li> <p>Uncertain risk of bias: Information was insufficient to permit assessment of whether missing data in combination with the method used to handle missing data were likely to induce bias for the results. </p> </li> <li> <p>High risk of bias: The results were likely to be biased as the result of missing data.</p> </li> </ul> </p> <p><b><i>Selective outcome reporting</i> </b> </p> <p> <ul id="CD005441-list-0008"> <li> <p>Low risk of bias: All outcomes were predefined and reported, or all clinically relevant and reasonably expected outcomes were reported. </p> </li> <li> <p>Uncertain risk of bias: It is unclear whether all predefined and clinically relevant and reasonably expected outcomes were reported. </p> </li> <li> <p>High risk of bias: One or more clinically relevant and reasonably expected outcomes were not reported, and data on these outcomes were likely to have been recorded. </p> </li> </ul> </p> <p><b><i>Other sources of bias</i> </b> </p> <p> <ul id="CD005441-list-0009"> <li> <p>Low risk of bias: The trial appears to be free of other components (e.g., academic bias) that could put it at risk of bias. </p> </li> <li> <p>Uncertain risk of bias: The trial may or may not be free of other components that could put it at risk of bias. </p> </li> <li> <p>High risk of bias: Other factors in the trial could put it at risk of bias (e.g., authors have conducted trials on the same topic). </p> </li> </ul> </p> <p>The risk of bias of the trials was assessed independently by two review authors, and disagreements were resolved by discussion and were arbitrated with a third review author. Trials with adequate sequence generation and allocation concealment and free of incomplete outcome data and selective outcome reporting were considered trials with lower risk of bias, as we expected all or most trials to be unblinded and to have obtained industry support. </p> </section> <section id="CD005441-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p><b><i>Dichotomous data</i> </b> </p> <p>Dichotomous data were expressed as risk ratios (RRs) and risk differences (RDs) with 95% confidence intervals (CIs). Furthermore, the number needed to treat for an additional beneficial outcome was derived from the RD in meta‐analyses in which the 95% CI did not include zero. Rare events (morbidity and mortality) were estimated by using the odds ratio (OR) as a measure of effect. </p> </section> <section id="CD005441-sec-0045"> <h4 class="title">Dealing with missing data</h4> <p>We planned to perform all analyses according to the intention‐to‐treat method, including all participants, irrespective of compliance or follow‐up. However, we performed analyses according to the intention‐to‐treat method only for dichotomous outcomes. For continuous outcomes, we performed available case analyses and included data only on those whose results were known. Regarding the primary outcome measures, we planned to include participants with incomplete or missing data in the sensitivity analyses by imputing them according to the two scenarios described below (<a href="./references#CD005441-bbs2-0068" title="HollisS , CampbellF . What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ (Clinical Research Ed)1999;319:670‐4. ">Hollis 1999</a>; <a href="./references#CD005441-bbs2-0059" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 12. Art. No.: LIVER. ">Gluud 2013</a>). </p> <p> <ul id="CD005441-list-0010"> <li> <p>'Best‐worst' case scenario analyses: Participants with missing outcomes are considered successes in the experimental group and failures in the control group. The denominator will include all participants in the trial. </p> </li> <li> <p>'Worst‐best' case scenario analyses: Participants with missing outcomes data are considered failures in the experimental group and successes in the control group. The denominator will include all participants in the trial. </p> </li> </ul> </p> <p>As very few data were available, we decided not to conduct these extreme case scenario analyses. When sufficient data become available in the future, we will conduct such analyses. </p> </section> <section id="CD005441-sec-0046"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was explored by the Chi<sup>2</sup> test, and the quantity of heterogeneity was measured by the I<sup>2</sup> statistic (<a href="./references#CD005441-bbs2-0064" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002;</a><a href="./references#CD005441-bbs2-0065" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). Sources of heterogeneity were assessed by subgroup analyses and meta‐regression when possible. Subgroup analyses were carried out only when data from at least two trials were available for each subgroup. Meta‐regression was carried out only for meta‐analyses that included more than 10 trials. Whether sensitivity analyses needed to be performed was determined during the review process. </p> </section> <section id="CD005441-sec-0047"> <h4 class="title">Assessment of reporting biases</h4> <p>Different types of reporting biases (e.g., publication bias, time lag bias, outcome reporting bias) were handled according to the recommendations of The Cochrane Collaboration (<a href="./references#CD005441-bbs2-0065" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). For dichotomous outcomes with intervention effects measured as odds ratios, the arcsine test proposed by <a href="./references#CD005441-bbs2-0088" title="RückerG , SchwarzerG , CarpenterJ . Arcsine test for publication bias in meta‐analyses with binary outcomes. Statistics in Medicine2008;27:746‐63. ">Rücker 2008</a> was used to test for funnel plot asymmetry. Nevertheless, asymmetrical funnel plots are not necessarily caused by publication bias, and publication bias does not necessarily cause asymmetry in a funnel plot (<a href="http://archie.cochrane.org/sections/documents/view?document=0E5DDDFE82E26AA200AA39D65E0B0373%26format=REVMAN#REF-Egger-1997" target="_blank">Egger 1997</a>). </p> </section> <section id="CD005441-sec-0048"> <h4 class="title">Data synthesis</h4> <p><b>Meta‐analysis</b> <br/> For all analyses, we used both random‐effects (<a href="./references#CD005441-bbs2-0051" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>) and fixed‐effect models (<a href="./references#CD005441-bbs2-0050" title="DeMetsDL . Methods of combining randomized clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341‐50. ">DeMets 1987</a>). Because of underlying assumptive differences, results from the random‐effects model and from the fixed‐effect model may differ to a non‐ignorable extent. In case such discrepancies were observed, P values were ignored, and results were interpreted according to the implications of the subgroup and heterogeneity analyses according to confidence intervals of the two models.<br/> <br/> <b>Trial sequential analysis</b> <br/> Random errors may play an important role in the evaluation of cumulative meta‐analyses as the result of sparse data and multiplicity from repetitive testing of accumulating data. To assess the reliability of inferences from our meta‐analysis on sustained virological response, we calculated the diversity‐adjusted required information size (DARIS). We defined DARIS as the required sample size for the meta‐analysis to detect a 10% relative risk reduction in sustained virological response, assuming an average outcome proportion of 50% in the control group, a diversity observed in the meta‐analysis, and statistical error levels of alpha = 5% and beta = 10% (90% power). Meta‐analyses conducted before they surpassed the DARIS are considered analogous to interim analyses in a single randomised trial, and thus they necessitate adjustment of the threshold for statistical significance to maintain the predetermined maximum risk of obtaining a false positive (set to alpha = 5% in our analysis). Therefore, we substituted the conventional 5% threshold for statistical significance with those of Lan‐DeMets trial sequential monitoring boundaries (<a href="./references#CD005441-bbs2-0039" title="BangaloreS , WetterslevJ , PraneshS , SawhneyS , GluudC , MesserliF . Perioperative beta blockers in patients having non‐cardiac surgery: a meta‐analysis. Lancet2008;372(9654):1962‐76. ">Bangalore 2008</a>; <a href="./references#CD005441-bbs2-0042" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology2008;61(8):763‐9. ">Brok 2008</a>; <a href="./references#CD005441-bbs2-0104" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD005441-bbs2-0043" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Apparently conclusive meta‐analyses may be inconclusive—trial sequential analysis adjustment for random error risk in conclusive Cochrane neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [DOI: 10.1093/ije/dyn188] ">Brok 2009</a>; <a href="./references#CD005441-bbs2-0100" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJPA , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [DOI: 10.1093/ije/dyn179] ">Thorlund 2009</a>, <a href="./references#CD005441-bbs2-0105" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>; <a href="./references#CD005441-bbs2-0101" title="ThorlundK , AnemaA , MillsE . Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology2010;2:57‐66. ">Thorlund 2010</a>). To minimise the risk of random errors, we used trial sequential analysis (<a href="./references#CD005441-bbs2-0048" title="Copenhagen Trial Unit. TSA—Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 28 May 2013). ">CTU 2011</a>; <a href="./references#CD005441-bbs2-0102" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual forTrial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 23 April 2013). ">Thorlund 2011</a>). On the basis of the required information size and the risk for type I (5%) and type II (10% or 20%) errors, trial sequential monitoring boundaries were constructed (<a href="./references#CD005441-bbs2-0104" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD005441-bbs2-0048" title="Copenhagen Trial Unit. TSA—Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 28 May 2013). ">CTU 2011</a>; <a href="./references#CD005441-bbs2-0102" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual forTrial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 23 April 2013). ">Thorlund 2011</a>). These boundaries determine the statistical inference that one may draw regarding the cumulative meta‐analysis that has not reached the required information size. If the cumulative Z‐score crosses a trial sequential monitoring boundary before the required information size is reached in a cumulative meta‐analysis, firm evidence may have been established, and further trials may be superfluous, provided that systematic errors can be excluded. On the other hand, if the monitoring boundaries are not surpassed, it is most probably necessary to continue doing further trials to detect or reject a certain intervention effect. We used as default a type I error of 5%, a type II error of 10%, and adjusted information size for heterogeneity with diversity, unless otherwise stated (<a href="./references#CD005441-bbs2-0104" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD005441-bbs2-0105" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>; <a href="./references#CD005441-bbs2-0048" title="Copenhagen Trial Unit. TSA—Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 28 May 2013). ">CTU 2011</a>; <a href="./references#CD005441-bbs2-0102" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual forTrial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 23 April 2013). ">Thorlund 2011</a>). Posthoc, we also challenged the trial sequential analysis on sustained virological response by a type I error of 1%. </p> </section> <section id="CD005441-sec-0049"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The following subgroup analyses were considered and performed when feasible.</p> <p> <ul id="CD005441-list-0011"> <li> <p>Risk of bias: trials assessed to have low risk of bias compared to trials with high risk of bias. </p> </li> <li> <p>Participants: trials with treatment‐naive participants compared to trials with relapsers or non‐responders. </p> </li> <li> <p>Genotype: comparisons of trials with participants infected with different hepatitis C virus genotypes. </p> </li> <li> <p>Baseline viral load: trials assessed as having high or low risk of viral load on the basis of 800,000 IU (˜ four million copies/mL) threshold. </p> </li> <li> <p>Type of peginterferon: trials with peginterferon alpha‐2a compared to trials with peginterferon alpha‐2b. </p> </li> </ul> </p> <p>We performed a test of interaction between subgroups within each of the five categories. We performed tests of interaction only between subgroups that both included at least three trials. </p> </section> <section id="CD005441-sec-0050"> <h4 class="title">Sensitivity analysis</h4> <p>Suitable sensitivity analyses were identified during the review process. For example, if zero‐event trials occurred, we employed a number of different continuity corrections according to the sensitivity analysis proposed by <a href="./references#CD005441-bbs2-0041" title="BradburnMJ , DeeksJJ , BerlinJA , LocalioAR . Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events. Statistics in Medicine2006;26(1):53‐77. ">Bradburn 2006</a> using the TSA programme (<a href="./references#CD005441-bbs2-0048" title="Copenhagen Trial Unit. TSA—Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 28 May 2013). ">CTU 2011</a>; <a href="./references#CD005441-bbs2-0102" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual forTrial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 23 April 2013). ">Thorlund 2011</a>). We also carried out a sensitivity analysis from which we excluded trials that provided triple therapy with amantadine. </p> <section id="CD005441-sec-0051"> <h5 class="title">Summary of findings table</h5> <p>To minimise wrong interpretations of our findings and recommendations, we planned to rate the available evidence for all outcomes following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guidelines in order to prepare a Summary of Findings (SoFs) table (<a href="./references#CD005441-bbs2-0061" title="GuyattGH , OxmanAD , VistG , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed)2008;336:924‐6. ">Guyatt 2008</a>). A SoFs table consists of three parts: information about the review, a summary of the statistical results, and the grade of the quality of evidence. The quality assessment comprises three parts: the number of studies, the types of studies (randomised or observational), and the factors that affect the quality of the evidence (see below). </p> <p><b>Factors that affect the quality of the evidence</b> </p> <p> <div class="table" id="CD005441-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Decrease quality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Increase quality</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Large magnitude of effect</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inconsistency of results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Demonstrated effect reduced by all plausible confounding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirectness of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dose‐response gradient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Publication bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> </table> </div> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005441-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005441-sec-0052"></div> <section id="CD005441-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD005441-sec-0054"> <h4 class="title">Results of the search</h4> <p>We identified a total of 8089 references through electronic searches until September 2013. The Cochrane Hepato‐Biliary Group Controlled Trials Register identified 923 references. We excluded 2459 duplicates and 3346 clearly irrelevant references by reading abstracts. Accordingly, 2284 references were retrieved for further assessment. We excluded 2225 references because they were not randomised clinical trials or because interventions or participants did not meet our inclusion criteria. <br/> <br/> Fifty‐nine references describing a total of 27 randomised clinical trials fulfilled our inclusion criteria (see the <a href="./references#CD005441-sec-0090" title="">Characteristics of included studies</a> table) (<a href="./references#CD005441-bbs2-0015" title="ButiM , MedinaM , CasadoMA , WongJB , FosbrookL , EstebanR . A cost‐effectiveness analysis of peginterferon alfa‐2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Alimentary Pharmacology &amp; Therapeutics2003;17:687‐94. CondatB . Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b and ribavirin for the treatment of chronic hepatitis C: A randomized trial. Hepato‐Gastroenterology2002;9(2):141‐2. GishR , BzowejN , BrooksL , BrassC , WengW . Treatment with pegylated interferon alfa‐2b in combination with ribavirin improved health‐related quality of life compared with interferon alfa‐2b plus ribavirin in chronic hepatitis C [AASLD abstract]. Hepatology2002;36(4 Pt 2):582A. JenJ , LaughlinM , ChungC , HeftS , AffrimeMB , GuptaSK , et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic‐pharmacodynamic models. Clinical Pharmacology and Therapeutics2002;72(4):349‐61. MannsMP , McHutchisonJG , GordonS , RustgiV , ShiffmanML , LeeWM , et al. Peginterferon alfa‐2b plus ribavirin compared to interferon alfa‐2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [AASLD abstract]. Hepatology2000;32(4 Pt 2):297A. MannsMP , McHutchisonJG , GordonSC , RustgiVK , ShiffmanM , ReindollarR , et al. Peginterferon alfa‐2a plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001;358:958‐65. McHutchisonJ , MannsM , HarveyJ , AlbrechtJK . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peg‐interferon alfa‐2b plus ribavirin [abstract]. Journal of Hepatology2001;34(1):2‐3. McHutchisonJG , MannsM , PatelK , PoynardT , LindsayKL , TrepoC , et al. Adherence to combination therapy enhances sustained response in genotype‐1‐infected patients with chronic hepatitis C. Gastroenterology2002;123(4):1061‐9. McHutchisonJG , MannsMP , HarveyJ , GaraudJ‐J , AlbrechtJ . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peginterferon alfa 2b plus ribavirin. Hepatology2001;34(4 Pt 2):417A. McHutchisonJG , MannsMP , LingM‐H , AlbrechtJK . Peginterferon alfa‐2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factor for sustained virological response when ribavirin dose is expressed as mg/kg of body weight? [AASLD abstract]. Hepatology2001;34(4 Pt 2):329A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated‐interferon alpfa‐2b and ribavirin combination [AASLD abstract]. Hepatology2002;36(4 Pt 2):351A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa‐2b and ribavirin. Hepatology2003;38(2):481‐92. PoynardT , RatziuV , McHutchisonJ , MannsM , GoodmanZ , ZeuzemS , et al. Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology2003;38(1):75‐85. SiebertU , SroczynskiG , RossolS , WasemJ , Ravens‐SiebererU , KurthBM , et al. Cost effectiveness of peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C. Gut2003;52:425‐32. WongJB , DavisGL , McHutchisonJG , MannsMP , AlbrechtJK . Economic and clinical effects of evaluating rapid viral response to peginterferon alfa‐2b plus ribavirin for the initial treatment of chronic hepatitis C. American Journal of Gastroenterology2003;98(11):2354‐62. ">Manns 2001</a>; <a href="./references#CD005441-bbs2-0003" title="CaritiG , AndreoniM , CalleriG , MancaA , RosinaF , SartoriM , et al. PEG‐INF alpha‐2A (40KD) plus ribavirin (RBV) vs IFN alpha‐2A (ROFERON‐A) in naive patients with chronic hepatitis C (CHC) and genotype 1 [AASLD abstract]. Hepatology2002;36(4 Pt 2):595A. ">Cariti 2002</a>; <a href="./references#CD005441-bbs2-0009" title="Bosques‐PadillaF , Trejo‐EstradaR , Campollo‐RivasO , Cortez‐HernandezC , Dehesa‐ViolanteM , Maldonado‐GarzaH , et al. Peginterferon alfa‐2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Annals of Hepatology2003;2(3):135‐9. FriedMW , ShiffmanML , ReddyKR , SmithC , MarinosG , GoncalesFLJr , et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine2002;347(13):975‐82. HassaneinT , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. The impact of peginterferon alfa‐2a plus ribavirin combination therapy on health‐related quality of life in chronic hepatitis C. Journal of Hepatology2004;40(4):675‐81. HassaneinTI , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. Treatment with 40 kDa peginterferon alfa‐2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alfa‐2b plus ribavirin [AASLD abstract]. Hepatology2001;34(4 Pt 2):243A. HassaneinTI , CooksleyWGE , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. QOL benefits observed as early as week 2 with peginterferon alfa‐2a (40kD) (Pegasys) in combination with ribavirin (RBV) versus interferon alfa‐2b plus RBV [EASL abstract]. Journal of Hepatology2002;36(1):110. HerrmannE , LeeJ‐H , MarinosG , ModiM , ZeuzemS . Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology2003;37(6):1351‐8. LutchmanG , HoofnagleJH . Viral kinetics in hepatitis C. Hepatology2003;37(6):1257‐9. SullivanSD , CraxiA , AlbertiA , GiulianiG , DeCarliC , WintfeldN , et al. Cost effectiveness of peginterferon alpha‐2a plus ribavirin versus interferon alpha‐2b plus ribavirin as initial therapy for treatment‐naive chronic hepatitis C. Pharmacoeconomics2004;22(4):257‐65. SullivanSD , GreenJ , PatelKK , CraxiA , AlbertiA , GiulianiG , et al. A comparison of cost‐effectiveness of peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (Copegus) vs interferon alfa‐2b plus ribavirin as first treatment of chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):174‐5. SullivanSD , JensenDM , BernsteinDE , HassaneinTI , FosterGR , LeeSS , et al. Cost‐effectiveness of combination peginterferon alpha‐2a and ribavirin compared with interferon alpha‐2b and ribavirin in patients with chronic hepatitis C. American Journal of Gastroenterology2004;99:1490‐6. ZeuzemS , HerrmannE , LeeJ‐H , MarinosG , ModiM , RothWK . Effect of ribavirin on viral kinetics in hepatitis C virus genotype 1 infected patients treated with pegylated interferon alpha2a [AASLD abstract]. Hepatology2001;34(4 Pt 2):558A. ">Fried 2002</a>; <a href="./references#CD005441-bbs2-0010" title="HinrichsenH , BuggischP , NasserS , FoelschUR . A prospective randomised 24 week trial of peg‐interferon alpha2b plus ribavirin versus standard combination therapy in untreated hepatitis C genotype 2 and 3 patients [AASLD abstract]. Hepatology2002;36(4 Pt 2):311A. ">Hinrichsen 2002</a>; <a href="./references#CD005441-bbs2-0007" title="EsmatGH , AbouziedA , Abdel‐HamidM , MohamedMK , ZalataK , ElRazikyMS , et al. Results of a randomized clinical trial of genotype‐4 infected subjects when treated with standard or pegylated interferon alfa‐2b in combination with ribavirin [AASLD abstract]. Hepatology2003;38(4 Suppl 1):314A‐315A. ">Esmat 2003</a>; <a href="./references#CD005441-bbs2-0023" title="ShobokshiA , SerebourFE , SkakniL , Al‐JasserN , TantawiAO , SabahA , et al. Combination therapy of peginterferon alfa‐2a (40kD) (Pegasys(R)) and ribavirin (Copegus(R)) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia [AASLD abstract]. Hepatology2003;38(4 Suppl 1):636A. ShobokshiO , SerebourF , SkakniL , TantawiA , DinishT , Al QuaizM , et al. Efficacy of pegylated (40kDa) IFN alfa‐2a (Pegasys) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia. Journal of Hepatology2002;36(Suppl 1):129. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Early virological response at week 12 has positive predictive value for end of treatment response for hepatitis C virus genotype 4 chronic active hepatitis cases treated with combination therapy of pegylated interferon plus ribavirin. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Pegylated interferon alfa‐2a (40KDA) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ">Shobokshi 2003</a>; <a href="./references#CD005441-bbs2-0025" title="ThakebFIA , OmarMM , ElAwadyMM , IsshakSY . Randomized controlled trial of peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus‐genotype 4 among Egyptian patients [AASLD abstract]. Hepatology2003;38(4 Suppl 1):278A. ">Thakeb 2003</a>; <a href="./references#CD005441-bbs2-0001" title="AlfalehFZ , HadadQ , KhurooMS , AljumahA , AlgamediA , AlashgarH , et al. Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver International2004;24:568‐74. ">Al‐Faleh 2004</a>; <a href="./references#CD005441-bbs2-0002" title="BrunoS , CammaC , DiMarcoV , RumiM , VinciM , CamozziM , et al. Peginterferon alfa‐2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. Journal of Hepatology2004;41:474‐81. BrunoS , CammaC , DiMarcoV , RumiMG , VinciM , CamozziM , et al. Chronic hepatitis C (CH‐C) genotype 1: an independent, multicenter RCT comparing PEG‐IFN alfa‐2b 12 kD plus ribavirin (RBV) and IFN alfa‐2b plus RBV in naive patients. Journal of Hepatology2003;38(Suppl 2):131‐2. ">Bruno 2004</a>; <a href="./references#CD005441-bbs2-0008" title="FargionS , BorzioM , CargnelA . End of treatment and sustained response to peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) (Copegus) and amantadine (AMA), and to induction therapy with interferon (IFN) alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponders with chronic hepatitis C (CHC) [AASLD abstract]. Hepatology2003;38(4 Suppl 1):733A. FargionS , BorzioM , CargnelA . Peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):139‐40. FargionS , BorzioM , CargnelA . Peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC) [AASLD abstract]. Hepatology2002;36(4 Pt 2):572A. FargionS , BorzioM , MaraschiA , CargnelA . Sustained virological response (SVR) to peginterferon alfa‐2a (40 kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC). Journal of Hepatology2004;40(Suppl 1):140. ">Fargion 2004</a>; <a href="./references#CD005441-bbs2-0012" title="IzumiN , AsahinaY , KurosakiM , UchiharaM , NishimuraY , InoueK , et al. A comparison of the exponential decay slope between PEG‐IFN alfa‐2b/ribavirin and IFN alfa‐2b/ribavirin combination therapy in patients with chronic hepatitis C. Intervirology2004;47:102‐7. ">Izumi 2004</a>; <a href="./references#CD005441-bbs2-0004" title="DerbalaM , AmerA , BenerB , LopezA , OmarM , ElGhannamM . Pegylated interferon‐alpha 2b‐ ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. Journal of Viral Hepatitis2005;12(4):380‐5. [DOI: 10.1111/j.1365‐2893.2005.00604.x] ">Derbala 2005</a>; <a href="./references#CD005441-bbs2-0006" title="DollingerMM , DridiY , LesskeJ , BehlS , FleigWE . Efficacy of daily consensus interferon and ribavirin compared to peg‐interferon alpha‐2B and interferon in non‐responders with chronic hepatitis C [AASLD abstract]. Hepatology2005;42(4 Suppl 1):691‐2. ">Dollinger 2005</a>; <a href="./references#CD005441-bbs2-0013" title="LeeSD , YuML , ChengPN , LaiMY , ChaoYC , HwangSJ , et al. Comparison of a 6‐month course peginterferon alpha‐2b plus ribavirin and interferon alpha‐2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. Journal of Viral Hepatitis2005;12:283‐91. ">Lee 2005</a>; <a href="./references#CD005441-bbs2-0014" title="MangiaA , RicciGL , PersicoM , MinervaN , CarettaV , BaccaD , et al. A randomized controlled trial of peginterferon alpha‐2a (40 kD) or interferon alpha‐2a plus ribavirin and amantadine vs interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C. Journal of Viral Hepatitis2005;12(3):292‐9. ">Mangia 2005</a>; <a href="./references#CD005441-bbs2-0016" title="NapoliN , GiannelliG , ParisiCV , AntonaciA , MaddalenaG , AntonaciS . Predictive value of early virological response to treatment with different interferon‐based regimens plus ribavirin in patients with chronic hepatitis C. New Microbiologica2005;28:13‐21. ">Napoli 2005</a>; <a href="./references#CD005441-bbs2-0018" title="MangiaA , CiminoL , PersicoM , DemeliaL , RumiM , SpinziG , et al. Enhanced response to peginterferon‐alpha‐2a‐based triple therapy in previously non‐responsive chronic hepatitis C: final results of PRETTY study. Journal of Hepatology2005;42(2):200‐1. ">PRETTY 2005</a>; <a href="./references#CD005441-bbs2-0022" title="ScottoG , FazioV , PalumboE , CibelliDC , SaracinoA , AngaranoG . Treatment of genotype 1b HCV‐related chronic hepatitis: efficacy and toxicity of three different interferon alfa‐2b/ribavirin combined regimens in naive patients. New Microbiologica2005;28:23‐9. ">Scotto 2005</a>; <a href="./references#CD005441-bbs2-0026" title="TsubotaA , AraseY , SomeyaT , SuzukiY , SuzukiF , SaitohS , et al. Early viral kinetics and treatment outcome in combination of high‐dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. Journal of Medical Virology2005;75:27‐34. ">Tsubota 2005</a>; <a href="./references#CD005441-bbs2-0005" title="DerbalaMF , KaabiSR , DweikNZ , PasicF , ButtMT , YakoobR , et al. Treatment of hepatitis C virus genotype 4 with pegylated interferon alpha 2a:Impact of bilharziasis and fibrosis stage. World Journal of Gastroenterology2006;12(35):5692‐8. ">Derbala 2006</a>; <a href="./references#CD005441-bbs2-0027" title="WakilRM , MontasserMF , MansourMA , SalmanTA , El‐BatanonyMH , HelailEH , et al. Peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for treatment of chronic hepatitis C in treatment‐naive Egyptian patients. Journal of Clinical Virology2006;36:S142‐S143. ">Wakil 2006</a>; <a href="./references#CD005441-bbs2-0019" title="RahmanF , SchuchmannM , LohrHF , LinkR , BuggischP , FuchsM , et al. Daily consensus interferon versus peg‐interferon alfa2b with weight based or 800 mg ribavirin in treatment‐naive patients with chronic hepatitis C genotype 1. Hepatology2007;46(4 Suppl 1):826A. ">Rahman 2007a</a>; <a href="./references#CD005441-bbs2-0020" title="RahmanF , SchuchmannM , LohrHF , LinkR , BuggischP , FuchsM , et al. Daily consensus interferon versus peg‐interferon alfa2b with weight based or 800 mg ribavirin in treatment‐naive patients with chronic hepatitis C genotypes 2 or 3. Hepatology2007;46(4 Suppl 1):826A. ">Rahman 2007b</a>; <a href="./references#CD005441-bbs2-0024" title="SjogrenMH , SjogrenR , LyonsMF , RyanM , SantoroJ , SmithC , et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Digestive Diseases and Sciences2007;52(6):1540‐7. ">Sjögren 2007</a>; <a href="./references#CD005441-bbs2-0011" title="HorsmansY , ColleI , VanVlierbergheH , LangletP , AdlerM , BourgeoisN , et al. Weekly pegylated Interferon alpha‐2b vs daily interferon a‐2b versus standard regimen of Interferon a‐2b in the treatment of patients with chronic hepatitis C virus infection. Acto Gastro‐Enterologica Belgica2008;71(3):293‐7. ">Horsmans 2008</a>; <a href="./references#CD005441-bbs2-0021" title="RoffiL , ColloredoG , DelPoggioP , FornaciariG , CastagnettiE , CerianiR , et al. Efficacy and safety of low doses of interferon (IFN) alfa‐2b plus ribavirin (RBV) in advanced HCV related liver disease [AASLD abstract]. Hepatology2004;40(4 Suppl 1):322A. RoffiL , ColloredoG , PioltelliP , BellatiG , PozzpiM , ParraviciniP , et al. Pegylated interferon‐alpha2b plus ribavirin: an efficacious and well‐tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antiviral Therapy2008;13(5):663‐73. ">Roffi 2008</a>; <a href="./references#CD005441-bbs2-0017" title="NevensF , VanVlierbergheH , D'HeygereE , DelwaideJ , AdlerM , HenrionJ , et al. A randomised, open‐label, multicenter study evaluating the efficacy of peginterferon alfa‐2a versus interferon alfa‐2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients. Acta Gastroenterologica Belgica2010;73:223‐8. ">Nevens 2010</a>). Accordingly, several of the trials were published multiple times. Seventeen trials were published as full‐paper articles, and 10 trials were published in abstract form only. </p> </section> <section id="CD005441-sec-0055"> <h4 class="title">Included studies</h4> <section id="CD005441-sec-0056"> <h5 class="title">Participants</h5> <p>A total of 5938 participants were randomly assigned in the 27 trials. The number of participants in each trial ranged from 40 to 1530. Twenty‐three trials included treatment‐naive participants, and four trials included non‐responders or relapsers. In 10 trials, all participants were infected with hepatitis C virus genotype one. In two trials, all participants were infected with genotype two or three. In seven trials, all participants were infected with genotype four. In eight trials, participants infected with different genotypes were included. </p> </section> <section id="CD005441-sec-0057"> <h5 class="title">Experimental interventions</h5> <p>The type of peginterferon was alpha‐2a (nine trials) or alpha‐2b (18 trials).</p> <p>The dose of peginterferon alpha‐2a was 180 μg/wk (<a href="./references#CD005441-bbs2-0003" title="CaritiG , AndreoniM , CalleriG , MancaA , RosinaF , SartoriM , et al. PEG‐INF alpha‐2A (40KD) plus ribavirin (RBV) vs IFN alpha‐2A (ROFERON‐A) in naive patients with chronic hepatitis C (CHC) and genotype 1 [AASLD abstract]. Hepatology2002;36(4 Pt 2):595A. ">Cariti 2002</a>; <a href="./references#CD005441-bbs2-0009" title="Bosques‐PadillaF , Trejo‐EstradaR , Campollo‐RivasO , Cortez‐HernandezC , Dehesa‐ViolanteM , Maldonado‐GarzaH , et al. Peginterferon alfa‐2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Annals of Hepatology2003;2(3):135‐9. FriedMW , ShiffmanML , ReddyKR , SmithC , MarinosG , GoncalesFLJr , et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine2002;347(13):975‐82. HassaneinT , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. The impact of peginterferon alfa‐2a plus ribavirin combination therapy on health‐related quality of life in chronic hepatitis C. Journal of Hepatology2004;40(4):675‐81. HassaneinTI , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. Treatment with 40 kDa peginterferon alfa‐2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alfa‐2b plus ribavirin [AASLD abstract]. Hepatology2001;34(4 Pt 2):243A. HassaneinTI , CooksleyWGE , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. QOL benefits observed as early as week 2 with peginterferon alfa‐2a (40kD) (Pegasys) in combination with ribavirin (RBV) versus interferon alfa‐2b plus RBV [EASL abstract]. Journal of Hepatology2002;36(1):110. HerrmannE , LeeJ‐H , MarinosG , ModiM , ZeuzemS . Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology2003;37(6):1351‐8. LutchmanG , HoofnagleJH . Viral kinetics in hepatitis C. Hepatology2003;37(6):1257‐9. SullivanSD , CraxiA , AlbertiA , GiulianiG , DeCarliC , WintfeldN , et al. Cost effectiveness of peginterferon alpha‐2a plus ribavirin versus interferon alpha‐2b plus ribavirin as initial therapy for treatment‐naive chronic hepatitis C. Pharmacoeconomics2004;22(4):257‐65. SullivanSD , GreenJ , PatelKK , CraxiA , AlbertiA , GiulianiG , et al. A comparison of cost‐effectiveness of peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (Copegus) vs interferon alfa‐2b plus ribavirin as first treatment of chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):174‐5. SullivanSD , JensenDM , BernsteinDE , HassaneinTI , FosterGR , LeeSS , et al. Cost‐effectiveness of combination peginterferon alpha‐2a and ribavirin compared with interferon alpha‐2b and ribavirin in patients with chronic hepatitis C. American Journal of Gastroenterology2004;99:1490‐6. ZeuzemS , HerrmannE , LeeJ‐H , MarinosG , ModiM , RothWK . Effect of ribavirin on viral kinetics in hepatitis C virus genotype 1 infected patients treated with pegylated interferon alpha2a [AASLD abstract]. Hepatology2001;34(4 Pt 2):558A. ">Fried 2002</a>; <a href="./references#CD005441-bbs2-0023" title="ShobokshiA , SerebourFE , SkakniL , Al‐JasserN , TantawiAO , SabahA , et al. Combination therapy of peginterferon alfa‐2a (40kD) (Pegasys(R)) and ribavirin (Copegus(R)) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia [AASLD abstract]. Hepatology2003;38(4 Suppl 1):636A. ShobokshiO , SerebourF , SkakniL , TantawiA , DinishT , Al QuaizM , et al. Efficacy of pegylated (40kDa) IFN alfa‐2a (Pegasys) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia. Journal of Hepatology2002;36(Suppl 1):129. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Early virological response at week 12 has positive predictive value for end of treatment response for hepatitis C virus genotype 4 chronic active hepatitis cases treated with combination therapy of pegylated interferon plus ribavirin. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Pegylated interferon alfa‐2a (40KDA) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ">Shobokshi 2003</a>; <a href="./references#CD005441-bbs2-0025" title="ThakebFIA , OmarMM , ElAwadyMM , IsshakSY . Randomized controlled trial of peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus‐genotype 4 among Egyptian patients [AASLD abstract]. Hepatology2003;38(4 Suppl 1):278A. ">Thakeb 2003</a>; <a href="./references#CD005441-bbs2-0008" title="FargionS , BorzioM , CargnelA . End of treatment and sustained response to peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) (Copegus) and amantadine (AMA), and to induction therapy with interferon (IFN) alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponders with chronic hepatitis C (CHC) [AASLD abstract]. Hepatology2003;38(4 Suppl 1):733A. FargionS , BorzioM , CargnelA . Peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):139‐40. FargionS , BorzioM , CargnelA . Peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC) [AASLD abstract]. Hepatology2002;36(4 Pt 2):572A. FargionS , BorzioM , MaraschiA , CargnelA . Sustained virological response (SVR) to peginterferon alfa‐2a (40 kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC). Journal of Hepatology2004;40(Suppl 1):140. ">Fargion 2004</a>; <a href="./references#CD005441-bbs2-0014" title="MangiaA , RicciGL , PersicoM , MinervaN , CarettaV , BaccaD , et al. A randomized controlled trial of peginterferon alpha‐2a (40 kD) or interferon alpha‐2a plus ribavirin and amantadine vs interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C. Journal of Viral Hepatitis2005;12(3):292‐9. ">Mangia 2005</a>; <a href="./references#CD005441-bbs2-0018" title="MangiaA , CiminoL , PersicoM , DemeliaL , RumiM , SpinziG , et al. Enhanced response to peginterferon‐alpha‐2a‐based triple therapy in previously non‐responsive chronic hepatitis C: final results of PRETTY study. Journal of Hepatology2005;42(2):200‐1. ">PRETTY 2005</a>; <a href="./references#CD005441-bbs2-0005" title="DerbalaMF , KaabiSR , DweikNZ , PasicF , ButtMT , YakoobR , et al. Treatment of hepatitis C virus genotype 4 with pegylated interferon alpha 2a:Impact of bilharziasis and fibrosis stage. World Journal of Gastroenterology2006;12(35):5692‐8. ">Derbala 2006</a>; <a href="./references#CD005441-bbs2-0017" title="NevensF , VanVlierbergheH , D'HeygereE , DelwaideJ , AdlerM , HenrionJ , et al. A randomised, open‐label, multicenter study evaluating the efficacy of peginterferon alfa‐2a versus interferon alfa‐2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients. Acta Gastroenterologica Belgica2010;73:223‐8. ">Nevens 2010</a>). </p> <p>The dose of peginterferon alpha‐2b was 1.0 μg/kg/wk (<a href="./references#CD005441-bbs2-0010" title="HinrichsenH , BuggischP , NasserS , FoelschUR . A prospective randomised 24 week trial of peg‐interferon alpha2b plus ribavirin versus standard combination therapy in untreated hepatitis C genotype 2 and 3 patients [AASLD abstract]. Hepatology2002;36(4 Pt 2):311A. ">Hinrichsen 2002</a>; <a href="./references#CD005441-bbs2-0007" title="EsmatGH , AbouziedA , Abdel‐HamidM , MohamedMK , ZalataK , ElRazikyMS , et al. Results of a randomized clinical trial of genotype‐4 infected subjects when treated with standard or pegylated interferon alfa‐2b in combination with ribavirin [AASLD abstract]. Hepatology2003;38(4 Suppl 1):314A‐315A. ">Esmat 2003</a>; <a href="./references#CD005441-bbs2-0001" title="AlfalehFZ , HadadQ , KhurooMS , AljumahA , AlgamediA , AlashgarH , et al. Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver International2004;24:568‐74. ">Al‐Faleh 2004</a>) or 1.5 μg/kg/wk (<a href="./references#CD005441-bbs2-0015" title="ButiM , MedinaM , CasadoMA , WongJB , FosbrookL , EstebanR . A cost‐effectiveness analysis of peginterferon alfa‐2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Alimentary Pharmacology &amp; Therapeutics2003;17:687‐94. CondatB . Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b and ribavirin for the treatment of chronic hepatitis C: A randomized trial. Hepato‐Gastroenterology2002;9(2):141‐2. GishR , BzowejN , BrooksL , BrassC , WengW . Treatment with pegylated interferon alfa‐2b in combination with ribavirin improved health‐related quality of life compared with interferon alfa‐2b plus ribavirin in chronic hepatitis C [AASLD abstract]. Hepatology2002;36(4 Pt 2):582A. JenJ , LaughlinM , ChungC , HeftS , AffrimeMB , GuptaSK , et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic‐pharmacodynamic models. Clinical Pharmacology and Therapeutics2002;72(4):349‐61. MannsMP , McHutchisonJG , GordonS , RustgiV , ShiffmanML , LeeWM , et al. Peginterferon alfa‐2b plus ribavirin compared to interferon alfa‐2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [AASLD abstract]. Hepatology2000;32(4 Pt 2):297A. MannsMP , McHutchisonJG , GordonSC , RustgiVK , ShiffmanM , ReindollarR , et al. Peginterferon alfa‐2a plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001;358:958‐65. McHutchisonJ , MannsM , HarveyJ , AlbrechtJK . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peg‐interferon alfa‐2b plus ribavirin [abstract]. Journal of Hepatology2001;34(1):2‐3. McHutchisonJG , MannsM , PatelK , PoynardT , LindsayKL , TrepoC , et al. Adherence to combination therapy enhances sustained response in genotype‐1‐infected patients with chronic hepatitis C. Gastroenterology2002;123(4):1061‐9. McHutchisonJG , MannsMP , HarveyJ , GaraudJ‐J , AlbrechtJ . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peginterferon alfa 2b plus ribavirin. Hepatology2001;34(4 Pt 2):417A. McHutchisonJG , MannsMP , LingM‐H , AlbrechtJK . Peginterferon alfa‐2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factor for sustained virological response when ribavirin dose is expressed as mg/kg of body weight? [AASLD abstract]. Hepatology2001;34(4 Pt 2):329A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated‐interferon alpfa‐2b and ribavirin combination [AASLD abstract]. Hepatology2002;36(4 Pt 2):351A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa‐2b and ribavirin. Hepatology2003;38(2):481‐92. PoynardT , RatziuV , McHutchisonJ , MannsM , GoodmanZ , ZeuzemS , et al. Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology2003;38(1):75‐85. SiebertU , SroczynskiG , RossolS , WasemJ , Ravens‐SiebererU , KurthBM , et al. Cost effectiveness of peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C. Gut2003;52:425‐32. WongJB , DavisGL , McHutchisonJG , MannsMP , AlbrechtJK . Economic and clinical effects of evaluating rapid viral response to peginterferon alfa‐2b plus ribavirin for the initial treatment of chronic hepatitis C. American Journal of Gastroenterology2003;98(11):2354‐62. ">Manns 2001</a>; <a href="./references#CD005441-bbs2-0012" title="IzumiN , AsahinaY , KurosakiM , UchiharaM , NishimuraY , InoueK , et al. A comparison of the exponential decay slope between PEG‐IFN alfa‐2b/ribavirin and IFN alfa‐2b/ribavirin combination therapy in patients with chronic hepatitis C. Intervirology2004;47:102‐7. ">Izumi 2004</a>; <a href="./references#CD005441-bbs2-0004" title="DerbalaM , AmerA , BenerB , LopezA , OmarM , ElGhannamM . Pegylated interferon‐alpha 2b‐ ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. Journal of Viral Hepatitis2005;12(4):380‐5. [DOI: 10.1111/j.1365‐2893.2005.00604.x] ">Derbala 2005</a>; <a href="./references#CD005441-bbs2-0006" title="DollingerMM , DridiY , LesskeJ , BehlS , FleigWE . Efficacy of daily consensus interferon and ribavirin compared to peg‐interferon alpha‐2B and interferon in non‐responders with chronic hepatitis C [AASLD abstract]. Hepatology2005;42(4 Suppl 1):691‐2. ">Dollinger 2005</a>; <a href="./references#CD005441-bbs2-0013" title="LeeSD , YuML , ChengPN , LaiMY , ChaoYC , HwangSJ , et al. Comparison of a 6‐month course peginterferon alpha‐2b plus ribavirin and interferon alpha‐2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. Journal of Viral Hepatitis2005;12:283‐91. ">Lee 2005</a>; <a href="./references#CD005441-bbs2-0016" title="NapoliN , GiannelliG , ParisiCV , AntonaciA , MaddalenaG , AntonaciS . Predictive value of early virological response to treatment with different interferon‐based regimens plus ribavirin in patients with chronic hepatitis C. New Microbiologica2005;28:13‐21. ">Napoli 2005</a>; <a href="./references#CD005441-bbs2-0022" title="ScottoG , FazioV , PalumboE , CibelliDC , SaracinoA , AngaranoG . Treatment of genotype 1b HCV‐related chronic hepatitis: efficacy and toxicity of three different interferon alfa‐2b/ribavirin combined regimens in naive patients. New Microbiologica2005;28:23‐9. ">Scotto 2005</a>; <a href="./references#CD005441-bbs2-0026" title="TsubotaA , AraseY , SomeyaT , SuzukiY , SuzukiF , SaitohS , et al. Early viral kinetics and treatment outcome in combination of high‐dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. Journal of Medical Virology2005;75:27‐34. ">Tsubota 2005</a>; <a href="./references#CD005441-bbs2-0027" title="WakilRM , MontasserMF , MansourMA , SalmanTA , El‐BatanonyMH , HelailEH , et al. Peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for treatment of chronic hepatitis C in treatment‐naive Egyptian patients. Journal of Clinical Virology2006;36:S142‐S143. ">Wakil 2006</a>; <a href="./references#CD005441-bbs2-0019" title="RahmanF , SchuchmannM , LohrHF , LinkR , BuggischP , FuchsM , et al. Daily consensus interferon versus peg‐interferon alfa2b with weight based or 800 mg ribavirin in treatment‐naive patients with chronic hepatitis C genotype 1. Hepatology2007;46(4 Suppl 1):826A. ">Rahman 2007a</a>; <a href="./references#CD005441-bbs2-0020" title="RahmanF , SchuchmannM , LohrHF , LinkR , BuggischP , FuchsM , et al. Daily consensus interferon versus peg‐interferon alfa2b with weight based or 800 mg ribavirin in treatment‐naive patients with chronic hepatitis C genotypes 2 or 3. Hepatology2007;46(4 Suppl 1):826A. ">Rahman 2007b</a>; <a href="./references#CD005441-bbs2-0024" title="SjogrenMH , SjogrenR , LyonsMF , RyanM , SantoroJ , SmithC , et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Digestive Diseases and Sciences2007;52(6):1540‐7. ">Sjögren 2007</a>). In the <a href="./references#CD005441-bbs2-0015" title="ButiM , MedinaM , CasadoMA , WongJB , FosbrookL , EstebanR . A cost‐effectiveness analysis of peginterferon alfa‐2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Alimentary Pharmacology &amp; Therapeutics2003;17:687‐94. CondatB . Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b and ribavirin for the treatment of chronic hepatitis C: A randomized trial. Hepato‐Gastroenterology2002;9(2):141‐2. GishR , BzowejN , BrooksL , BrassC , WengW . Treatment with pegylated interferon alfa‐2b in combination with ribavirin improved health‐related quality of life compared with interferon alfa‐2b plus ribavirin in chronic hepatitis C [AASLD abstract]. Hepatology2002;36(4 Pt 2):582A. JenJ , LaughlinM , ChungC , HeftS , AffrimeMB , GuptaSK , et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic‐pharmacodynamic models. Clinical Pharmacology and Therapeutics2002;72(4):349‐61. MannsMP , McHutchisonJG , GordonS , RustgiV , ShiffmanML , LeeWM , et al. Peginterferon alfa‐2b plus ribavirin compared to interferon alfa‐2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [AASLD abstract]. Hepatology2000;32(4 Pt 2):297A. MannsMP , McHutchisonJG , GordonSC , RustgiVK , ShiffmanM , ReindollarR , et al. Peginterferon alfa‐2a plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001;358:958‐65. McHutchisonJ , MannsM , HarveyJ , AlbrechtJK . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peg‐interferon alfa‐2b plus ribavirin [abstract]. Journal of Hepatology2001;34(1):2‐3. McHutchisonJG , MannsM , PatelK , PoynardT , LindsayKL , TrepoC , et al. Adherence to combination therapy enhances sustained response in genotype‐1‐infected patients with chronic hepatitis C. Gastroenterology2002;123(4):1061‐9. McHutchisonJG , MannsMP , HarveyJ , GaraudJ‐J , AlbrechtJ . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peginterferon alfa 2b plus ribavirin. Hepatology2001;34(4 Pt 2):417A. McHutchisonJG , MannsMP , LingM‐H , AlbrechtJK . Peginterferon alfa‐2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factor for sustained virological response when ribavirin dose is expressed as mg/kg of body weight? [AASLD abstract]. Hepatology2001;34(4 Pt 2):329A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated‐interferon alpfa‐2b and ribavirin combination [AASLD abstract]. Hepatology2002;36(4 Pt 2):351A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa‐2b and ribavirin. Hepatology2003;38(2):481‐92. PoynardT , RatziuV , McHutchisonJ , MannsM , GoodmanZ , ZeuzemS , et al. Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology2003;38(1):75‐85. SiebertU , SroczynskiG , RossolS , WasemJ , Ravens‐SiebererU , KurthBM , et al. Cost effectiveness of peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C. Gut2003;52:425‐32. WongJB , DavisGL , McHutchisonJG , MannsMP , AlbrechtJK . Economic and clinical effects of evaluating rapid viral response to peginterferon alfa‐2b plus ribavirin for the initial treatment of chronic hepatitis C. American Journal of Gastroenterology2003;98(11):2354‐62. ">Manns 2001</a> trial, a third intervention group was given peginterferon alpha‐2b 1.5 μg/kg/wk for four weeks, followed by 0.5 μg/kg/wk for an additional 44 weeks. In the <a href="./references#CD005441-bbs2-0021" title="RoffiL , ColloredoG , DelPoggioP , FornaciariG , CastagnettiE , CerianiR , et al. Efficacy and safety of low doses of interferon (IFN) alfa‐2b plus ribavirin (RBV) in advanced HCV related liver disease [AASLD abstract]. Hepatology2004;40(4 Suppl 1):322A. RoffiL , ColloredoG , PioltelliP , BellatiG , PozzpiM , ParraviciniP , et al. Pegylated interferon‐alpha2b plus ribavirin: an efficacious and well‐tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antiviral Therapy2008;13(5):663‐73. ">Roffi 2008</a> trial, participants were given peginterferon alpha‐2b 1.0 μg/kg/wk for four weeks, followed by 0.5 μg/kg/wk for an additional two weeks. </p> </section> <section id="CD005441-sec-0058"> <h5 class="title">Control interventions</h5> <p>The type of interferon was alpha‐2a (eight trials), alpha‐2b (14 trials), consensus interferon (four trials), or leucocyte interferon‐alpha (one trial). </p> <p>The dose of interferon alpha‐2a was 3 MU (<a href="./references#CD005441-bbs2-0025" title="ThakebFIA , OmarMM , ElAwadyMM , IsshakSY . Randomized controlled trial of peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus‐genotype 4 among Egyptian patients [AASLD abstract]. Hepatology2003;38(4 Suppl 1):278A. ">Thakeb 2003</a>; <a href="./references#CD005441-bbs2-0014" title="MangiaA , RicciGL , PersicoM , MinervaN , CarettaV , BaccaD , et al. A randomized controlled trial of peginterferon alpha‐2a (40 kD) or interferon alpha‐2a plus ribavirin and amantadine vs interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C. Journal of Viral Hepatitis2005;12(3):292‐9. ">Mangia 2005;</a><a href="./references#CD005441-bbs2-0005" title="DerbalaMF , KaabiSR , DweikNZ , PasicF , ButtMT , YakoobR , et al. Treatment of hepatitis C virus genotype 4 with pegylated interferon alpha 2a:Impact of bilharziasis and fibrosis stage. World Journal of Gastroenterology2006;12(35):5692‐8. ">Derbala 2006</a>), 4.5 MU (<a href="./references#CD005441-bbs2-0023" title="ShobokshiA , SerebourFE , SkakniL , Al‐JasserN , TantawiAO , SabahA , et al. Combination therapy of peginterferon alfa‐2a (40kD) (Pegasys(R)) and ribavirin (Copegus(R)) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia [AASLD abstract]. Hepatology2003;38(4 Suppl 1):636A. ShobokshiO , SerebourF , SkakniL , TantawiA , DinishT , Al QuaizM , et al. Efficacy of pegylated (40kDa) IFN alfa‐2a (Pegasys) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia. Journal of Hepatology2002;36(Suppl 1):129. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Early virological response at week 12 has positive predictive value for end of treatment response for hepatitis C virus genotype 4 chronic active hepatitis cases treated with combination therapy of pegylated interferon plus ribavirin. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Pegylated interferon alfa‐2a (40KDA) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ">Shobokshi 2003</a>), or 6 MU (<a href="./references#CD005441-bbs2-0003" title="CaritiG , AndreoniM , CalleriG , MancaA , RosinaF , SartoriM , et al. PEG‐INF alpha‐2A (40KD) plus ribavirin (RBV) vs IFN alpha‐2A (ROFERON‐A) in naive patients with chronic hepatitis C (CHC) and genotype 1 [AASLD abstract]. Hepatology2002;36(4 Pt 2):595A. ">Cariti 2002</a>; <a href="./references#CD005441-bbs2-0018" title="MangiaA , CiminoL , PersicoM , DemeliaL , RumiM , SpinziG , et al. Enhanced response to peginterferon‐alpha‐2a‐based triple therapy in previously non‐responsive chronic hepatitis C: final results of PRETTY study. Journal of Hepatology2005;42(2):200‐1. ">PRETTY 2005</a>), given thrice weekly. In the <a href="./references#CD005441-bbs2-0008" title="FargionS , BorzioM , CargnelA . End of treatment and sustained response to peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) (Copegus) and amantadine (AMA), and to induction therapy with interferon (IFN) alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponders with chronic hepatitis C (CHC) [AASLD abstract]. Hepatology2003;38(4 Suppl 1):733A. FargionS , BorzioM , CargnelA . Peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):139‐40. FargionS , BorzioM , CargnelA . Peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC) [AASLD abstract]. Hepatology2002;36(4 Pt 2):572A. FargionS , BorzioM , MaraschiA , CargnelA . Sustained virological response (SVR) to peginterferon alfa‐2a (40 kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC). Journal of Hepatology2004;40(Suppl 1):140. ">Fargion 2004</a> trial, participants were given interferon alpha‐2a 6 MU daily for four weeks, then 3 MU daily for an additional 20 weeks, and then 3 MU thrice weekly for an additional 24 weeks. In the <a href="./references#CD005441-bbs2-0017" title="NevensF , VanVlierbergheH , D'HeygereE , DelwaideJ , AdlerM , HenrionJ , et al. A randomised, open‐label, multicenter study evaluating the efficacy of peginterferon alfa‐2a versus interferon alfa‐2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients. Acta Gastroenterologica Belgica2010;73:223‐8. ">Nevens 2010</a> trial, participants were given interferon alpha‐2a at a dose of 6 MU for eight weeks, and then 3 MU for an additional 40 weeks. </p> <p>The dose of interferon alpha‐2b was 3 MU (<a href="./references#CD005441-bbs2-0015" title="ButiM , MedinaM , CasadoMA , WongJB , FosbrookL , EstebanR . A cost‐effectiveness analysis of peginterferon alfa‐2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Alimentary Pharmacology &amp; Therapeutics2003;17:687‐94. CondatB . Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b and ribavirin for the treatment of chronic hepatitis C: A randomized trial. Hepato‐Gastroenterology2002;9(2):141‐2. GishR , BzowejN , BrooksL , BrassC , WengW . Treatment with pegylated interferon alfa‐2b in combination with ribavirin improved health‐related quality of life compared with interferon alfa‐2b plus ribavirin in chronic hepatitis C [AASLD abstract]. Hepatology2002;36(4 Pt 2):582A. JenJ , LaughlinM , ChungC , HeftS , AffrimeMB , GuptaSK , et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic‐pharmacodynamic models. Clinical Pharmacology and Therapeutics2002;72(4):349‐61. MannsMP , McHutchisonJG , GordonS , RustgiV , ShiffmanML , LeeWM , et al. Peginterferon alfa‐2b plus ribavirin compared to interferon alfa‐2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [AASLD abstract]. Hepatology2000;32(4 Pt 2):297A. MannsMP , McHutchisonJG , GordonSC , RustgiVK , ShiffmanM , ReindollarR , et al. Peginterferon alfa‐2a plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001;358:958‐65. McHutchisonJ , MannsM , HarveyJ , AlbrechtJK . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peg‐interferon alfa‐2b plus ribavirin [abstract]. Journal of Hepatology2001;34(1):2‐3. McHutchisonJG , MannsM , PatelK , PoynardT , LindsayKL , TrepoC , et al. Adherence to combination therapy enhances sustained response in genotype‐1‐infected patients with chronic hepatitis C. Gastroenterology2002;123(4):1061‐9. McHutchisonJG , MannsMP , HarveyJ , GaraudJ‐J , AlbrechtJ . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peginterferon alfa 2b plus ribavirin. Hepatology2001;34(4 Pt 2):417A. McHutchisonJG , MannsMP , LingM‐H , AlbrechtJK . Peginterferon alfa‐2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factor for sustained virological response when ribavirin dose is expressed as mg/kg of body weight? [AASLD abstract]. Hepatology2001;34(4 Pt 2):329A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated‐interferon alpfa‐2b and ribavirin combination [AASLD abstract]. Hepatology2002;36(4 Pt 2):351A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa‐2b and ribavirin. Hepatology2003;38(2):481‐92. PoynardT , RatziuV , McHutchisonJ , MannsM , GoodmanZ , ZeuzemS , et al. Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology2003;38(1):75‐85. SiebertU , SroczynskiG , RossolS , WasemJ , Ravens‐SiebererU , KurthBM , et al. Cost effectiveness of peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C. Gut2003;52:425‐32. WongJB , DavisGL , McHutchisonJG , MannsMP , AlbrechtJK . Economic and clinical effects of evaluating rapid viral response to peginterferon alfa‐2b plus ribavirin for the initial treatment of chronic hepatitis C. American Journal of Gastroenterology2003;98(11):2354‐62. ">Manns 2001</a>; <a href="./references#CD005441-bbs2-0009" title="Bosques‐PadillaF , Trejo‐EstradaR , Campollo‐RivasO , Cortez‐HernandezC , Dehesa‐ViolanteM , Maldonado‐GarzaH , et al. Peginterferon alfa‐2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Annals of Hepatology2003;2(3):135‐9. FriedMW , ShiffmanML , ReddyKR , SmithC , MarinosG , GoncalesFLJr , et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine2002;347(13):975‐82. HassaneinT , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. The impact of peginterferon alfa‐2a plus ribavirin combination therapy on health‐related quality of life in chronic hepatitis C. Journal of Hepatology2004;40(4):675‐81. HassaneinTI , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. Treatment with 40 kDa peginterferon alfa‐2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alfa‐2b plus ribavirin [AASLD abstract]. Hepatology2001;34(4 Pt 2):243A. HassaneinTI , CooksleyWGE , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. QOL benefits observed as early as week 2 with peginterferon alfa‐2a (40kD) (Pegasys) in combination with ribavirin (RBV) versus interferon alfa‐2b plus RBV [EASL abstract]. Journal of Hepatology2002;36(1):110. HerrmannE , LeeJ‐H , MarinosG , ModiM , ZeuzemS . Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology2003;37(6):1351‐8. LutchmanG , HoofnagleJH . Viral kinetics in hepatitis C. Hepatology2003;37(6):1257‐9. SullivanSD , CraxiA , AlbertiA , GiulianiG , DeCarliC , WintfeldN , et al. Cost effectiveness of peginterferon alpha‐2a plus ribavirin versus interferon alpha‐2b plus ribavirin as initial therapy for treatment‐naive chronic hepatitis C. Pharmacoeconomics2004;22(4):257‐65. SullivanSD , GreenJ , PatelKK , CraxiA , AlbertiA , GiulianiG , et al. A comparison of cost‐effectiveness of peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (Copegus) vs interferon alfa‐2b plus ribavirin as first treatment of chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):174‐5. SullivanSD , JensenDM , BernsteinDE , HassaneinTI , FosterGR , LeeSS , et al. Cost‐effectiveness of combination peginterferon alpha‐2a and ribavirin compared with interferon alpha‐2b and ribavirin in patients with chronic hepatitis C. American Journal of Gastroenterology2004;99:1490‐6. ZeuzemS , HerrmannE , LeeJ‐H , MarinosG , ModiM , RothWK . Effect of ribavirin on viral kinetics in hepatitis C virus genotype 1 infected patients treated with pegylated interferon alpha2a [AASLD abstract]. Hepatology2001;34(4 Pt 2):558A. ">Fried 2002</a>; <a href="./references#CD005441-bbs2-0010" title="HinrichsenH , BuggischP , NasserS , FoelschUR . A prospective randomised 24 week trial of peg‐interferon alpha2b plus ribavirin versus standard combination therapy in untreated hepatitis C genotype 2 and 3 patients [AASLD abstract]. Hepatology2002;36(4 Pt 2):311A. ">Hinrichsen 2002</a>; <a href="./references#CD005441-bbs2-0007" title="EsmatGH , AbouziedA , Abdel‐HamidM , MohamedMK , ZalataK , ElRazikyMS , et al. Results of a randomized clinical trial of genotype‐4 infected subjects when treated with standard or pegylated interferon alfa‐2b in combination with ribavirin [AASLD abstract]. Hepatology2003;38(4 Suppl 1):314A‐315A. ">Esmat 2003</a>; <a href="./references#CD005441-bbs2-0001" title="AlfalehFZ , HadadQ , KhurooMS , AljumahA , AlgamediA , AlashgarH , et al. Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver International2004;24:568‐74. ">Al‐Faleh 2004</a>; <a href="./references#CD005441-bbs2-0013" title="LeeSD , YuML , ChengPN , LaiMY , ChaoYC , HwangSJ , et al. Comparison of a 6‐month course peginterferon alpha‐2b plus ribavirin and interferon alpha‐2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. Journal of Viral Hepatitis2005;12:283‐91. ">Lee 2005</a>; <a href="./references#CD005441-bbs2-0022" title="ScottoG , FazioV , PalumboE , CibelliDC , SaracinoA , AngaranoG . Treatment of genotype 1b HCV‐related chronic hepatitis: efficacy and toxicity of three different interferon alfa‐2b/ribavirin combined regimens in naive patients. New Microbiologica2005;28:23‐9. ">Scotto 2005</a>; <a href="./references#CD005441-bbs2-0027" title="WakilRM , MontasserMF , MansourMA , SalmanTA , El‐BatanonyMH , HelailEH , et al. Peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for treatment of chronic hepatitis C in treatment‐naive Egyptian patients. Journal of Clinical Virology2006;36:S142‐S143. ">Wakil 2006</a>), 5 MU (<a href="./references#CD005441-bbs2-0027" title="WakilRM , MontasserMF , MansourMA , SalmanTA , El‐BatanonyMH , HelailEH , et al. Peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for treatment of chronic hepatitis C in treatment‐naive Egyptian patients. Journal of Clinical Virology2006;36:S142‐S143. ">Wakil 2006</a>), or 6 MU (<a href="./references#CD005441-bbs2-0002" title="BrunoS , CammaC , DiMarcoV , RumiM , VinciM , CamozziM , et al. Peginterferon alfa‐2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. Journal of Hepatology2004;41:474‐81. BrunoS , CammaC , DiMarcoV , RumiMG , VinciM , CamozziM , et al. Chronic hepatitis C (CH‐C) genotype 1: an independent, multicenter RCT comparing PEG‐IFN alfa‐2b 12 kD plus ribavirin (RBV) and IFN alfa‐2b plus RBV in naive patients. Journal of Hepatology2003;38(Suppl 2):131‐2. ">Bruno 2004</a>; <a href="./references#CD005441-bbs2-0004" title="DerbalaM , AmerA , BenerB , LopezA , OmarM , ElGhannamM . Pegylated interferon‐alpha 2b‐ ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. Journal of Viral Hepatitis2005;12(4):380‐5. [DOI: 10.1111/j.1365‐2893.2005.00604.x] ">Derbala 2005</a>; <a href="./references#CD005441-bbs2-0022" title="ScottoG , FazioV , PalumboE , CibelliDC , SaracinoA , AngaranoG . Treatment of genotype 1b HCV‐related chronic hepatitis: efficacy and toxicity of three different interferon alfa‐2b/ribavirin combined regimens in naive patients. New Microbiologica2005;28:23‐9. ">Scotto 2005</a>), given thrice weekly. In one trial (<a href="./references#CD005441-bbs2-0012" title="IzumiN , AsahinaY , KurosakiM , UchiharaM , NishimuraY , InoueK , et al. A comparison of the exponential decay slope between PEG‐IFN alfa‐2b/ribavirin and IFN alfa‐2b/ribavirin combination therapy in patients with chronic hepatitis C. Intervirology2004;47:102‐7. ">Izumi 2004</a>), interferon alpha‐2b was given daily at a dose of 3 MU for the first two weeks, and then thrice weekly for an additional 46 weeks. In the <a href="./references#CD005441-bbs2-0026" title="TsubotaA , AraseY , SomeyaT , SuzukiY , SuzukiF , SaitohS , et al. Early viral kinetics and treatment outcome in combination of high‐dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. Journal of Medical Virology2005;75:27‐34. ">Tsubota 2005</a> trial, interferon alpha‐2b was given daily at a dose of 6 MU for the first two weeks, and then thrice weekly for an additional 46 weeks. In the <a href="./references#CD005441-bbs2-0002" title="BrunoS , CammaC , DiMarcoV , RumiM , VinciM , CamozziM , et al. Peginterferon alfa‐2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. Journal of Hepatology2004;41:474‐81. BrunoS , CammaC , DiMarcoV , RumiMG , VinciM , CamozziM , et al. Chronic hepatitis C (CH‐C) genotype 1: an independent, multicenter RCT comparing PEG‐IFN alfa‐2b 12 kD plus ribavirin (RBV) and IFN alfa‐2b plus RBV in naive patients. Journal of Hepatology2003;38(Suppl 2):131‐2. ">Bruno 2004</a> trial, peginterferon alpha‐2b 100 µg was given to participants weighing 65 kg or more, and 80 µg to those weighing less than 65 kg, for the first eight weeks, followed by a fixed dose of 50 µg for the next 40 weeks. </p> <p>The dose of consensus interferon was 9 µg (<a href="./references#CD005441-bbs2-0019" title="RahmanF , SchuchmannM , LohrHF , LinkR , BuggischP , FuchsM , et al. Daily consensus interferon versus peg‐interferon alfa2b with weight based or 800 mg ribavirin in treatment‐naive patients with chronic hepatitis C genotype 1. Hepatology2007;46(4 Suppl 1):826A. ">Rahman 2007a</a>; <a href="./references#CD005441-bbs2-0020" title="RahmanF , SchuchmannM , LohrHF , LinkR , BuggischP , FuchsM , et al. Daily consensus interferon versus peg‐interferon alfa2b with weight based or 800 mg ribavirin in treatment‐naive patients with chronic hepatitis C genotypes 2 or 3. Hepatology2007;46(4 Suppl 1):826A. ">Rahman 2007b</a>) or 15 µg (<a href="./references#CD005441-bbs2-0024" title="SjogrenMH , SjogrenR , LyonsMF , RyanM , SantoroJ , SmithC , et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Digestive Diseases and Sciences2007;52(6):1540‐7. ">Sjögren 2007</a>) for 48 weeks. In the <a href="./references#CD005441-bbs2-0006" title="DollingerMM , DridiY , LesskeJ , BehlS , FleigWE . Efficacy of daily consensus interferon and ribavirin compared to peg‐interferon alpha‐2B and interferon in non‐responders with chronic hepatitis C [AASLD abstract]. Hepatology2005;42(4 Suppl 1):691‐2. ">Dollinger 2005</a> trial, consensus interferon was given at a dose of 18 µg/d for six weeks followed by 9 µg/d for 42 weeks. </p> <p>In the <a href="./references#CD005441-bbs2-0019" title="RahmanF , SchuchmannM , LohrHF , LinkR , BuggischP , FuchsM , et al. Daily consensus interferon versus peg‐interferon alfa2b with weight based or 800 mg ribavirin in treatment‐naive patients with chronic hepatitis C genotype 1. Hepatology2007;46(4 Suppl 1):826A. ">Rahman 2007a</a> trial, consensus interferon was given at a dose of 27 to 18 µg once a day for 12 weeks followed by 9 µg once a day for 36 weeks.The dose of leucocyte interferon‐alpha was 6 MIU daily (<a href="./references#CD005441-bbs2-0016" title="NapoliN , GiannelliG , ParisiCV , AntonaciA , MaddalenaG , AntonaciS . Predictive value of early virological response to treatment with different interferon‐based regimens plus ribavirin in patients with chronic hepatitis C. New Microbiologica2005;28:13‐21. ">Napoli 2005</a>). </p> <p>Two trials (<a href="./references#CD005441-bbs2-0023" title="ShobokshiA , SerebourFE , SkakniL , Al‐JasserN , TantawiAO , SabahA , et al. Combination therapy of peginterferon alfa‐2a (40kD) (Pegasys(R)) and ribavirin (Copegus(R)) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia [AASLD abstract]. Hepatology2003;38(4 Suppl 1):636A. ShobokshiO , SerebourF , SkakniL , TantawiA , DinishT , Al QuaizM , et al. Efficacy of pegylated (40kDa) IFN alfa‐2a (Pegasys) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia. Journal of Hepatology2002;36(Suppl 1):129. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Early virological response at week 12 has positive predictive value for end of treatment response for hepatitis C virus genotype 4 chronic active hepatitis cases treated with combination therapy of pegylated interferon plus ribavirin. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Pegylated interferon alfa‐2a (40KDA) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ">Shobokshi 2003</a>; <a href="./references#CD005441-bbs2-0011" title="HorsmansY , ColleI , VanVlierbergheH , LangletP , AdlerM , BourgeoisN , et al. Weekly pegylated Interferon alpha‐2b vs daily interferon a‐2b versus standard regimen of Interferon a‐2b in the treatment of patients with chronic hepatitis C virus infection. Acto Gastro‐Enterologica Belgica2008;71(3):293‐7. ">Horsmans 2008</a>) included three intervention groups. In the first trial (<a href="./references#CD005441-bbs2-0023" title="ShobokshiA , SerebourFE , SkakniL , Al‐JasserN , TantawiAO , SabahA , et al. Combination therapy of peginterferon alfa‐2a (40kD) (Pegasys(R)) and ribavirin (Copegus(R)) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia [AASLD abstract]. Hepatology2003;38(4 Suppl 1):636A. ShobokshiO , SerebourF , SkakniL , TantawiA , DinishT , Al QuaizM , et al. Efficacy of pegylated (40kDa) IFN alfa‐2a (Pegasys) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia. Journal of Hepatology2002;36(Suppl 1):129. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Early virological response at week 12 has positive predictive value for end of treatment response for hepatitis C virus genotype 4 chronic active hepatitis cases treated with combination therapy of pegylated interferon plus ribavirin. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Pegylated interferon alfa‐2a (40KDA) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ">Shobokshi 2003</a>), group one was given peginterferon alpha‐2a 180 µg plus ribavirin 800 mg for 48 weeks (n = 60); group two was given peginterferon alpha‐2a 180 µg (n = 60); and group three was given interferon alpha‐2a 4.5 MU plus ribavirin 800 mg for 48 weeks (n = 60). In the second trial (<a href="./references#CD005441-bbs2-0011" title="HorsmansY , ColleI , VanVlierbergheH , LangletP , AdlerM , BourgeoisN , et al. Weekly pegylated Interferon alpha‐2b vs daily interferon a‐2b versus standard regimen of Interferon a‐2b in the treatment of patients with chronic hepatitis C virus infection. Acto Gastro‐Enterologica Belgica2008;71(3):293‐7. ">Horsmans 2008</a>), group one was given daily interferon alpha‐2b at a dose of 4 MIU for participants weighing more than 65 kg, and 0.06 MIU/kg for those weighing 65 kg or less; group two was given interferon alpha‐2b three times a week at a dose of 3 MIU; and group three was given peginterferon alpha‐2b at a dose of 100 mcg/wk for participants weighing more than 65 kg, and 1.5 mcg/kg/d for participants weighing 65 kg or less. Participants were followed up for 24 weeks after the end of treatment. </p> </section> <section id="CD005441-sec-0059"> <h5 class="title">Cointerventions in both intervention groups</h5> <p>The dose of ribavirin was 600 mg, 800 mg, 1000 mg, or 1200 mg daily, based on body weight. Three trials also administered amantadine hydrochloride 200 mg daily to both intervention groups (<a href="./references#CD005441-bbs2-0008" title="FargionS , BorzioM , CargnelA . End of treatment and sustained response to peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) (Copegus) and amantadine (AMA), and to induction therapy with interferon (IFN) alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponders with chronic hepatitis C (CHC) [AASLD abstract]. Hepatology2003;38(4 Suppl 1):733A. FargionS , BorzioM , CargnelA . Peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):139‐40. FargionS , BorzioM , CargnelA . Peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC) [AASLD abstract]. Hepatology2002;36(4 Pt 2):572A. FargionS , BorzioM , MaraschiA , CargnelA . Sustained virological response (SVR) to peginterferon alfa‐2a (40 kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC). Journal of Hepatology2004;40(Suppl 1):140. ">Fargion 2004</a>; <a href="./references#CD005441-bbs2-0014" title="MangiaA , RicciGL , PersicoM , MinervaN , CarettaV , BaccaD , et al. A randomized controlled trial of peginterferon alpha‐2a (40 kD) or interferon alpha‐2a plus ribavirin and amantadine vs interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C. Journal of Viral Hepatitis2005;12(3):292‐9. ">Mangia 2005</a>; <a href="./references#CD005441-bbs2-0018" title="MangiaA , CiminoL , PersicoM , DemeliaL , RumiM , SpinziG , et al. Enhanced response to peginterferon‐alpha‐2a‐based triple therapy in previously non‐responsive chronic hepatitis C: final results of PRETTY study. Journal of Hepatology2005;42(2):200‐1. ">PRETTY 2005</a>). </p> </section> </section> <section id="CD005441-sec-0060"> <h4 class="title">Excluded studies</h4> <p>Seven publications were excluded for the reasons shown in the <a href="./references#CD005441-sec-0091" title="">Characteristics of excluded studies</a> table (<a href="./references#CD005441-bbs2-0030" title="MaussS , ValentiW , DePamphilisJ , DuffF , CupelliL , PasseS , et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon‐based therapy. AIDS2004;18(13):F21‐F25. TorrianiFJ , RibeiroRM , GilbertTL , SchrenkUM , ClausonM , PachecoDM , et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. Journal of Infectious Diseases2003;188:1498‐507. TorrianiFJ , Rodriguez‐TorresM , RockstrohJK , LissenE , Gonzalez‐GarciaJ , LazzarinA , et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection in HIV‐infected patients. New England Journal of Medicine2004;351(5):438‐50. ">APRICOT 2004</a>; <a href="./references#CD005441-bbs2-0031" title="AsahinaY , IzumiN , OnukiY , UedaK , NishimuraY , NakanishiH , et al. Enhanced interferon (IFN)‐stimulated gene expression and HCV dynamics in patients treated with pegylated IFN alfa 2b and ribavirin: effect of pharmacokinetic change of IFN and ribavirin. Hepatology2004;40(4 Suppl 1):338A. ">Asahina 2004</a>; <a href="./references#CD005441-bbs2-0032" title="GromovaNI , BogomolovBP . Comparative efficacy of combined treatment with Intron a and Pegintron in combination with ribavirin in patients with chronic hepatitis C. Terapevticheskii Arkhiv2004;76(2):31‐5. ">Gromova 2004</a>; <a href="./references#CD005441-bbs2-0033" title="LagunoM , MurillasJ , BlancoJL , MartinezE , MiquelR , Sanchez‐TapiasJM , et al. Peginterferon alfa‐2b plus ribavirin compared with interferon alfa‐2b plus ribavirin for treatment of HIV/HCV co‐infected patients. AIDS2004;18(13):F27‐F36. ">Laguno 2004</a>; <a href="./references#CD005441-bbs2-0034" title="CarratF , Bani‐SadrF , PolS , RosenthalE , Lunel‐FabianiF , BenzekriA , et al. Pegylated interferon alfa‐2b vs standard interferon alfa‐2b, plus ribavirin, for chronic hepatitis C in HIV‐infected patients. JAMA2004;292(23):2839‐48. LunelF , PivertA , PayanC . Comparison of HCV RNA and HCV core antigen kinetics in the follow up of a therapeutic protocol in HCV‐HIV co‐infected patients (RIBAVIC). Journal of Hepatology2004;40(Suppl 1):144‐5. PolS , CarratF , Bani‐SadrF , RosenthalE , LunelF , MorandP , et al. Final results of ANRS HC02‐RIBAVIC: a randomized controlled trial of pegylated‐interferon alfa‐2b plus ribavirin vs interferon alfa‐2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co‐infected [AASLD abstract]. Hepatology2004;40(4):315A. PolS , CarratF , Bani‐SadrF , RosenthalE , LunelF , MorandP , et al. Final results of ANRS HC02‐RIBAVIC: a randomized controlled trial of pegylated‐interferon alpha‐2b plus ribavirin vs interferon alpha‐2b plus ribavirin for naive HCV‐HIV co‐infected patients. Journal of Hepatology2005;42(Suppl 2):10‐1. ">RIBAVIC 2004</a>; <a href="./references#CD005441-bbs2-0028" title="ChungRT , AndersenJ , VolberdingP , RobbinsGK , LiuT , ShermanKE , et al. Peginterferon alfa‐2a plus ribavirin versus interferon alfa‐2a plus ribavirin for chronic hepatitis C in HIV‐coinfected persons. New England Journal of Medicine2004;351(5):451‐9. ShermanKE , ShireNJ , RousterSD , PetersMG , KozielMJ , ChungRT , et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus‐infected patients. Gastroenterology2005;128(2):313‐27. ">ACTG 2005</a>; <a href="./references#CD005441-bbs2-0029" title="AliS , NazirG , KhanSA , IramS , FatimaF . Comparative therapeutic response to pegylated interferon plus ribavirin versus interferon alpha‐2b in chronic hepatitis C patients. Journal of Ayub Medical College2010;22:127‐30. ">Ali 2010</a>). </p> </section> </section> <section id="CD005441-sec-0061"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias was unclearly reported in a considerable number of included trials, hence giving them a high risk of bias (<a href="#CD005441-fig-0001">Figure 1</a>; <a href="#CD005441-fig-0002">Figure 2</a>). Fourteen trials reported adequate sequence generation (generation of the allocation sequence ) (e.g., computer‐generated random numbers, table of random numbers, minimisation). Fourteen trials used adequate allocation concealment (e.g., central independent unit, sealed opaque envelopes). None of the trials were blinded. It is unclear to what extent the outcome assessors or the participants were blinded; therefore, a risk of bias might be present in the registration of subjective outcome measures (e.g., diagnosis of complications, adverse events). Only one trial had adequate blinding for the outcome assessors for sustained virological response (<a href="./references#CD005441-bbs2-0024" title="SjogrenMH , SjogrenR , LyonsMF , RyanM , SantoroJ , SmithC , et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Digestive Diseases and Sciences2007;52(6):1540‐7. ">Sjögren 2007</a>). Nineteen trials addressed incomplete outcome data adequately. Protocols were not available for any of the included trials, but most trials reported on the primary outcomes of our review. Several trials had possible vested interest bias (<a href="./references#CD005441-bbs2-0015" title="ButiM , MedinaM , CasadoMA , WongJB , FosbrookL , EstebanR . A cost‐effectiveness analysis of peginterferon alfa‐2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Alimentary Pharmacology &amp; Therapeutics2003;17:687‐94. CondatB . Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b and ribavirin for the treatment of chronic hepatitis C: A randomized trial. Hepato‐Gastroenterology2002;9(2):141‐2. GishR , BzowejN , BrooksL , BrassC , WengW . Treatment with pegylated interferon alfa‐2b in combination with ribavirin improved health‐related quality of life compared with interferon alfa‐2b plus ribavirin in chronic hepatitis C [AASLD abstract]. Hepatology2002;36(4 Pt 2):582A. JenJ , LaughlinM , ChungC , HeftS , AffrimeMB , GuptaSK , et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic‐pharmacodynamic models. Clinical Pharmacology and Therapeutics2002;72(4):349‐61. MannsMP , McHutchisonJG , GordonS , RustgiV , ShiffmanML , LeeWM , et al. Peginterferon alfa‐2b plus ribavirin compared to interferon alfa‐2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [AASLD abstract]. Hepatology2000;32(4 Pt 2):297A. MannsMP , McHutchisonJG , GordonSC , RustgiVK , ShiffmanM , ReindollarR , et al. Peginterferon alfa‐2a plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001;358:958‐65. McHutchisonJ , MannsM , HarveyJ , AlbrechtJK . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peg‐interferon alfa‐2b plus ribavirin [abstract]. Journal of Hepatology2001;34(1):2‐3. McHutchisonJG , MannsM , PatelK , PoynardT , LindsayKL , TrepoC , et al. Adherence to combination therapy enhances sustained response in genotype‐1‐infected patients with chronic hepatitis C. Gastroenterology2002;123(4):1061‐9. McHutchisonJG , MannsMP , HarveyJ , GaraudJ‐J , AlbrechtJ . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peginterferon alfa 2b plus ribavirin. Hepatology2001;34(4 Pt 2):417A. McHutchisonJG , MannsMP , LingM‐H , AlbrechtJK . Peginterferon alfa‐2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factor for sustained virological response when ribavirin dose is expressed as mg/kg of body weight? [AASLD abstract]. Hepatology2001;34(4 Pt 2):329A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated‐interferon alpfa‐2b and ribavirin combination [AASLD abstract]. Hepatology2002;36(4 Pt 2):351A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa‐2b and ribavirin. Hepatology2003;38(2):481‐92. PoynardT , RatziuV , McHutchisonJ , MannsM , GoodmanZ , ZeuzemS , et al. Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology2003;38(1):75‐85. SiebertU , SroczynskiG , RossolS , WasemJ , Ravens‐SiebererU , KurthBM , et al. Cost effectiveness of peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C. Gut2003;52:425‐32. WongJB , DavisGL , McHutchisonJG , MannsMP , AlbrechtJK . Economic and clinical effects of evaluating rapid viral response to peginterferon alfa‐2b plus ribavirin for the initial treatment of chronic hepatitis C. American Journal of Gastroenterology2003;98(11):2354‐62. ">Manns 2001</a>; <a href="./references#CD005441-bbs2-0009" title="Bosques‐PadillaF , Trejo‐EstradaR , Campollo‐RivasO , Cortez‐HernandezC , Dehesa‐ViolanteM , Maldonado‐GarzaH , et al. Peginterferon alfa‐2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Annals of Hepatology2003;2(3):135‐9. FriedMW , ShiffmanML , ReddyKR , SmithC , MarinosG , GoncalesFLJr , et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine2002;347(13):975‐82. HassaneinT , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. The impact of peginterferon alfa‐2a plus ribavirin combination therapy on health‐related quality of life in chronic hepatitis C. Journal of Hepatology2004;40(4):675‐81. HassaneinTI , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. Treatment with 40 kDa peginterferon alfa‐2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alfa‐2b plus ribavirin [AASLD abstract]. Hepatology2001;34(4 Pt 2):243A. HassaneinTI , CooksleyWGE , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. QOL benefits observed as early as week 2 with peginterferon alfa‐2a (40kD) (Pegasys) in combination with ribavirin (RBV) versus interferon alfa‐2b plus RBV [EASL abstract]. Journal of Hepatology2002;36(1):110. HerrmannE , LeeJ‐H , MarinosG , ModiM , ZeuzemS . Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology2003;37(6):1351‐8. LutchmanG , HoofnagleJH . Viral kinetics in hepatitis C. Hepatology2003;37(6):1257‐9. SullivanSD , CraxiA , AlbertiA , GiulianiG , DeCarliC , WintfeldN , et al. Cost effectiveness of peginterferon alpha‐2a plus ribavirin versus interferon alpha‐2b plus ribavirin as initial therapy for treatment‐naive chronic hepatitis C. Pharmacoeconomics2004;22(4):257‐65. SullivanSD , GreenJ , PatelKK , CraxiA , AlbertiA , GiulianiG , et al. A comparison of cost‐effectiveness of peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (Copegus) vs interferon alfa‐2b plus ribavirin as first treatment of chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):174‐5. SullivanSD , JensenDM , BernsteinDE , HassaneinTI , FosterGR , LeeSS , et al. Cost‐effectiveness of combination peginterferon alpha‐2a and ribavirin compared with interferon alpha‐2b and ribavirin in patients with chronic hepatitis C. American Journal of Gastroenterology2004;99:1490‐6. ZeuzemS , HerrmannE , LeeJ‐H , MarinosG , ModiM , RothWK . Effect of ribavirin on viral kinetics in hepatitis C virus genotype 1 infected patients treated with pegylated interferon alpha2a [AASLD abstract]. Hepatology2001;34(4 Pt 2):558A. ">Fried 2002</a>; <a href="./references#CD005441-bbs2-0023" title="ShobokshiA , SerebourFE , SkakniL , Al‐JasserN , TantawiAO , SabahA , et al. Combination therapy of peginterferon alfa‐2a (40kD) (Pegasys(R)) and ribavirin (Copegus(R)) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia [AASLD abstract]. Hepatology2003;38(4 Suppl 1):636A. ShobokshiO , SerebourF , SkakniL , TantawiA , DinishT , Al QuaizM , et al. Efficacy of pegylated (40kDa) IFN alfa‐2a (Pegasys) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia. Journal of Hepatology2002;36(Suppl 1):129. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Early virological response at week 12 has positive predictive value for end of treatment response for hepatitis C virus genotype 4 chronic active hepatitis cases treated with combination therapy of pegylated interferon plus ribavirin. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Pegylated interferon alfa‐2a (40KDA) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ">Shobokshi 2003</a>; <a href="./references#CD005441-bbs2-0001" title="AlfalehFZ , HadadQ , KhurooMS , AljumahA , AlgamediA , AlashgarH , et al. Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver International2004;24:568‐74. ">Al‐Faleh 2004</a>; <a href="./references#CD005441-bbs2-0002" title="BrunoS , CammaC , DiMarcoV , RumiM , VinciM , CamozziM , et al. Peginterferon alfa‐2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. Journal of Hepatology2004;41:474‐81. BrunoS , CammaC , DiMarcoV , RumiMG , VinciM , CamozziM , et al. Chronic hepatitis C (CH‐C) genotype 1: an independent, multicenter RCT comparing PEG‐IFN alfa‐2b 12 kD plus ribavirin (RBV) and IFN alfa‐2b plus RBV in naive patients. Journal of Hepatology2003;38(Suppl 2):131‐2. ">Bruno 2004</a>; <a href="./references#CD005441-bbs2-0006" title="DollingerMM , DridiY , LesskeJ , BehlS , FleigWE . Efficacy of daily consensus interferon and ribavirin compared to peg‐interferon alpha‐2B and interferon in non‐responders with chronic hepatitis C [AASLD abstract]. Hepatology2005;42(4 Suppl 1):691‐2. ">Dollinger 2005</a>; <a href="./references#CD005441-bbs2-0013" title="LeeSD , YuML , ChengPN , LaiMY , ChaoYC , HwangSJ , et al. Comparison of a 6‐month course peginterferon alpha‐2b plus ribavirin and interferon alpha‐2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. Journal of Viral Hepatitis2005;12:283‐91. ">Lee 2005</a>; <a href="./references#CD005441-bbs2-0014" title="MangiaA , RicciGL , PersicoM , MinervaN , CarettaV , BaccaD , et al. A randomized controlled trial of peginterferon alpha‐2a (40 kD) or interferon alpha‐2a plus ribavirin and amantadine vs interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C. Journal of Viral Hepatitis2005;12(3):292‐9. ">Mangia 2005</a>; <a href="./references#CD005441-bbs2-0011" title="HorsmansY , ColleI , VanVlierbergheH , LangletP , AdlerM , BourgeoisN , et al. Weekly pegylated Interferon alpha‐2b vs daily interferon a‐2b versus standard regimen of Interferon a‐2b in the treatment of patients with chronic hepatitis C virus infection. Acto Gastro‐Enterologica Belgica2008;71(3):293‐7. ">Horsmans 2008</a>), and in the remainder, the risk of vested interest bias was unclear. The risk of bias was high in all of the trials from one or more domains. </p> <div class="figure" id="CD005441-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about all methodological quality items presented as percentages across all included studies." data-id="CD005441-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about all methodological quality items presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD005441-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD005441-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <p>Disregarding the risk of bias from lack of blinding and vested interests, we considered 14/27 trials (51.9%) as having a lower risk of bias according to the following domains: generation of the allocation sequence, allocation concealment, incomplete outcome reporting, and selective outcome reporting. </p> </section> <section id="CD005441-sec-0062"> <h3 class="title" id="CD005441-sec-0062">Effects of interventions</h3> <p>See: <a href="./full#CD005441-tbl-0001"><b>Summary of findings for the main comparison</b> Peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin for chronic hepatitis C</a> </p> <section id="CD005441-sec-0063"> <h4 class="title">Liver‐related morbidity plus all‐cause mortality</h4> <p>Four deaths (suicide (suspected drug overdose), ruptured oesophageal varices, traffic‐related, and unexplained) on peginterferon plus ribavirin versus three deaths (following surgery for colon cancer, hypertensive heart disease, and brain tumour) on interferon plus ribavirin were reported (<a href="./references#CD005441-fig-0008" title="">Analysis 1.1</a>). Two participants developed hepatocellular carcinoma, one on each intervention. No significant difference in liver‐related morbidity or all‐cause mortality was noted between participants receiving peginterferon plus ribavirin versus interferon plus ribavirin (Peto OR 1.14, 95% CI 0.38 to 3.42; five trials). </p> </section> <section id="CD005441-sec-0064"> <h4 class="title">Adverse events</h4> <p>Data from 17 trials yielded a non‐significant difference regarding adverse events leading to treatment discontinuation of peginterferon plus ribavirin when compared with interferon plus ribavirin (332/2692 (12.3%) versus 409/2176 (18.8%); RR 0.86, 95% CI 0.66 to 1.12; 17 trials). When RR was used as the association measure of intervention effect, the Cochrane homogeneity test statistic yielded a P value of 0.003, and the heterogeneity was I<sup>2</sup> = 56% (<a href="./references#CD005441-fig-0009" title="">Analysis 1.2</a>). Funnel plot visual inspection did not reveal significant evidence of publication bias (<a href="#CD005441-fig-0003">Figure 3</a>).<br/> <br/> Peginterferon plus ribavirin compared with interferon plus ribavirin significantly increased the risk of neutropenia (RR 2.15, 95% CI 1.76 to 2.61; 13 trials) (<a href="./references#CD005441-fig-0011" title="">Analysis 2.1</a>), thrombocytopenia (RR 2.63, 95% CI 1.68 to 4.11; 10 trials) (<a href="./references#CD005441-fig-0011" title="">Analysis 2.1</a>), arthralgia (RR 1.19, 95% CI 1.05 to 1.35; four trials) (<a href="./references#CD005441-fig-0014" title="">Analysis 2.4</a>), injection site reaction (RR 1.71, 95% CI 1.50 to 1.93; four trials) (<a href="./references#CD005441-fig-0014" title="">Analysis 2.4</a>; <a href="#CD005441-fig-0001">Figure 1</a>), or nausea (RR 1.13, 95% CI 1.01 to 1.26; four trials) (<a href="./references#CD005441-fig-0016" title="">Analysis 2.6</a>).<br/> <br/> The most frequent adverse event was fatigue, which overall occurred in 57% (2024/3608). No significant difference was seen between the effects of peginterferon plus ribavirin versus interferon plus ribavirin on fatigue (RR 1.01, 95% CI 0.96 to 1.07; 10 trials) (<a href="./references#CD005441-fig-0012" title="">Analysis 2.2</a>). No significant differences were noted between the two interventions regarding anaemia (<a href="./references#CD005441-fig-0011" title="">Analysis 2.1</a>), headache, rigours, myalgia, pyrexia, weight loss, asthenia (<a href="./references#CD005441-fig-0014" title="">Analysis 2.4</a>), depression, insomnia, irritability (<a href="./references#CD005441-fig-0013" title="">Analysis 2.3</a>), alopecia, pruritus, skin rash (<a href="./references#CD005441-fig-0014" title="">Analysis 2.4</a>), thyroid malfunction (<a href="./references#CD005441-fig-0015" title="">Analysis 2.5</a>), or regarding decreased appetite and diarrhoea (<a href="./references#CD005441-fig-0016" title="">Analysis 2.6</a>). </p> <div class="figure" id="CD005441-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin, outcome: 1.2 Adverse events leading to treatment discontinuation." data-id="CD005441-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin, outcome: 1.2 Adverse events leading to treatment discontinuation. </p> </div> </div> </div> </section> <section id="CD005441-sec-0065"> <h4 class="title">Quality of life</h4> <p>Only one trial reported quality of life in the Methods section (<a href="./references#CD005441-bbs2-0010" title="HinrichsenH , BuggischP , NasserS , FoelschUR . A prospective randomised 24 week trial of peg‐interferon alpha2b plus ribavirin versus standard combination therapy in untreated hepatitis C genotype 2 and 3 patients [AASLD abstract]. Hepatology2002;36(4 Pt 2):311A. ">Hinrichsen 2002</a>). This trial is published only as an abstract, and we could not find the data in the Results section. We contacted the study authors to ask for further information, but no answer has been received. </p> </section> <section id="CD005441-sec-0066"> <h4 class="title">Sustained virological response</h4> <p>Peginterferon plus ribavirin seems to significantly increase the number of participants achieving sustained virological response compared with interferon plus ribavirin (1673/3300 (50.7%) versus 1081/2804 (38.6%); RR 1.39, 95% CI 1. 25 to 1.56; I<sup>2</sup> = 64%; 27 trials) (<a href="./references#CD005441-fig-0010" title="">Analysis 1.3</a>; <a href="#CD005441-fig-0004">Figure 4</a>). When RR was used as the measure of effect, the Cochran homogeneity test statistic yielded a P value less than 0.00001 and the heterogeneity was I<sup>2</sup> = 64%. The estimated number needed to treat for an additional beneficial outcome to achieve an extra participant with sustained virological response is seven participants (95% CI 5 to 10 participants) with peginterferon plus ribavirin versus interferon plus ribavirin. Funnel plot visual inspection did not reveal significant risk of publication bias (<a href="#CD005441-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD005441-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: pegylated interferon plus ribavirin versus interferon plus ribavirin, outcome: 1.1 Sustained virological response." data-id="CD005441-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: pegylated interferon plus ribavirin versus interferon plus ribavirin, outcome: 1.1 Sustained virological response. </p> </div> </div> </div> <div class="figure" id="CD005441-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: pegylated interferon plus ribavirin versus interferon plus ribavirin, outcome: 1.1 Sustained virological response." data-id="CD005441-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: pegylated interferon plus ribavirin versus interferon plus ribavirin, outcome: 1.1 Sustained virological response. </p> </div> </div> </div> <p>Because this meta‐analysis did not reach its required information size of 14,486 participants based on the assumption of a maximum type I error of 5%, we used a trial sequential analysis to assess the statistical significance. Based on the assumption of a maximum type I error of 1%, the required information size was 20,513 participants. Again, the estimated effects were statistically significant in favour of peginterferon plus ribavirin (<a href="#CD005441-fig-0006">Figure 6</a>; <a href="#CD005441-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD005441-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Trial sequential analysis (TSA): pegylated interferon plus ribavirin versus interferon plus ribavirin ‐ sustained virological response.    Lan‐DeMets statistical monitoring boundaries for assessing statistical significance regarding sustained virological response to pegylated interferon plus ribavirin versus interferon plus ribavirin. The diversity‐adjusted required information size of n = 14,486 was calculated based on an event proportion of 50.6% of participants in the interferon‐treated group (Pc) with a risk ratio (RR) reduction of 10% in pegylated interferon group; an alpha (a, type I error) of 5%, a beta (b, type II error) of 10%, and the observed diversity D = 72%.    The solid blue curve presents the cumulative meta‐analysis test Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential boundaries. The cumulative Z‐score crosses the boundaries for superiority, and this corresponds with superiority of pegylated interferon." data-id="CD005441-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis (TSA): pegylated interferon plus ribavirin versus interferon plus ribavirin ‐ sustained virological response.<br/> <br/> Lan‐DeMets statistical monitoring boundaries for assessing statistical significance regarding sustained virological response to pegylated interferon plus ribavirin versus interferon plus ribavirin. The diversity‐adjusted required information size of n = 14,486 was calculated based on an event proportion of 50.6% of participants in the interferon‐treated group (Pc) with a risk ratio (RR) reduction of 10% in pegylated interferon group; an alpha (a, type I error) of 5%, a beta (b, type II error) of 10%, and the observed diversity D = 72%.<br/> <br/> The solid blue curve presents the cumulative meta‐analysis test Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential boundaries. The cumulative Z‐score crosses the boundaries for superiority, and this corresponds with superiority of pegylated interferon. </p> </div> </div> </div> <div class="figure" id="CD005441-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Trial sequential analysis (TSA): pegylated interferon plus ribavirin versus interferon plus ribavirin ‐ sustained virological response.    Lan‐DeMets statistical monitoring boundaries for assessing statistical significance regarding sustained virological response to pegylated interferon plus ribavirin versus interferon plus ribavirin. The diversity‐adjusted required information size of n = 20,513 was calculated based on an event proportion of 50.6% of participants in the interferon‐treated group (Pc) with a risk ratio (RR) reduction of 10% in the pegylated interferon group; an alpha (a, type I error) of 1%, a beta (b, type II error) of 10%, and the observed diversity D = 72%.    The solid blue curve presents the cumulative meta‐analysis test Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score crosses the boundaries for superiority, and this corresponds with the superiority of pegylated interferon." data-id="CD005441-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis (TSA): pegylated interferon plus ribavirin versus interferon plus ribavirin ‐ sustained virological response.<br/> <br/> Lan‐DeMets statistical monitoring boundaries for assessing statistical significance regarding sustained virological response to pegylated interferon plus ribavirin versus interferon plus ribavirin. The diversity‐adjusted required information size of n = 20,513 was calculated based on an event proportion of 50.6% of participants in the interferon‐treated group (Pc) with a risk ratio (RR) reduction of 10% in the pegylated interferon group; an alpha (a, type I error) of 1%, a beta (b, type II error) of 10%, and the observed diversity D = 72%.<br/> <br/> The solid blue curve presents the cumulative meta‐analysis test Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score crosses the boundaries for superiority, and this corresponds with the superiority of pegylated interferon. </p> </div> </div> </div> <p>Subgroup analyses showed pronounced differences in comparative treatment effects according to the genotype of the virus (<a href="./references#CD005441-fig-0019" title="">Analysis 3.3</a>). Data from 16 trials (<a href="./references#CD005441-bbs2-0015" title="ButiM , MedinaM , CasadoMA , WongJB , FosbrookL , EstebanR . A cost‐effectiveness analysis of peginterferon alfa‐2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Alimentary Pharmacology &amp; Therapeutics2003;17:687‐94. CondatB . Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b and ribavirin for the treatment of chronic hepatitis C: A randomized trial. Hepato‐Gastroenterology2002;9(2):141‐2. GishR , BzowejN , BrooksL , BrassC , WengW . Treatment with pegylated interferon alfa‐2b in combination with ribavirin improved health‐related quality of life compared with interferon alfa‐2b plus ribavirin in chronic hepatitis C [AASLD abstract]. Hepatology2002;36(4 Pt 2):582A. JenJ , LaughlinM , ChungC , HeftS , AffrimeMB , GuptaSK , et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic‐pharmacodynamic models. Clinical Pharmacology and Therapeutics2002;72(4):349‐61. MannsMP , McHutchisonJG , GordonS , RustgiV , ShiffmanML , LeeWM , et al. Peginterferon alfa‐2b plus ribavirin compared to interferon alfa‐2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [AASLD abstract]. Hepatology2000;32(4 Pt 2):297A. MannsMP , McHutchisonJG , GordonSC , RustgiVK , ShiffmanM , ReindollarR , et al. Peginterferon alfa‐2a plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001;358:958‐65. McHutchisonJ , MannsM , HarveyJ , AlbrechtJK . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peg‐interferon alfa‐2b plus ribavirin [abstract]. Journal of Hepatology2001;34(1):2‐3. McHutchisonJG , MannsM , PatelK , PoynardT , LindsayKL , TrepoC , et al. Adherence to combination therapy enhances sustained response in genotype‐1‐infected patients with chronic hepatitis C. Gastroenterology2002;123(4):1061‐9. McHutchisonJG , MannsMP , HarveyJ , GaraudJ‐J , AlbrechtJ . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peginterferon alfa 2b plus ribavirin. Hepatology2001;34(4 Pt 2):417A. McHutchisonJG , MannsMP , LingM‐H , AlbrechtJK . Peginterferon alfa‐2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factor for sustained virological response when ribavirin dose is expressed as mg/kg of body weight? [AASLD abstract]. Hepatology2001;34(4 Pt 2):329A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated‐interferon alpfa‐2b and ribavirin combination [AASLD abstract]. Hepatology2002;36(4 Pt 2):351A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa‐2b and ribavirin. Hepatology2003;38(2):481‐92. PoynardT , RatziuV , McHutchisonJ , MannsM , GoodmanZ , ZeuzemS , et al. Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology2003;38(1):75‐85. SiebertU , SroczynskiG , RossolS , WasemJ , Ravens‐SiebererU , KurthBM , et al. Cost effectiveness of peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C. Gut2003;52:425‐32. WongJB , DavisGL , McHutchisonJG , MannsMP , AlbrechtJK . Economic and clinical effects of evaluating rapid viral response to peginterferon alfa‐2b plus ribavirin for the initial treatment of chronic hepatitis C. American Journal of Gastroenterology2003;98(11):2354‐62. ">Manns 2001</a>; <a href="./references#CD005441-bbs2-0003" title="CaritiG , AndreoniM , CalleriG , MancaA , RosinaF , SartoriM , et al. PEG‐INF alpha‐2A (40KD) plus ribavirin (RBV) vs IFN alpha‐2A (ROFERON‐A) in naive patients with chronic hepatitis C (CHC) and genotype 1 [AASLD abstract]. Hepatology2002;36(4 Pt 2):595A. ">Cariti 2002</a>; <a href="./references#CD005441-bbs2-0009" title="Bosques‐PadillaF , Trejo‐EstradaR , Campollo‐RivasO , Cortez‐HernandezC , Dehesa‐ViolanteM , Maldonado‐GarzaH , et al. Peginterferon alfa‐2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Annals of Hepatology2003;2(3):135‐9. FriedMW , ShiffmanML , ReddyKR , SmithC , MarinosG , GoncalesFLJr , et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine2002;347(13):975‐82. HassaneinT , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. The impact of peginterferon alfa‐2a plus ribavirin combination therapy on health‐related quality of life in chronic hepatitis C. Journal of Hepatology2004;40(4):675‐81. HassaneinTI , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. Treatment with 40 kDa peginterferon alfa‐2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alfa‐2b plus ribavirin [AASLD abstract]. Hepatology2001;34(4 Pt 2):243A. HassaneinTI , CooksleyWGE , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. QOL benefits observed as early as week 2 with peginterferon alfa‐2a (40kD) (Pegasys) in combination with ribavirin (RBV) versus interferon alfa‐2b plus RBV [EASL abstract]. Journal of Hepatology2002;36(1):110. HerrmannE , LeeJ‐H , MarinosG , ModiM , ZeuzemS . Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology2003;37(6):1351‐8. LutchmanG , HoofnagleJH . Viral kinetics in hepatitis C. Hepatology2003;37(6):1257‐9. SullivanSD , CraxiA , AlbertiA , GiulianiG , DeCarliC , WintfeldN , et al. Cost effectiveness of peginterferon alpha‐2a plus ribavirin versus interferon alpha‐2b plus ribavirin as initial therapy for treatment‐naive chronic hepatitis C. Pharmacoeconomics2004;22(4):257‐65. SullivanSD , GreenJ , PatelKK , CraxiA , AlbertiA , GiulianiG , et al. A comparison of cost‐effectiveness of peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (Copegus) vs interferon alfa‐2b plus ribavirin as first treatment of chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):174‐5. SullivanSD , JensenDM , BernsteinDE , HassaneinTI , FosterGR , LeeSS , et al. Cost‐effectiveness of combination peginterferon alpha‐2a and ribavirin compared with interferon alpha‐2b and ribavirin in patients with chronic hepatitis C. American Journal of Gastroenterology2004;99:1490‐6. ZeuzemS , HerrmannE , LeeJ‐H , MarinosG , ModiM , RothWK . Effect of ribavirin on viral kinetics in hepatitis C virus genotype 1 infected patients treated with pegylated interferon alpha2a [AASLD abstract]. Hepatology2001;34(4 Pt 2):558A. ">Fried 2002</a>; <a href="./references#CD005441-bbs2-0002" title="BrunoS , CammaC , DiMarcoV , RumiM , VinciM , CamozziM , et al. Peginterferon alfa‐2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. Journal of Hepatology2004;41:474‐81. BrunoS , CammaC , DiMarcoV , RumiMG , VinciM , CamozziM , et al. Chronic hepatitis C (CH‐C) genotype 1: an independent, multicenter RCT comparing PEG‐IFN alfa‐2b 12 kD plus ribavirin (RBV) and IFN alfa‐2b plus RBV in naive patients. Journal of Hepatology2003;38(Suppl 2):131‐2. ">Bruno 2004</a>; <a href="./references#CD005441-bbs2-0012" title="IzumiN , AsahinaY , KurosakiM , UchiharaM , NishimuraY , InoueK , et al. A comparison of the exponential decay slope between PEG‐IFN alfa‐2b/ribavirin and IFN alfa‐2b/ribavirin combination therapy in patients with chronic hepatitis C. Intervirology2004;47:102‐7. ">Izumi 2004</a>; <a href="./references#CD005441-bbs2-0006" title="DollingerMM , DridiY , LesskeJ , BehlS , FleigWE . Efficacy of daily consensus interferon and ribavirin compared to peg‐interferon alpha‐2B and interferon in non‐responders with chronic hepatitis C [AASLD abstract]. Hepatology2005;42(4 Suppl 1):691‐2. ">Dollinger 2005</a>; <a href="./references#CD005441-bbs2-0013" title="LeeSD , YuML , ChengPN , LaiMY , ChaoYC , HwangSJ , et al. Comparison of a 6‐month course peginterferon alpha‐2b plus ribavirin and interferon alpha‐2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. Journal of Viral Hepatitis2005;12:283‐91. ">Lee 2005</a>; <a href="./references#CD005441-bbs2-0014" title="MangiaA , RicciGL , PersicoM , MinervaN , CarettaV , BaccaD , et al. A randomized controlled trial of peginterferon alpha‐2a (40 kD) or interferon alpha‐2a plus ribavirin and amantadine vs interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C. Journal of Viral Hepatitis2005;12(3):292‐9. ">Mangia 2005</a>; <a href="./references#CD005441-bbs2-0016" title="NapoliN , GiannelliG , ParisiCV , AntonaciA , MaddalenaG , AntonaciS . Predictive value of early virological response to treatment with different interferon‐based regimens plus ribavirin in patients with chronic hepatitis C. New Microbiologica2005;28:13‐21. ">Napoli 2005</a>; <a href="./references#CD005441-bbs2-0018" title="MangiaA , CiminoL , PersicoM , DemeliaL , RumiM , SpinziG , et al. Enhanced response to peginterferon‐alpha‐2a‐based triple therapy in previously non‐responsive chronic hepatitis C: final results of PRETTY study. Journal of Hepatology2005;42(2):200‐1. ">PRETTY 2005</a>; <a href="./references#CD005441-bbs2-0022" title="ScottoG , FazioV , PalumboE , CibelliDC , SaracinoA , AngaranoG . Treatment of genotype 1b HCV‐related chronic hepatitis: efficacy and toxicity of three different interferon alfa‐2b/ribavirin combined regimens in naive patients. New Microbiologica2005;28:23‐9. ">Scotto 2005</a>; <a href="./references#CD005441-bbs2-0026" title="TsubotaA , AraseY , SomeyaT , SuzukiY , SuzukiF , SaitohS , et al. Early viral kinetics and treatment outcome in combination of high‐dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. Journal of Medical Virology2005;75:27‐34. ">Tsubota 2005</a>; <a href="./references#CD005441-bbs2-0019" title="RahmanF , SchuchmannM , LohrHF , LinkR , BuggischP , FuchsM , et al. Daily consensus interferon versus peg‐interferon alfa2b with weight based or 800 mg ribavirin in treatment‐naive patients with chronic hepatitis C genotype 1. Hepatology2007;46(4 Suppl 1):826A. ">Rahman 2007a</a>; <a href="./references#CD005441-bbs2-0024" title="SjogrenMH , SjogrenR , LyonsMF , RyanM , SantoroJ , SmithC , et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Digestive Diseases and Sciences2007;52(6):1540‐7. ">Sjögren 2007</a>; <a href="./references#CD005441-bbs2-0021" title="RoffiL , ColloredoG , DelPoggioP , FornaciariG , CastagnettiE , CerianiR , et al. Efficacy and safety of low doses of interferon (IFN) alfa‐2b plus ribavirin (RBV) in advanced HCV related liver disease [AASLD abstract]. Hepatology2004;40(4 Suppl 1):322A. RoffiL , ColloredoG , PioltelliP , BellatiG , PozzpiM , ParraviciniP , et al. Pegylated interferon‐alpha2b plus ribavirin: an efficacious and well‐tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antiviral Therapy2008;13(5):663‐73. ">Roffi 2008</a>; <a href="./references#CD005441-bbs2-0017" title="NevensF , VanVlierbergheH , D'HeygereE , DelwaideJ , AdlerM , HenrionJ , et al. A randomised, open‐label, multicenter study evaluating the efficacy of peginterferon alfa‐2a versus interferon alfa‐2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients. Acta Gastroenterologica Belgica2010;73:223‐8. ">Nevens 2010</a>) for genotype one yielded RR 1.47, 95% CI 1.27 to 1.70, when the random‐effects model was used. Data from nine trials (<a href="./references#CD005441-bbs2-0015" title="ButiM , MedinaM , CasadoMA , WongJB , FosbrookL , EstebanR . A cost‐effectiveness analysis of peginterferon alfa‐2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Alimentary Pharmacology &amp; Therapeutics2003;17:687‐94. CondatB . Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b and ribavirin for the treatment of chronic hepatitis C: A randomized trial. Hepato‐Gastroenterology2002;9(2):141‐2. GishR , BzowejN , BrooksL , BrassC , WengW . Treatment with pegylated interferon alfa‐2b in combination with ribavirin improved health‐related quality of life compared with interferon alfa‐2b plus ribavirin in chronic hepatitis C [AASLD abstract]. Hepatology2002;36(4 Pt 2):582A. JenJ , LaughlinM , ChungC , HeftS , AffrimeMB , GuptaSK , et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic‐pharmacodynamic models. Clinical Pharmacology and Therapeutics2002;72(4):349‐61. MannsMP , McHutchisonJG , GordonS , RustgiV , ShiffmanML , LeeWM , et al. Peginterferon alfa‐2b plus ribavirin compared to interferon alfa‐2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [AASLD abstract]. Hepatology2000;32(4 Pt 2):297A. MannsMP , McHutchisonJG , GordonSC , RustgiVK , ShiffmanM , ReindollarR , et al. Peginterferon alfa‐2a plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001;358:958‐65. McHutchisonJ , MannsM , HarveyJ , AlbrechtJK . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peg‐interferon alfa‐2b plus ribavirin [abstract]. Journal of Hepatology2001;34(1):2‐3. McHutchisonJG , MannsM , PatelK , PoynardT , LindsayKL , TrepoC , et al. Adherence to combination therapy enhances sustained response in genotype‐1‐infected patients with chronic hepatitis C. Gastroenterology2002;123(4):1061‐9. McHutchisonJG , MannsMP , HarveyJ , GaraudJ‐J , AlbrechtJ . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peginterferon alfa 2b plus ribavirin. Hepatology2001;34(4 Pt 2):417A. McHutchisonJG , MannsMP , LingM‐H , AlbrechtJK . Peginterferon alfa‐2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factor for sustained virological response when ribavirin dose is expressed as mg/kg of body weight? [AASLD abstract]. Hepatology2001;34(4 Pt 2):329A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated‐interferon alpfa‐2b and ribavirin combination [AASLD abstract]. Hepatology2002;36(4 Pt 2):351A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa‐2b and ribavirin. Hepatology2003;38(2):481‐92. PoynardT , RatziuV , McHutchisonJ , MannsM , GoodmanZ , ZeuzemS , et al. Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology2003;38(1):75‐85. SiebertU , SroczynskiG , RossolS , WasemJ , Ravens‐SiebererU , KurthBM , et al. Cost effectiveness of peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C. Gut2003;52:425‐32. WongJB , DavisGL , McHutchisonJG , MannsMP , AlbrechtJK . Economic and clinical effects of evaluating rapid viral response to peginterferon alfa‐2b plus ribavirin for the initial treatment of chronic hepatitis C. American Journal of Gastroenterology2003;98(11):2354‐62. ">Manns 2001</a>; <a href="./references#CD005441-bbs2-0009" title="Bosques‐PadillaF , Trejo‐EstradaR , Campollo‐RivasO , Cortez‐HernandezC , Dehesa‐ViolanteM , Maldonado‐GarzaH , et al. Peginterferon alfa‐2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Annals of Hepatology2003;2(3):135‐9. FriedMW , ShiffmanML , ReddyKR , SmithC , MarinosG , GoncalesFLJr , et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine2002;347(13):975‐82. HassaneinT , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. The impact of peginterferon alfa‐2a plus ribavirin combination therapy on health‐related quality of life in chronic hepatitis C. Journal of Hepatology2004;40(4):675‐81. HassaneinTI , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. Treatment with 40 kDa peginterferon alfa‐2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alfa‐2b plus ribavirin [AASLD abstract]. Hepatology2001;34(4 Pt 2):243A. HassaneinTI , CooksleyWGE , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. QOL benefits observed as early as week 2 with peginterferon alfa‐2a (40kD) (Pegasys) in combination with ribavirin (RBV) versus interferon alfa‐2b plus RBV [EASL abstract]. Journal of Hepatology2002;36(1):110. HerrmannE , LeeJ‐H , MarinosG , ModiM , ZeuzemS . Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology2003;37(6):1351‐8. LutchmanG , HoofnagleJH . Viral kinetics in hepatitis C. Hepatology2003;37(6):1257‐9. SullivanSD , CraxiA , AlbertiA , GiulianiG , DeCarliC , WintfeldN , et al. Cost effectiveness of peginterferon alpha‐2a plus ribavirin versus interferon alpha‐2b plus ribavirin as initial therapy for treatment‐naive chronic hepatitis C. Pharmacoeconomics2004;22(4):257‐65. SullivanSD , GreenJ , PatelKK , CraxiA , AlbertiA , GiulianiG , et al. A comparison of cost‐effectiveness of peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (Copegus) vs interferon alfa‐2b plus ribavirin as first treatment of chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):174‐5. SullivanSD , JensenDM , BernsteinDE , HassaneinTI , FosterGR , LeeSS , et al. Cost‐effectiveness of combination peginterferon alpha‐2a and ribavirin compared with interferon alpha‐2b and ribavirin in patients with chronic hepatitis C. American Journal of Gastroenterology2004;99:1490‐6. ZeuzemS , HerrmannE , LeeJ‐H , MarinosG , ModiM , RothWK . Effect of ribavirin on viral kinetics in hepatitis C virus genotype 1 infected patients treated with pegylated interferon alpha2a [AASLD abstract]. Hepatology2001;34(4 Pt 2):558A. ">Fried 2002</a>; <a href="./references#CD005441-bbs2-0010" title="HinrichsenH , BuggischP , NasserS , FoelschUR . A prospective randomised 24 week trial of peg‐interferon alpha2b plus ribavirin versus standard combination therapy in untreated hepatitis C genotype 2 and 3 patients [AASLD abstract]. Hepatology2002;36(4 Pt 2):311A. ">Hinrichsen 2002</a>; <a href="./references#CD005441-bbs2-0008" title="FargionS , BorzioM , CargnelA . End of treatment and sustained response to peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) (Copegus) and amantadine (AMA), and to induction therapy with interferon (IFN) alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponders with chronic hepatitis C (CHC) [AASLD abstract]. Hepatology2003;38(4 Suppl 1):733A. FargionS , BorzioM , CargnelA . Peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):139‐40. FargionS , BorzioM , CargnelA . Peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC) [AASLD abstract]. Hepatology2002;36(4 Pt 2):572A. FargionS , BorzioM , MaraschiA , CargnelA . Sustained virological response (SVR) to peginterferon alfa‐2a (40 kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC). Journal of Hepatology2004;40(Suppl 1):140. ">Fargion 2004</a>; <a href="./references#CD005441-bbs2-0014" title="MangiaA , RicciGL , PersicoM , MinervaN , CarettaV , BaccaD , et al. A randomized controlled trial of peginterferon alpha‐2a (40 kD) or interferon alpha‐2a plus ribavirin and amantadine vs interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C. Journal of Viral Hepatitis2005;12(3):292‐9. ">Mangia 2005</a>; <a href="./references#CD005441-bbs2-0016" title="NapoliN , GiannelliG , ParisiCV , AntonaciA , MaddalenaG , AntonaciS . Predictive value of early virological response to treatment with different interferon‐based regimens plus ribavirin in patients with chronic hepatitis C. New Microbiologica2005;28:13‐21. ">Napoli 2005</a>; <a href="./references#CD005441-bbs2-0020" title="RahmanF , SchuchmannM , LohrHF , LinkR , BuggischP , FuchsM , et al. Daily consensus interferon versus peg‐interferon alfa2b with weight based or 800 mg ribavirin in treatment‐naive patients with chronic hepatitis C genotypes 2 or 3. Hepatology2007;46(4 Suppl 1):826A. ">Rahman 2007b</a>; <a href="./references#CD005441-bbs2-0011" title="HorsmansY , ColleI , VanVlierbergheH , LangletP , AdlerM , BourgeoisN , et al. Weekly pegylated Interferon alpha‐2b vs daily interferon a‐2b versus standard regimen of Interferon a‐2b in the treatment of patients with chronic hepatitis C virus infection. Acto Gastro‐Enterologica Belgica2008;71(3):293‐7. ">Horsmans 2008</a>; <a href="./references#CD005441-bbs2-0021" title="RoffiL , ColloredoG , DelPoggioP , FornaciariG , CastagnettiE , CerianiR , et al. Efficacy and safety of low doses of interferon (IFN) alfa‐2b plus ribavirin (RBV) in advanced HCV related liver disease [AASLD abstract]. Hepatology2004;40(4 Suppl 1):322A. RoffiL , ColloredoG , PioltelliP , BellatiG , PozzpiM , ParraviciniP , et al. Pegylated interferon‐alpha2b plus ribavirin: an efficacious and well‐tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antiviral Therapy2008;13(5):663‐73. ">Roffi 2008</a>) for genotype two or three yielded RR 1.10, 95% CI 1.03 to 1.19, when the random‐effects model was used. Data from nine trials (<a href="./references#CD005441-bbs2-0015" title="ButiM , MedinaM , CasadoMA , WongJB , FosbrookL , EstebanR . A cost‐effectiveness analysis of peginterferon alfa‐2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Alimentary Pharmacology &amp; Therapeutics2003;17:687‐94. CondatB . Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b and ribavirin for the treatment of chronic hepatitis C: A randomized trial. Hepato‐Gastroenterology2002;9(2):141‐2. GishR , BzowejN , BrooksL , BrassC , WengW . Treatment with pegylated interferon alfa‐2b in combination with ribavirin improved health‐related quality of life compared with interferon alfa‐2b plus ribavirin in chronic hepatitis C [AASLD abstract]. Hepatology2002;36(4 Pt 2):582A. JenJ , LaughlinM , ChungC , HeftS , AffrimeMB , GuptaSK , et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic‐pharmacodynamic models. Clinical Pharmacology and Therapeutics2002;72(4):349‐61. MannsMP , McHutchisonJG , GordonS , RustgiV , ShiffmanML , LeeWM , et al. Peginterferon alfa‐2b plus ribavirin compared to interferon alfa‐2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [AASLD abstract]. Hepatology2000;32(4 Pt 2):297A. MannsMP , McHutchisonJG , GordonSC , RustgiVK , ShiffmanM , ReindollarR , et al. Peginterferon alfa‐2a plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001;358:958‐65. McHutchisonJ , MannsM , HarveyJ , AlbrechtJK . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peg‐interferon alfa‐2b plus ribavirin [abstract]. Journal of Hepatology2001;34(1):2‐3. McHutchisonJG , MannsM , PatelK , PoynardT , LindsayKL , TrepoC , et al. Adherence to combination therapy enhances sustained response in genotype‐1‐infected patients with chronic hepatitis C. Gastroenterology2002;123(4):1061‐9. McHutchisonJG , MannsMP , HarveyJ , GaraudJ‐J , AlbrechtJ . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peginterferon alfa 2b plus ribavirin. Hepatology2001;34(4 Pt 2):417A. McHutchisonJG , MannsMP , LingM‐H , AlbrechtJK . Peginterferon alfa‐2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factor for sustained virological response when ribavirin dose is expressed as mg/kg of body weight? [AASLD abstract]. Hepatology2001;34(4 Pt 2):329A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated‐interferon alpfa‐2b and ribavirin combination [AASLD abstract]. Hepatology2002;36(4 Pt 2):351A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa‐2b and ribavirin. Hepatology2003;38(2):481‐92. PoynardT , RatziuV , McHutchisonJ , MannsM , GoodmanZ , ZeuzemS , et al. Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology2003;38(1):75‐85. SiebertU , SroczynskiG , RossolS , WasemJ , Ravens‐SiebererU , KurthBM , et al. Cost effectiveness of peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C. Gut2003;52:425‐32. WongJB , DavisGL , McHutchisonJG , MannsMP , AlbrechtJK . Economic and clinical effects of evaluating rapid viral response to peginterferon alfa‐2b plus ribavirin for the initial treatment of chronic hepatitis C. American Journal of Gastroenterology2003;98(11):2354‐62. ">Manns 2001</a>; <a href="./references#CD005441-bbs2-0009" title="Bosques‐PadillaF , Trejo‐EstradaR , Campollo‐RivasO , Cortez‐HernandezC , Dehesa‐ViolanteM , Maldonado‐GarzaH , et al. Peginterferon alfa‐2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Annals of Hepatology2003;2(3):135‐9. FriedMW , ShiffmanML , ReddyKR , SmithC , MarinosG , GoncalesFLJr , et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine2002;347(13):975‐82. HassaneinT , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. The impact of peginterferon alfa‐2a plus ribavirin combination therapy on health‐related quality of life in chronic hepatitis C. Journal of Hepatology2004;40(4):675‐81. HassaneinTI , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. Treatment with 40 kDa peginterferon alfa‐2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alfa‐2b plus ribavirin [AASLD abstract]. Hepatology2001;34(4 Pt 2):243A. HassaneinTI , CooksleyWGE , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. QOL benefits observed as early as week 2 with peginterferon alfa‐2a (40kD) (Pegasys) in combination with ribavirin (RBV) versus interferon alfa‐2b plus RBV [EASL abstract]. Journal of Hepatology2002;36(1):110. HerrmannE , LeeJ‐H , MarinosG , ModiM , ZeuzemS . Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology2003;37(6):1351‐8. LutchmanG , HoofnagleJH . Viral kinetics in hepatitis C. Hepatology2003;37(6):1257‐9. SullivanSD , CraxiA , AlbertiA , GiulianiG , DeCarliC , WintfeldN , et al. Cost effectiveness of peginterferon alpha‐2a plus ribavirin versus interferon alpha‐2b plus ribavirin as initial therapy for treatment‐naive chronic hepatitis C. Pharmacoeconomics2004;22(4):257‐65. SullivanSD , GreenJ , PatelKK , CraxiA , AlbertiA , GiulianiG , et al. A comparison of cost‐effectiveness of peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (Copegus) vs interferon alfa‐2b plus ribavirin as first treatment of chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):174‐5. SullivanSD , JensenDM , BernsteinDE , HassaneinTI , FosterGR , LeeSS , et al. Cost‐effectiveness of combination peginterferon alpha‐2a and ribavirin compared with interferon alpha‐2b and ribavirin in patients with chronic hepatitis C. American Journal of Gastroenterology2004;99:1490‐6. ZeuzemS , HerrmannE , LeeJ‐H , MarinosG , ModiM , RothWK . Effect of ribavirin on viral kinetics in hepatitis C virus genotype 1 infected patients treated with pegylated interferon alpha2a [AASLD abstract]. Hepatology2001;34(4 Pt 2):558A. ">Fried 2002</a>; <a href="./references#CD005441-bbs2-0007" title="EsmatGH , AbouziedA , Abdel‐HamidM , MohamedMK , ZalataK , ElRazikyMS , et al. Results of a randomized clinical trial of genotype‐4 infected subjects when treated with standard or pegylated interferon alfa‐2b in combination with ribavirin [AASLD abstract]. Hepatology2003;38(4 Suppl 1):314A‐315A. ">Esmat 2003</a>; <a href="./references#CD005441-bbs2-0023" title="ShobokshiA , SerebourFE , SkakniL , Al‐JasserN , TantawiAO , SabahA , et al. Combination therapy of peginterferon alfa‐2a (40kD) (Pegasys(R)) and ribavirin (Copegus(R)) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia [AASLD abstract]. Hepatology2003;38(4 Suppl 1):636A. ShobokshiO , SerebourF , SkakniL , TantawiA , DinishT , Al QuaizM , et al. Efficacy of pegylated (40kDa) IFN alfa‐2a (Pegasys) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia. Journal of Hepatology2002;36(Suppl 1):129. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Early virological response at week 12 has positive predictive value for end of treatment response for hepatitis C virus genotype 4 chronic active hepatitis cases treated with combination therapy of pegylated interferon plus ribavirin. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Pegylated interferon alfa‐2a (40KDA) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ">Shobokshi 2003</a>; <a href="./references#CD005441-bbs2-0025" title="ThakebFIA , OmarMM , ElAwadyMM , IsshakSY . Randomized controlled trial of peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus‐genotype 4 among Egyptian patients [AASLD abstract]. Hepatology2003;38(4 Suppl 1):278A. ">Thakeb 2003</a>; <a href="./references#CD005441-bbs2-0001" title="AlfalehFZ , HadadQ , KhurooMS , AljumahA , AlgamediA , AlashgarH , et al. Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver International2004;24:568‐74. ">Al‐Faleh 2004</a>; <a href="./references#CD005441-bbs2-0004" title="DerbalaM , AmerA , BenerB , LopezA , OmarM , ElGhannamM . Pegylated interferon‐alpha 2b‐ ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. Journal of Viral Hepatitis2005;12(4):380‐5. [DOI: 10.1111/j.1365‐2893.2005.00604.x] ">Derbala 2005</a>; <a href="./references#CD005441-bbs2-0005" title="DerbalaMF , KaabiSR , DweikNZ , PasicF , ButtMT , YakoobR , et al. Treatment of hepatitis C virus genotype 4 with pegylated interferon alpha 2a:Impact of bilharziasis and fibrosis stage. World Journal of Gastroenterology2006;12(35):5692‐8. ">Derbala 2006</a>; <a href="./references#CD005441-bbs2-0027" title="WakilRM , MontasserMF , MansourMA , SalmanTA , El‐BatanonyMH , HelailEH , et al. Peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for treatment of chronic hepatitis C in treatment‐naive Egyptian patients. Journal of Clinical Virology2006;36:S142‐S143. ">Wakil 2006</a>) for genotype four yielded RR 1.76, 95% CI 1.30 to 2.39, when the random‐effects model was used. These differences were substantiated by tests of interaction that yielded statistically significant differences between genotype one and genotype two or three (P value &lt; 0.002) and between genotype two or three and genotype four (P value &lt; 0.029). </p> <p>Subgroup analyses showed a pronounced difference in comparative treatment effects by type of peginterferon (<a href="./references#CD005441-fig-0021" title="">Analysis 3.5</a>; <a href="./references#CD005441-fig-0022" title="">Analysis 3.6</a>). Data from nine trials (<a href="./references#CD005441-bbs2-0003" title="CaritiG , AndreoniM , CalleriG , MancaA , RosinaF , SartoriM , et al. PEG‐INF alpha‐2A (40KD) plus ribavirin (RBV) vs IFN alpha‐2A (ROFERON‐A) in naive patients with chronic hepatitis C (CHC) and genotype 1 [AASLD abstract]. Hepatology2002;36(4 Pt 2):595A. ">Cariti 2002</a>; <a href="./references#CD005441-bbs2-0009" title="Bosques‐PadillaF , Trejo‐EstradaR , Campollo‐RivasO , Cortez‐HernandezC , Dehesa‐ViolanteM , Maldonado‐GarzaH , et al. Peginterferon alfa‐2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Annals of Hepatology2003;2(3):135‐9. FriedMW , ShiffmanML , ReddyKR , SmithC , MarinosG , GoncalesFLJr , et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine2002;347(13):975‐82. HassaneinT , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. The impact of peginterferon alfa‐2a plus ribavirin combination therapy on health‐related quality of life in chronic hepatitis C. Journal of Hepatology2004;40(4):675‐81. HassaneinTI , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. Treatment with 40 kDa peginterferon alfa‐2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alfa‐2b plus ribavirin [AASLD abstract]. Hepatology2001;34(4 Pt 2):243A. HassaneinTI , CooksleyWGE , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. QOL benefits observed as early as week 2 with peginterferon alfa‐2a (40kD) (Pegasys) in combination with ribavirin (RBV) versus interferon alfa‐2b plus RBV [EASL abstract]. Journal of Hepatology2002;36(1):110. HerrmannE , LeeJ‐H , MarinosG , ModiM , ZeuzemS . Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology2003;37(6):1351‐8. LutchmanG , HoofnagleJH . Viral kinetics in hepatitis C. Hepatology2003;37(6):1257‐9. SullivanSD , CraxiA , AlbertiA , GiulianiG , DeCarliC , WintfeldN , et al. Cost effectiveness of peginterferon alpha‐2a plus ribavirin versus interferon alpha‐2b plus ribavirin as initial therapy for treatment‐naive chronic hepatitis C. Pharmacoeconomics2004;22(4):257‐65. SullivanSD , GreenJ , PatelKK , CraxiA , AlbertiA , GiulianiG , et al. A comparison of cost‐effectiveness of peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (Copegus) vs interferon alfa‐2b plus ribavirin as first treatment of chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):174‐5. SullivanSD , JensenDM , BernsteinDE , HassaneinTI , FosterGR , LeeSS , et al. Cost‐effectiveness of combination peginterferon alpha‐2a and ribavirin compared with interferon alpha‐2b and ribavirin in patients with chronic hepatitis C. American Journal of Gastroenterology2004;99:1490‐6. ZeuzemS , HerrmannE , LeeJ‐H , MarinosG , ModiM , RothWK . Effect of ribavirin on viral kinetics in hepatitis C virus genotype 1 infected patients treated with pegylated interferon alpha2a [AASLD abstract]. Hepatology2001;34(4 Pt 2):558A. ">Fried 2002</a>; <a href="./references#CD005441-bbs2-0023" title="ShobokshiA , SerebourFE , SkakniL , Al‐JasserN , TantawiAO , SabahA , et al. Combination therapy of peginterferon alfa‐2a (40kD) (Pegasys(R)) and ribavirin (Copegus(R)) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia [AASLD abstract]. Hepatology2003;38(4 Suppl 1):636A. ShobokshiO , SerebourF , SkakniL , TantawiA , DinishT , Al QuaizM , et al. Efficacy of pegylated (40kDa) IFN alfa‐2a (Pegasys) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia. Journal of Hepatology2002;36(Suppl 1):129. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Early virological response at week 12 has positive predictive value for end of treatment response for hepatitis C virus genotype 4 chronic active hepatitis cases treated with combination therapy of pegylated interferon plus ribavirin. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ShobokshiO , SerebourFE , SkakniL , Al‐JaserN , TantaweAO , SabahA , et al. Pegylated interferon alfa‐2a (40KDA) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients. Saudi Medical Journal2003;24(Suppl 2):S92‐S93. ">Shobokshi 2003</a>; <a href="./references#CD005441-bbs2-0025" title="ThakebFIA , OmarMM , ElAwadyMM , IsshakSY . Randomized controlled trial of peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus‐genotype 4 among Egyptian patients [AASLD abstract]. Hepatology2003;38(4 Suppl 1):278A. ">Thakeb 2003</a>; <a href="./references#CD005441-bbs2-0008" title="FargionS , BorzioM , CargnelA . End of treatment and sustained response to peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) (Copegus) and amantadine (AMA), and to induction therapy with interferon (IFN) alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponders with chronic hepatitis C (CHC) [AASLD abstract]. Hepatology2003;38(4 Suppl 1):733A. FargionS , BorzioM , CargnelA . Peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):139‐40. FargionS , BorzioM , CargnelA . Peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC) [AASLD abstract]. Hepatology2002;36(4 Pt 2):572A. FargionS , BorzioM , MaraschiA , CargnelA . Sustained virological response (SVR) to peginterferon alfa‐2a (40 kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa‐2a (Roferon‐A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC). Journal of Hepatology2004;40(Suppl 1):140. ">Fargion 2004</a>; <a href="./references#CD005441-bbs2-0014" title="MangiaA , RicciGL , PersicoM , MinervaN , CarettaV , BaccaD , et al. A randomized controlled trial of peginterferon alpha‐2a (40 kD) or interferon alpha‐2a plus ribavirin and amantadine vs interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C. Journal of Viral Hepatitis2005;12(3):292‐9. ">Mangia 2005</a>; <a href="./references#CD005441-bbs2-0018" title="MangiaA , CiminoL , PersicoM , DemeliaL , RumiM , SpinziG , et al. Enhanced response to peginterferon‐alpha‐2a‐based triple therapy in previously non‐responsive chronic hepatitis C: final results of PRETTY study. Journal of Hepatology2005;42(2):200‐1. ">PRETTY 2005</a>; <a href="./references#CD005441-bbs2-0005" title="DerbalaMF , KaabiSR , DweikNZ , PasicF , ButtMT , YakoobR , et al. Treatment of hepatitis C virus genotype 4 with pegylated interferon alpha 2a:Impact of bilharziasis and fibrosis stage. World Journal of Gastroenterology2006;12(35):5692‐8. ">Derbala 2006</a>; <a href="./references#CD005441-bbs2-0017" title="NevensF , VanVlierbergheH , D'HeygereE , DelwaideJ , AdlerM , HenrionJ , et al. A randomised, open‐label, multicenter study evaluating the efficacy of peginterferon alfa‐2a versus interferon alfa‐2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients. Acta Gastroenterologica Belgica2010;73:223‐8. ">Nevens 2010</a>) assessing peginterferon alpha‐2a yielded RR 1.85 (95% CI 1.46 to 2.35) by using the random‐effects model. Data from 18 trials (<a href="./references#CD005441-bbs2-0015" title="ButiM , MedinaM , CasadoMA , WongJB , FosbrookL , EstebanR . A cost‐effectiveness analysis of peginterferon alfa‐2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Alimentary Pharmacology &amp; Therapeutics2003;17:687‐94. CondatB . Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b and ribavirin for the treatment of chronic hepatitis C: A randomized trial. Hepato‐Gastroenterology2002;9(2):141‐2. GishR , BzowejN , BrooksL , BrassC , WengW . Treatment with pegylated interferon alfa‐2b in combination with ribavirin improved health‐related quality of life compared with interferon alfa‐2b plus ribavirin in chronic hepatitis C [AASLD abstract]. Hepatology2002;36(4 Pt 2):582A. JenJ , LaughlinM , ChungC , HeftS , AffrimeMB , GuptaSK , et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic‐pharmacodynamic models. Clinical Pharmacology and Therapeutics2002;72(4):349‐61. MannsMP , McHutchisonJG , GordonS , RustgiV , ShiffmanML , LeeWM , et al. Peginterferon alfa‐2b plus ribavirin compared to interferon alfa‐2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [AASLD abstract]. Hepatology2000;32(4 Pt 2):297A. MannsMP , McHutchisonJG , GordonSC , RustgiVK , ShiffmanM , ReindollarR , et al. Peginterferon alfa‐2a plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001;358:958‐65. McHutchisonJ , MannsM , HarveyJ , AlbrechtJK . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peg‐interferon alfa‐2b plus ribavirin [abstract]. Journal of Hepatology2001;34(1):2‐3. McHutchisonJG , MannsM , PatelK , PoynardT , LindsayKL , TrepoC , et al. Adherence to combination therapy enhances sustained response in genotype‐1‐infected patients with chronic hepatitis C. Gastroenterology2002;123(4):1061‐9. McHutchisonJG , MannsMP , HarveyJ , GaraudJ‐J , AlbrechtJ . Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peginterferon alfa 2b plus ribavirin. Hepatology2001;34(4 Pt 2):417A. McHutchisonJG , MannsMP , LingM‐H , AlbrechtJK . Peginterferon alfa‐2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factor for sustained virological response when ribavirin dose is expressed as mg/kg of body weight? [AASLD abstract]. Hepatology2001;34(4 Pt 2):329A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated‐interferon alpfa‐2b and ribavirin combination [AASLD abstract]. Hepatology2002;36(4 Pt 2):351A. PoynardT , McHutchisonJ , MannsM , MyersRP , AlbrechtJ . Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa‐2b and ribavirin. Hepatology2003;38(2):481‐92. PoynardT , RatziuV , McHutchisonJ , MannsM , GoodmanZ , ZeuzemS , et al. Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology2003;38(1):75‐85. SiebertU , SroczynskiG , RossolS , WasemJ , Ravens‐SiebererU , KurthBM , et al. Cost effectiveness of peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C. Gut2003;52:425‐32. WongJB , DavisGL , McHutchisonJG , MannsMP , AlbrechtJK . Economic and clinical effects of evaluating rapid viral response to peginterferon alfa‐2b plus ribavirin for the initial treatment of chronic hepatitis C. American Journal of Gastroenterology2003;98(11):2354‐62. ">Manns 2001</a>; <a href="./references#CD005441-bbs2-0010" title="HinrichsenH , BuggischP , NasserS , FoelschUR . A prospective randomised 24 week trial of peg‐interferon alpha2b plus ribavirin versus standard combination therapy in untreated hepatitis C genotype 2 and 3 patients [AASLD abstract]. Hepatology2002;36(4 Pt 2):311A. ">Hinrichsen 2002</a>; <a href="./references#CD005441-bbs2-0007" title="EsmatGH , AbouziedA , Abdel‐HamidM , MohamedMK , ZalataK , ElRazikyMS , et al. Results of a randomized clinical trial of genotype‐4 infected subjects when treated with standard or pegylated interferon alfa‐2b in combination with ribavirin [AASLD abstract]. Hepatology2003;38(4 Suppl 1):314A‐315A. ">Esmat 2003</a>; <a href="./references#CD005441-bbs2-0001" title="AlfalehFZ , HadadQ , KhurooMS , AljumahA , AlgamediA , AlashgarH , et al. Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver International2004;24:568‐74. ">Al‐Faleh 2004</a>; <a href="./references#CD005441-bbs2-0002" title="BrunoS , CammaC , DiMarcoV , RumiM , VinciM , CamozziM , et al. Peginterferon alfa‐2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. Journal of Hepatology2004;41:474‐81. BrunoS , CammaC , DiMarcoV , RumiMG , VinciM , CamozziM , et al. Chronic hepatitis C (CH‐C) genotype 1: an independent, multicenter RCT comparing PEG‐IFN alfa‐2b 12 kD plus ribavirin (RBV) and IFN alfa‐2b plus RBV in naive patients. Journal of Hepatology2003;38(Suppl 2):131‐2. ">Bruno 2004</a>; <a href="./references#CD005441-bbs2-0012" title="IzumiN , AsahinaY , KurosakiM , UchiharaM , NishimuraY , InoueK , et al. A comparison of the exponential decay slope between PEG‐IFN alfa‐2b/ribavirin and IFN alfa‐2b/ribavirin combination therapy in patients with chronic hepatitis C. Intervirology2004;47:102‐7. ">Izumi 2004</a>; <a href="./references#CD005441-bbs2-0004" title="DerbalaM , AmerA , BenerB , LopezA , OmarM , ElGhannamM . Pegylated interferon‐alpha 2b‐ ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. Journal of Viral Hepatitis2005;12(4):380‐5. [DOI: 10.1111/j.1365‐2893.2005.00604.x] ">Derbala 2005</a>; <a href="./references#CD005441-bbs2-0006" title="DollingerMM , DridiY , LesskeJ , BehlS , FleigWE . Efficacy of daily consensus interferon and ribavirin compared to peg‐interferon alpha‐2B and interferon in non‐responders with chronic hepatitis C [AASLD abstract]. Hepatology2005;42(4 Suppl 1):691‐2. ">Dollinger 2005</a>; <a href="./references#CD005441-bbs2-0013" title="LeeSD , YuML , ChengPN , LaiMY , ChaoYC , HwangSJ , et al. Comparison of a 6‐month course peginterferon alpha‐2b plus ribavirin and interferon alpha‐2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. Journal of Viral Hepatitis2005;12:283‐91. ">Lee 2005</a>; <a href="./references#CD005441-bbs2-0016" title="NapoliN , GiannelliG , ParisiCV , AntonaciA , MaddalenaG , AntonaciS . Predictive value of early virological response to treatment with different interferon‐based regimens plus ribavirin in patients with chronic hepatitis C. New Microbiologica2005;28:13‐21. ">Napoli 2005</a>; <a href="./references#CD005441-bbs2-0022" title="ScottoG , FazioV , PalumboE , CibelliDC , SaracinoA , AngaranoG . Treatment of genotype 1b HCV‐related chronic hepatitis: efficacy and toxicity of three different interferon alfa‐2b/ribavirin combined regimens in naive patients. New Microbiologica2005;28:23‐9. ">Scotto 2005</a>; <a href="./references#CD005441-bbs2-0026" title="TsubotaA , AraseY , SomeyaT , SuzukiY , SuzukiF , SaitohS , et al. Early viral kinetics and treatment outcome in combination of high‐dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. Journal of Medical Virology2005;75:27‐34. ">Tsubota 2005</a>; <a href="./references#CD005441-bbs2-0027" title="WakilRM , MontasserMF , MansourMA , SalmanTA , El‐BatanonyMH , HelailEH , et al. Peginterferon alpha‐2b plus ribavirin versus interferon alpha‐2b plus ribavirin for treatment of chronic hepatitis C in treatment‐naive Egyptian patients. Journal of Clinical Virology2006;36:S142‐S143. ">Wakil 2006</a>; <a href="./references#CD005441-bbs2-0019" title="RahmanF , SchuchmannM , LohrHF , LinkR , BuggischP , FuchsM , et al. Daily consensus interferon versus peg‐interferon alfa2b with weight based or 800 mg ribavirin in treatment‐naive patients with chronic hepatitis C genotype 1. Hepatology2007;46(4 Suppl 1):826A. ">Rahman 2007a</a>; <a href="./references#CD005441-bbs2-0020" title="RahmanF , SchuchmannM , LohrHF , LinkR , BuggischP , FuchsM , et al. Daily consensus interferon versus peg‐interferon alfa2b with weight based or 800 mg ribavirin in treatment‐naive patients with chronic hepatitis C genotypes 2 or 3. Hepatology2007;46(4 Suppl 1):826A. ">Rahman 2007b</a>; <a href="./references#CD005441-bbs2-0024" title="SjogrenMH , SjogrenR , LyonsMF , RyanM , SantoroJ , SmithC , et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Digestive Diseases and Sciences2007;52(6):1540‐7. ">Sjögren 2007</a>; <a href="./references#CD005441-bbs2-0011" title="HorsmansY , ColleI , VanVlierbergheH , LangletP , AdlerM , BourgeoisN , et al. Weekly pegylated Interferon alpha‐2b vs daily interferon a‐2b versus standard regimen of Interferon a‐2b in the treatment of patients with chronic hepatitis C virus infection. Acto Gastro‐Enterologica Belgica2008;71(3):293‐7. ">Horsmans 2008</a>; <a href="./references#CD005441-bbs2-0021" title="RoffiL , ColloredoG , DelPoggioP , FornaciariG , CastagnettiE , CerianiR , et al. Efficacy and safety of low doses of interferon (IFN) alfa‐2b plus ribavirin (RBV) in advanced HCV related liver disease [AASLD abstract]. Hepatology2004;40(4 Suppl 1):322A. RoffiL , ColloredoG , PioltelliP , BellatiG , PozzpiM , ParraviciniP , et al. Pegylated interferon‐alpha2b plus ribavirin: an efficacious and well‐tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antiviral Therapy2008;13(5):663‐73. ">Roffi 2008</a>) assessing peginterferon alpha‐2b yielded RR 1.14, 95% CI 1.06 to 1.22, when the random‐effects model was used. These differences were substantiated by tests of interaction that yielded statistically significant differences between peginterferon alpha‐2a plus ribavirin and peginterferon alpha‐2b plus ribavirin (P &lt; 0.001). </p> <p>Subgroup analyses on risk of bias (<a href="./references#CD005441-fig-0017" title="">Analysis 3.1</a>), treatment history (<a href="./references#CD005441-fig-0018" title="">Analysis 3.2</a>), and baseline viral load (<a href="./references#CD005441-fig-0020" title="">Analysis 3.4</a>) using RR as the measure of effect yielded similar results favouring peginterferon over interferon. Tests of interactions of the latter subgroup analyses were non‐significant. </p> <p>A sensitivity analysis from which we excluded the three trials in which amantadine was used as triple therapy in both the peginterferon plus ribavirin group and the interferon plus ribavirin group yielded similar significant results favouring peginterferon (<a href="./references#CD005441-fig-0023" title="">Analysis 3.7</a>). </p> </section> <section id="CD005441-sec-0067"> <h4 class="title">Summary of findings table</h4> <p>We prepared a Summary of Findings (SoFs) table for all outcomes but one, ie, quality of life (<a href="./full#CD005441-tbl-0001">summary of findings Table for the main comparison</a>). The SoFs table presents that we can have low confidence in the current evidence on harms measured as morbidity plus mortality and adverse events leading to treatment discontinuation. The meta‐analysis on morbidity plus mortality showed a very serious imprecision because only nine events were included in the meta‐analysis with five trials. In the meta‐analysis on adverse events, serious discrepancies across trials and lack of precision were evident. The proportions of observed adverse events differ substantially across the trials, and the direction of effect is heterogeneous. However, because the event proportion is still relatively low across the trials, all included trials may be subject to a considerable risk of random errors, thus explaining the apparent heterogeneity in direction of estimates. The observed treatment effects differ in magnitude as well, but most confidence intervals show considerable overlap. In addition, we can have a very low confidence in the current evidence on treatment benefits measured as sustained virological response. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005441-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005441-sec-0068"></div> <section id="CD005441-sec-0069"> <h3 class="title" id="CD005441-sec-0069">Summary of main results</h3> <p>A major obstacle to treatment and patient compliance is the association of combined antiviral therapy with frequent and sometimes serious adverse events. Timely recognition of adverse events has a crucial role in the continuation of antiviral therapy with a hope for successful virological treatment results. In clinical trials, approximately 10% to 15% of participants discontinue peginterferon and ribavirin therapy because of adverse effects; in clinical practice, the rate of treatment discontinuation has been reported as substantially higher (<a href="./references#CD005441-bbs2-0099" title="SulkowskiMS , CooperC , HunyadyB , JiaJ , OgurtsovP , Peck‐RadosavljevicM , et al. Management of adverse effects of Peg‐IFN and ribavirin therapy for hepatitis C. Nature Reviews. Gastroenterology &amp; Hepatology2011;8:212‐23. ">Sulkowski 2011</a>). The adverse effects of combined antiviral therapy are numerous and can be observed in many organ systems. The most common adverse effects are haematological, dermatological, neurological, immunological, gastrointestinal, pulmonary, cardiovascular, and ocular (<a href="./references#CD005441-bbs2-0099" title="SulkowskiMS , CooperC , HunyadyB , JiaJ , OgurtsovP , Peck‐RadosavljevicM , et al. Management of adverse effects of Peg‐IFN and ribavirin therapy for hepatitis C. Nature Reviews. Gastroenterology &amp; Hepatology2011;8:212‐23. ">Sulkowski 2011</a>). We are lacking data on direct comparisons of different types of interferons. Among the most frequent adverse effects is myelosuppression. Neutrophil count decreases by an average of 34% (<a href="./references#CD005441-bbs2-0097" title="SozaA , EverhartJE , GhanyMG , DooE , HellerT , PromratK , et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology2002;36:1273‐9. ">Soza 2002</a>), and mean platelet drop is around 42% (<a href="./references#CD005441-bbs2-0085" title="RoomerR , HansenBE , JanssenHL , deKnegtRJ . Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Journal of Hepatology2010;53:455‐9. ">Roomer 2010</a>). Regarding haemoglobin levels, more than 50% of participants experienced a decrease in haemoglobin to around 30 g/L. Women are more prone to experiencing a haemoglobin level less than 100 g/L (<a href="./references#CD005441-bbs2-0098" title="SulkowskiMS , WassermanR , BrooksL , BallL , GishR . Changes in haemoglobin during interferon alpha‐2b plus ribavirin combination therapy for chronic hepatitis C virus infection. Journal of Viral Hepatitis2004;11:243‐50. ">Sulkowski 2004</a>). Many of those adverse effects usually require only adjustment of antiviral therapy. In some patients, application of growth factors is needed because of haematological disturbances. Psychiatric disturbances and mood alterations associated with long‐term interferon therapy are well described. In some trials (<a href="./references#CD005441-bbs2-0047" title="ConstantA , CasteraL , DantzerR , CouzigouP , deLedinghenV , Demotes‐MainardJ , et al. Mood alterations during interferon‐alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. Journal of Clinical Psychiatry2005;66:105‐23. ">Constant 2005</a>), mood alterations occurred in 32% of participants, and significant depressive symptoms were noted in 21% to 58% of participants (<a href="./references#CD005441-bbs2-0082" title="RaisonCL , DemetrashviliM , CapuronL , MillerAH . Neuropsychiatric adverse effects of interferon‐alpha: recognition and management. CNS Drugs2005;19:105‐23. ">Raison 2005</a>). Retinopathy associated with pegylated interferon therapy has been reported in 21% of participants, but the vast majority of participants recovered without cessation of treatment (<a href="./references#CD005441-bbs2-0075" title="LimJW , ShinMC . Pegylated‐interferon‐associated retinopathy in chronic hepatitis patients. Ophtalmologica2010;224:224‐9. ">Lim 2010</a>). Among the rare adverse events that could be linked to combined antiviral therapy are some potentially fatal disorders that are usually reported as case reports. Pulmonary complications such as pneumonitis and pulmonary hypertension are rare but require early detection and premature cessation of antiviral therapy (<a href="./references#CD005441-bbs2-0074" title="KumarKS , RussoMW , BorczukAC , BrownM , EspositoSP , LobrittoSJ , et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. American Journal of Gastroenterology2002;97:2432‐40. ">Kumar 2002</a>; <a href="./references#CD005441-bbs2-0052" title="DhillonS , KakerA , DosanjhA , JapraD , VanthielDH . Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Digestive Diseases and Sciences2010;55:1785‐90. ">Dhillon 2010</a>; <a href="./references#CD005441-bbs2-0096" title="SlavenburgS , HeijdraYF , DrenthJP . Pneumonitis as a consequence of (peg)interferon‐ribavirin combination therapy for hepatitis C: a review of the literature. Digestive Diseases and Sciences2010;55:579‐85. ">Slavenburg 2010</a>). In one trial, mortality secondary to pneumonitis was seen exclusively with peginterferon alpha‐2b (<a href="./references#CD005441-bbs2-0096" title="SlavenburgS , HeijdraYF , DrenthJP . Pneumonitis as a consequence of (peg)interferon‐ribavirin combination therapy for hepatitis C: a review of the literature. Digestive Diseases and Sciences2010;55:579‐85. ">Slavenburg 2010</a>). </p> <p>In this systematic review, we have summarised the available evidence from randomised clinical trials comparing peginterferon alpha versus interferon alpha, both given in combination with ribavirin. Because of the high risk of bias in the trials, our results seem to suggest that the combination of peginterferon plus ribavirin is associated with a moderate or low beneficial effect on sustained virological response when compared with interferon plus ribavirin. Our results show that evidence on liver‐related morbidity plus all‐cause mortality is sparse, and that the meta‐analysis is underpowered to detect any difference in risk of liver‐related morbidity plus all‐cause mortality. However, regarding adverse events, the two regimens seem to differ significantly, with interferon plus ribavirin causing less harm than peginterferon plus ribavirin. </p> <p>Both peginterferon alpha‐2a and peginterferon alpha‐2b plus ribavirin were superior in terms of sustained virological response when compared with interferon plus ribavirin for participants with chronic hepatitis. Our subgroup analyses demonstrated that peginterferon alpha‐2a was associated with a significantly higher sustained virological response than peginterferon alpha‐2b versus interferon. This indirect observation is in harmony with our previous observations from head‐to‐head trials that peginterferon alpha‐2a leads to sustained virological response in a greater number of participants than is seen with peginterferon alpha‐2b (<a href="./references#CD005441-bbs2-0037" title="AwadT , ThorlundK , HauserG , StimacD , MabroukM , GluudC . Peginterferon alpha‐2a is associated with higher sustained virological response than peginterferon alfa‐2b in chronic hepatitis C: systematic review of randomized trials. Hepatology2010;51:1176‐84. [DOI: 10.1002/hep.23504.] ">Awad 2010</a>; <a href="./references#CD005441-bbs2-0063" title="HauserG , AwadT , ThorlundK , ŠtimacD , MabroukM , GluudC . Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C (Review). Cochrane Database of Systematic Reviews2014, Issue 2. ">Hauser 2014</a>). </p> </section> <section id="CD005441-sec-0070"> <h3 class="title" id="CD005441-sec-0070">Overall completeness and applicability of evidence</h3> <p>The Summary of Findings table that we have prepared reveals that, in generalwe can have only low confidence in the current evidence on harms measured as liver‐related morbidity plus all‐cause mortality, and adverse events or adverse events leading to treatment discontinuation. In addition, we can have very low confidence in the current evidence on treatment benefits measured as sustained virological response (<a href="./full#CD005441-tbl-0001">summary of findings Table for the main comparison</a>). All trials had high risks of bias. If we disregarded bias due to lack of blinding and due to vested interests, about half of the trials could be considered trials with a lower risk of bias. Our sensitivity analyses, however, showed no important influence of bias risk on our estimates of intervention effects. This may be due to the fact that we were unable to identify trials with a lower risk of bias. In our study, trials that adequately reported on the methodology of trial performance are large trials that dominate the pooled estimates of effect. Therefore, it is less likely that the pooled estimates are biased. In the meta‐analysis for sustained virological response, no serious inconsistencies were seen across trials, and the meta‐analyses crossed the Lan‐DeMets monitoring boundary, leaving out any random error. The only trial with blinded assessment of sustained virological response showed no significant differences between the two interventions but suffered from the fact that it was very small (<a href="./references#CD005441-bbs2-0024" title="SjogrenMH , SjogrenR , LyonsMF , RyanM , SantoroJ , SmithC , et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Digestive Diseases and Sciences2007;52(6):1540‐7. ">Sjögren 2007</a>).<br/> <br/> Subgroup analyses for sustained virological response showed a pronounced difference in comparative treatment effects by genotype and type of peginterferon. Data from 16 trials for genotype one yielded RR 1.5, 95% CI 1.3 to 1.7. Data from nine trials for genotype two or three yielded RR 1.1, 95% CI 1.0 to 1.2. Data from nine trials for genotype four yielded RR 1.8, 95% CI 1.3 to 2.4. These differences were substantiated by tests of interaction that yielded statistically significant differences between genotype one and genotype two or three (P value 0.0002) and between genotype two or three and genotype four (P value 0.029). The larger effects of peginterferons versus interferons on sustained virological response were observed in participants infected with genotype one and genotype four, whereas the difference between peginterferon and interferon was least for participants infected with genotype two or three.<br/> <br/> Moreover, peginterferon alpha‐2a plus ribavirin seemed significantly more effective than peginterferon alpha‐2b plus ribavirin when compared with interferon plus ribavirin in subgroup analyses. Data from nine trials for peginterferon alpha‐2a yielded RR 1.9, 95% CI 1.5 to 2.4. Data from 18 trials for peginterferon alpha‐2b yielded only RR 1.1, 95% CI 1.1 to 1.2. These differences were substantiated by tests of interaction that yielded statistically significant differences between peginterferon alpha‐2a plus ribavirin and peginterferon alpha‐2b plus ribavirin trials (P &lt; 0.0001). This is in accordance with our previous observations based on head‐to‐head randomised clinical trials comparing peginterferon alpha‐2a versus peginterferon alpha‐2b (<a href="./references#CD005441-bbs2-0037" title="AwadT , ThorlundK , HauserG , StimacD , MabroukM , GluudC . Peginterferon alpha‐2a is associated with higher sustained virological response than peginterferon alfa‐2b in chronic hepatitis C: systematic review of randomized trials. Hepatology2010;51:1176‐84. [DOI: 10.1002/hep.23504.] ">Awad 2010</a>; <a href="./references#CD005441-bbs2-0063" title="HauserG , AwadT , ThorlundK , ŠtimacD , MabroukM , GluudC . Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C (Review). Cochrane Database of Systematic Reviews2014, Issue 2. ">Hauser 2014</a>).<br/> <br/> All other tests of interaction regarding risk of bias (lower risk of bias compared with high risk of bias), treatment history, and baseline viral load yielded non‐significant results.<br/> <br/> We found three trials that used amantadine cointervention, four trials that used consensus interferon, and one trial that used leucocyte interferon. However, the paucity of evidence precludes any firm conclusions on effects of triple therapy regimens with the use of amantadine, leucocyte interferon, or consensus interferon. Our analyses strengthen the evidence that peginterferon plus ribavirin increases sustained virological response for participants with chronic hepatitis C, irrespective of genotype, previous antiviral status, or viral load, and with or without amantadine as cointervention. </p> </section> <section id="CD005441-sec-0071"> <h3 class="title" id="CD005441-sec-0071">Quality of the evidence</h3> <p>The methodological quality was unclearly reported in a considerable number of included trials. Only 14 of the 27 trials (51.9%) reported adequate randomisation and allocation concealment. Most trial reports described unclearly blinded outcome assessment. These aspects may be essential in minimising the risks of selection, performance, and ascertainment bias in individual trials (<a href="./references#CD005441-bbs2-0091" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a>; <a href="./references#CD005441-bbs2-0077" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352:609‐13. ">Moher 1998</a>; <a href="./references#CD005441-bbs2-0071" title="KjaergardLL , VillumsenJ , GluudC . Reported methodological quality and discrepancies between small and large randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001</a>; <a href="./references#CD005441-bbs2-0108" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanGD , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336:601‐5. ">Wood 2008</a>; <a href="./references#CD005441-bbs2-0076" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>; <a href="./references#CD005441-bbs2-0089" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment2012;16(35):1‐82. ">Savovic 2012</a>; <a href="./references#CD005441-bbs2-0090" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. ">Savovic 2012a</a>). However, we found no significant association between methodological quality and trial results (<a href="./references#CD005441-fig-0017" title="">Analysis 3.1</a>).These findings may support the robustness of our results but do not exclude the possibility of bias, especially as we could not assess risk of bias from blinding and vested interests. Industry support is known to significantly bias trial results (<a href="./references#CD005441-bbs2-0076" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>). Regarding blinding, only one trial assessed sustained virological response with blinding and found no significant effect of pegylated interferon versus interferon (<a href="./references#CD005441-bbs2-0024" title="SjogrenMH , SjogrenR , LyonsMF , RyanM , SantoroJ , SmithC , et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Digestive Diseases and Sciences2007;52(6):1540‐7. ">Sjögren 2007</a>). However, this trial was small, and the confidence interval was accordingly wide (<a href="./references#CD005441-bbs2-0024" title="SjogrenMH , SjogrenR , LyonsMF , RyanM , SantoroJ , SmithC , et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Digestive Diseases and Sciences2007;52(6):1540‐7. ">Sjögren 2007</a>). </p> <p>Selective outcome reporting was difficult to assess in this review. None of the included trials was adequately registered or had its protocol publicly available before trial completion (<a href="./references#CD005441-bbs2-0073" title="Krleza‐JericK , ChanAW , DickersinK , SimI , GrimshawJ , GluudC . Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement. BMJ (Clinical Research Ed)2005;330(7497):956‐8. ">Krleza‐Jeric 2005</a>; <a href="./references#CD005441-bbs2-0107" title="WHO . International Clinical Trials Registry Platform (ICTRP). www.who.int/ictrp/en/ (accessed 27 May 2013). ">WHO 2009</a>). It is hoped that the initiation of the World Health Organization International Clinical Trials Registry Platform will facilitate such assessments for future trials (<a href="./references#CD005441-bbs2-0107" title="WHO . International Clinical Trials Registry Platform (ICTRP). www.who.int/ictrp/en/ (accessed 27 May 2013). ">WHO 2009</a>). Another limitation in this review was insufficient design and reporting. Investigators of future trials therefore are well advised to adhere to the guidelines of Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) (<a href="./references#CD005441-bbs2-0045" title="ChanAW , TetzlaffJM , GøtzschePC , AltmanDG , MannH , BerlinJA , et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (Clinical Research Ed.)2013;8:346:e7586. ">Chan 2013</a>) and the Consolidated Standards for Reporting of Trials (CONSORT) (<a href="./references#CD005441-bbs2-0078" title="MoherD , HopewellS , SchulzKF , MontoriV , GøtzschePC , DevereauxPJ , et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. International Journal of Surgery2012;10:28‐55. ">Moher 2012</a>) to improve the quality of trials. </p> <p>In general, we can have only low confidence in the current evidence on harms measured as morbidity plus mortality and adverse events leading to discontinuation, whereas we can have moderate confidence in the current evidence on treatment benefits measured as sustained virological response (<a href="./full#CD005441-tbl-0001">summary of findings Table for the main comparison</a>). In the meta‐analysis for morbidity plus mortality, very serious imprecision was evident because only nine events were included in the meta‐analysis from five trials (<a href="./references#CD005441-bbs2-0009" title="Bosques‐PadillaF , Trejo‐EstradaR , Campollo‐RivasO , Cortez‐HernandezC , Dehesa‐ViolanteM , Maldonado‐GarzaH , et al. Peginterferon alfa‐2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Annals of Hepatology2003;2(3):135‐9. FriedMW , ShiffmanML , ReddyKR , SmithC , MarinosG , GoncalesFLJr , et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine2002;347(13):975‐82. HassaneinT , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. The impact of peginterferon alfa‐2a plus ribavirin combination therapy on health‐related quality of life in chronic hepatitis C. Journal of Hepatology2004;40(4):675‐81. HassaneinTI , CooksleyG , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. Treatment with 40 kDa peginterferon alfa‐2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alfa‐2b plus ribavirin [AASLD abstract]. Hepatology2001;34(4 Pt 2):243A. HassaneinTI , CooksleyWGE , SulkowskiM , SmithC , MarinosG , LaiM‐Y , et al. QOL benefits observed as early as week 2 with peginterferon alfa‐2a (40kD) (Pegasys) in combination with ribavirin (RBV) versus interferon alfa‐2b plus RBV [EASL abstract]. Journal of Hepatology2002;36(1):110. HerrmannE , LeeJ‐H , MarinosG , ModiM , ZeuzemS . Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology2003;37(6):1351‐8. LutchmanG , HoofnagleJH . Viral kinetics in hepatitis C. Hepatology2003;37(6):1257‐9. SullivanSD , CraxiA , AlbertiA , GiulianiG , DeCarliC , WintfeldN , et al. Cost effectiveness of peginterferon alpha‐2a plus ribavirin versus interferon alpha‐2b plus ribavirin as initial therapy for treatment‐naive chronic hepatitis C. Pharmacoeconomics2004;22(4):257‐65. SullivanSD , GreenJ , PatelKK , CraxiA , AlbertiA , GiulianiG , et al. A comparison of cost‐effectiveness of peginterferon alfa‐2a (40kD) (Pegasys) plus ribavirin (Copegus) vs interferon alfa‐2b plus ribavirin as first treatment of chronic hepatitis C (CHC). Journal of Hepatology2003;38(Suppl 2):174‐5. SullivanSD , JensenDM , BernsteinDE , HassaneinTI , FosterGR , LeeSS , et al. Cost‐effectiveness of combination peginterferon alpha‐2a and ribavirin compared with interferon alpha‐2b and ribavirin in patients with chronic hepatitis C. American Journal of Gastroenterology2004;99:1490‐6. ZeuzemS , HerrmannE , LeeJ‐H , MarinosG , ModiM , RothWK . Effect of ribavirin on viral kinetics in hepatitis C virus genotype 1 infected patients treated with pegylated interferon alpha2a [AASLD abstract]. Hepatology2001;34(4 Pt 2):558A. ">Fried 2002</a>; <a href="./references#CD005441-bbs2-0007" title="EsmatGH , AbouziedA , Abdel‐HamidM , MohamedMK , ZalataK , ElRazikyMS , et al. Results of a randomized clinical trial of genotype‐4 infected subjects when treated with standard or pegylated interferon alfa‐2b in combination with ribavirin [AASLD abstract]. Hepatology2003;38(4 Suppl 1):314A‐315A. ">Esmat 2003</a>; <a href="./references#CD005441-bbs2-0001" title="AlfalehFZ , HadadQ , KhurooMS , AljumahA , AlgamediA , AlashgarH , et al. Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver International2004;24:568‐74. ">Al‐Faleh 2004</a>; <a href="./references#CD005441-bbs2-0013" title="LeeSD , YuML , ChengPN , LaiMY , ChaoYC , HwangSJ , et al. Comparison of a 6‐month course peginterferon alpha‐2b plus ribavirin and interferon alpha‐2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. Journal of Viral Hepatitis2005;12:283‐91. ">Lee 2005</a>; <a href="./references#CD005441-bbs2-0017" title="NevensF , VanVlierbergheH , D'HeygereE , DelwaideJ , AdlerM , HenrionJ , et al. A randomised, open‐label, multicenter study evaluating the efficacy of peginterferon alfa‐2a versus interferon alfa‐2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients. Acta Gastroenterologica Belgica2010;73:223‐8. ">Nevens 2010</a>).<br/> <br/> In the meta‐analysis on adverse events, serious discrepancies across trials and lack of precision were noted. The proportions of observed adverse events differ substantially across trials, and the direction of effect is heterogeneous. However, because the event rate is still relatively low across trials, all of the included trials may be subject to considerable random error, thus explaining the apparent heterogeneity in direction of estimates. The observed treatment effects differ in magnitude as well, but most confidence intervals show considerable overlap. In the meta‐analysis for sustained virological response, no serious inconsistencies across studies were evident, and the meta‐analyses showed adequate precision (i.e., the TSA alpha‐spending monitoring boundary for benefit was crossed, favouring pegylated interferon). Nonetheless, we had some concerns regarding bias (which was high in all trials) and indirectness, as all included randomised clinical trials had virological response as the predominant measure of benefit. Many of the trials measured sustained virological response, which is currently the commonly used surrogate outcome measure of benefit. Recent large cohort studies show a positive correlation between the presence of viraemia and mortality (<a href="./references#CD005441-bbs2-0035" title="AdeelAB , XiaoqiangWang , CharityGM . Effect of hepatitis C virus and its treatment on survival. Hepatology2009;50(2):387‐92. ">Adeel 2009</a>; <a href="./references#CD005441-bbs2-0066" title="UtoH , SherriOS , HayashiK , KumagaiK , SasakiF , KanmuraS , et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody‐positive subjects in a community‐based cohort study. Hepatology2009;50(2):393‐9. ">Hirofumi 2009</a>). However, it is important to remember that sustained virological response still is only a putative (unvalidated) surrogate outcome for the patient‐relevant intervention effects of antivirals (<a href="./references#CD005441-bbs2-0058" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734‐42. ">Gluud 2007</a>; <a href="./references#CD005441-bbs2-0072" title="KoretzRL , PleguezueloM , ArvanitiV , Barrera BaenaP , CiriaR , GurusamyKS . Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD003617] ">Koretz 2013</a>; <a href="./references#CD005441-bbs2-0060" title="GurusamyKS , WilsonE , KoretzRL , AllenVB , DavidsonBR , BurroughsAK , et al. Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?. PLoS ONE2013;8(12):e83313. ">Gurusamy 2013</a>). Because randomised clinical trials need to inform clinical practice, clinical outcomes such as risk of liver failure, hepatocellular carcinoma, mortality, and quality of life would be of greater interest to patients and clinicians. Such measures nevertheless require a follow‐up of maybe up to five years. Currently, no randomised clinical trials assessing the two pegylated interferons are of such long duration. </p> </section> <section id="CD005441-sec-0072"> <h3 class="title" id="CD005441-sec-0072">Potential biases in the review process</h3> <p>The included meta‐analyses had a seemingly reasonable mix of small and large studies, yielding fairly consistent results, thus causing little concern about the presence of publication bias. </p> <p>The strengths of this Cochrane Hepato‐Biliary Group systematic review are that it builds on a peer‐reviewed published protocol, uses extensive searches until recently (<a href="./appendices#CD005441-sec-0080">Appendix 1</a>), considers risks of systematic errors (‘bias’) (<a href="./references#CD005441-bbs2-0091" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a>; <a href="./references#CD005441-bbs2-0077" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352:609‐13. ">Moher 1998</a>; <a href="./references#CD005441-bbs2-0071" title="KjaergardLL , VillumsenJ , GluudC . Reported methodological quality and discrepancies between small and large randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001</a>; <a href="./references#CD005441-bbs2-0108" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanGD , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336:601‐5. ">Wood 2008</a>; <a href="./references#CD005441-bbs2-0076" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>; <a href="./references#CD005441-bbs2-0089" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment2012;16(35):1‐82. ">Savovic 2012</a>; <a href="./references#CD005441-bbs2-0090" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. ">Savovic 2012a</a>), and considers risks of random errors (‘play of chance’) by adjusting the threshold for statistical significance according to the information and strength of evidence present in the cumulative meta‐analysis (<a href="./references#CD005441-bbs2-0042" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology2008;61(8):763‐9. ">Brok 2008</a>; <a href="./references#CD005441-bbs2-0104" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD005441-bbs2-0043" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Apparently conclusive meta‐analyses may be inconclusive—trial sequential analysis adjustment for random error risk in conclusive Cochrane neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [DOI: 10.1093/ije/dyn188] ">Brok 2009</a>; <a href="./references#CD005441-bbs2-0100" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJPA , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [DOI: 10.1093/ije/dyn179] ">Thorlund 2009</a>, <a href="./references#CD005441-bbs2-0105" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>; <a href="./references#CD005441-bbs2-0101" title="ThorlundK , AnemaA , MillsE . Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology2010;2:57‐66. ">Thorlund 2010</a>). Furthermore, to avoid publication and ascertainment bias, we included trials regardless of publication status and language, and all data were abstracted independently by at least two review authors to avoid information bias. However, our review has potential limitations that may lower our confidence in the estimates of intervention effect. First, we are aware of possible inclusion bias in excluding special patient groups (hepatitis B virus, human immunodeficiency virus, cancer, and liver‐transplanted patients). Future systematic reviews should assess the intervention effects of antivirals in these patient groups. Second, a possible limitation of our review is the lack of availability of full reports of all included trials. Ten of the 27 included trials were available only as abstracts. However, including these abstracts in our systematic review may likely be a strength rather than a limitation. By including abstracts, we are looking at the complete available body of evidence. By excluding abstracts, we would have been looking only at a subset defined through present‐day publication mechanisms, favouring trials that show beneficial effects. This would considerably increase the likelihood of publication bias. Third, in general, adverse events were reported insufficiently. Most of the participants treated with peginterferon alpha or interferon alpha experience one or more adverse effects (e.g., influenza‐like symptoms, depression, neutropenia, thrombocytopenia). The proportions of observed adverse events differed greatly across trials, and the direction of effect was heterogeneous. </p> </section> <section id="CD005441-sec-0073"> <h3 class="title" id="CD005441-sec-0073">Agreements and disagreements with other studies or reviews</h3> <p>By comparing our results with those of the other meta‐analyses, we have found two main differences. Our searches of the literature were much more detailed than searches previously conducted. In previous meta‐analyses, authors usually did not perform grey literature searches and did not include meeting abstracts. Some authors excluded trials that were not published in English or used just two databases (<a href="./references#CD005441-bbs2-0046" title="ChanderG , SulkowskiMS , JenckesMW , TorbensonMS , HerlongHF , BassEB , et al. Treatment of chronic hepatitis C: a systematic review. Hepatology2002;36(S1):135‐44. ">Chander 2002</a>; <a href="./references#CD005441-bbs2-0109" title="ZamanA , FennertyMB , KeeffeEB . Peginterferon vs. standard interferon in the treatment of chronic hepatitis C. Alimentary Pharmacology &amp; Therapeutics2003;18(7):661‐70. ">Zaman 2003</a>), performed only cost‐effectives analysis (<a href="./references#CD005441-bbs2-0094" title="ShepherdJ , BrodinH , KanFT , CaveCB , WaughNR , PriceA , et al. Clinical‐ and cost‐effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. International Journal of Technology Assessment in Health Care2005;21(1):47‐54. ">Shepherd 2005</a>; <a href="./references#CD005441-bbs2-0095" title="SiebertU , SroczynskiG , German Hepatitis C Model GEHMO Group, HTA Expert Panel on HepatitisC . Effectiveness and cost‐effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. International Journal of Technology Assessment in Health Care2005;21(1):55‐65. ">Siebert 2005</a>), or evaluated only one genotype (<a href="./references#CD005441-bbs2-0070" title="KhurooMS , KhurooMS , DahabST . Meta‐analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Alimentary Pharmacology and Therapeutics2004;20(9):931‐8. ">Khuroo 2004</a>; <a href="./references#CD005441-bbs2-0036" title="AljumahAA , MuradMH . Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: a systematic review and meta‐analysis. Hepatology Research2013;43(12):1255‐63. [DOI: 10.1111/hepr.12084] ">Aljumah 2013</a>). Second, we performed several sensitivity analyses to ensure the robustness of the results of our systematic review; this procedure is lacking in previously published meta‐analyses. Moreover, our number of included trials is much higher than the number included in the meta‐analyses mentioned above. Fourth, we considered risk of bias. Fifth, we also took precautions to interpret the statistical inference according to the strength of the evidence. In this vein, we constructed adjusted thresholds for statistical significance by using TSA. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005441-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about all methodological quality items presented as percentages across all included studies." data-id="CD005441-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about all methodological quality items presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD005441-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin, outcome: 1.2 Adverse events leading to treatment discontinuation." data-id="CD005441-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin, outcome: 1.2 Adverse events leading to treatment discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: pegylated interferon plus ribavirin versus interferon plus ribavirin, outcome: 1.1 Sustained virological response." data-id="CD005441-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: pegylated interferon plus ribavirin versus interferon plus ribavirin, outcome: 1.1 Sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: pegylated interferon plus ribavirin versus interferon plus ribavirin, outcome: 1.1 Sustained virological response." data-id="CD005441-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: pegylated interferon plus ribavirin versus interferon plus ribavirin, outcome: 1.1 Sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis (TSA): pegylated interferon plus ribavirin versus interferon plus ribavirin ‐ sustained virological response.    Lan‐DeMets statistical monitoring boundaries for assessing statistical significance regarding sustained virological response to pegylated interferon plus ribavirin versus interferon plus ribavirin. The diversity‐adjusted required information size of n = 14,486 was calculated based on an event proportion of 50.6% of participants in the interferon‐treated group (Pc) with a risk ratio (RR) reduction of 10% in pegylated interferon group; an alpha (a, type I error) of 5%, a beta (b, type II error) of 10%, and the observed diversity D = 72%.    The solid blue curve presents the cumulative meta‐analysis test Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential boundaries. The cumulative Z‐score crosses the boundaries for superiority, and this corresponds with superiority of pegylated interferon." data-id="CD005441-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Trial sequential analysis (TSA): pegylated interferon plus ribavirin versus interferon plus ribavirin ‐ sustained virological response.<br/> <br/> Lan‐DeMets statistical monitoring boundaries for assessing statistical significance regarding sustained virological response to pegylated interferon plus ribavirin versus interferon plus ribavirin. The diversity‐adjusted required information size of n = 14,486 was calculated based on an event proportion of 50.6% of participants in the interferon‐treated group (Pc) with a risk ratio (RR) reduction of 10% in pegylated interferon group; an alpha (a, type I error) of 5%, a beta (b, type II error) of 10%, and the observed diversity D = 72%.<br/> <br/> The solid blue curve presents the cumulative meta‐analysis test Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential boundaries. The cumulative Z‐score crosses the boundaries for superiority, and this corresponds with superiority of pegylated interferon. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis (TSA): pegylated interferon plus ribavirin versus interferon plus ribavirin ‐ sustained virological response.    Lan‐DeMets statistical monitoring boundaries for assessing statistical significance regarding sustained virological response to pegylated interferon plus ribavirin versus interferon plus ribavirin. The diversity‐adjusted required information size of n = 20,513 was calculated based on an event proportion of 50.6% of participants in the interferon‐treated group (Pc) with a risk ratio (RR) reduction of 10% in the pegylated interferon group; an alpha (a, type I error) of 1%, a beta (b, type II error) of 10%, and the observed diversity D = 72%.    The solid blue curve presents the cumulative meta‐analysis test Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score crosses the boundaries for superiority, and this corresponds with the superiority of pegylated interferon." data-id="CD005441-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Trial sequential analysis (TSA): pegylated interferon plus ribavirin versus interferon plus ribavirin ‐ sustained virological response.<br/> <br/> Lan‐DeMets statistical monitoring boundaries for assessing statistical significance regarding sustained virological response to pegylated interferon plus ribavirin versus interferon plus ribavirin. The diversity‐adjusted required information size of n = 20,513 was calculated based on an event proportion of 50.6% of participants in the interferon‐treated group (Pc) with a risk ratio (RR) reduction of 10% in the pegylated interferon group; an alpha (a, type I error) of 1%, a beta (b, type II error) of 10%, and the observed diversity D = 72%.<br/> <br/> The solid blue curve presents the cumulative meta‐analysis test Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score crosses the boundaries for superiority, and this corresponds with the superiority of pegylated interferon. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin, Outcome 1 Liver‐related morbidity plus all‐cause mortality." data-id="CD005441-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin, Outcome 1 Liver‐related morbidity plus all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin, Outcome 2 Adverse events leading to treatment discontinuation." data-id="CD005441-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin, Outcome 2 Adverse events leading to treatment discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin, Outcome 3 Sustained virological response." data-id="CD005441-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin, Outcome 3 Sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adverse events, Outcome 1 Haematological effects." data-id="CD005441-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Adverse events, Outcome 1 Haematological effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adverse events, Outcome 2 Fatigue and flu‐like symptoms." data-id="CD005441-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Adverse events, Outcome 2 Fatigue and flu‐like symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adverse events, Outcome 3 Psychiatric symptoms." data-id="CD005441-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Adverse events, Outcome 3 Psychiatric symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adverse events, Outcome 4 Dermatological symptoms." data-id="CD005441-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Adverse events, Outcome 4 Dermatological symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adverse events, Outcome 5 Thyroid malfunction." data-id="CD005441-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Adverse events, Outcome 5 Thyroid malfunction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adverse events, Outcome 6 Gastrointestinal symptoms." data-id="CD005441-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Adverse events, Outcome 6 Gastrointestinal symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup and sensitivity analysis, Outcome 1 Sustanied virological response according to trial methodological quality." data-id="CD005441-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Subgroup and sensitivity analysis, Outcome 1 Sustanied virological response according to trial methodological quality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup and sensitivity analysis, Outcome 2 Sustanied virological response according to baseline treatment history." data-id="CD005441-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Subgroup and sensitivity analysis, Outcome 2 Sustanied virological response according to baseline treatment history. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup and sensitivity analysis, Outcome 3 Sustained virological response according to genotype." data-id="CD005441-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Subgroup and sensitivity analysis, Outcome 3 Sustained virological response according to genotype. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup and sensitivity analysis, Outcome 4 Sustained virological response according to baseline viral load." data-id="CD005441-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Subgroup and sensitivity analysis, Outcome 4 Sustained virological response according to baseline viral load. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup and sensitivity analysis, Outcome 5 Sustained virological response according to the type of peginterferon." data-id="CD005441-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Subgroup and sensitivity analysis, Outcome 5 Sustained virological response according to the type of peginterferon. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup and sensitivity analysis, Outcome 6 Sustained virological response according to the type of peginterferon and the type of interferon." data-id="CD005441-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Subgroup and sensitivity analysis, Outcome 6 Sustained virological response according to the type of peginterferon and the type of interferon. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005441-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/urn:x-wiley:14651858:media:CD005441:CD005441-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_t/tCD005441-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup and sensitivity analysis, Outcome 7 Sustained virological response in trials with or without amantadine." data-id="CD005441-fig-0023" src="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Subgroup and sensitivity analysis, Outcome 7 Sustained virological response in trials with or without amantadine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/media/CDSR/CD005441/image_n/nCD005441-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005441-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin for chronic hepatitis C</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin for chronic hepatitis C</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic hepatitis C.<br/> <b>Settings:</b> mainly outpatients.<br/> <b>Intervention:</b> peginterferon.<br/> <b>Comparison:</b> non‐pegylated. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Non‐pegylated</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Peginterferon </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Liver‐related morbidity plus all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Five per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Six per 1000</b> <br/> (two to 17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.14</b> <br/> (0.38 to 3.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1789<br/> (five studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events leading to treatment discontinuation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>207 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b> <br/> (141 to 226) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/> (0.68 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4571<br/> (15 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sustained virological response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>386 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>537 per 1000</b> <br/> (482 to 602) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.39</b> <br/> (1.25 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6104<br/> (27 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>4,5</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All trials had high risks of bias.</p> <p>Only an unvalidated surrogate outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Low due to imprecision and indirectness wide confidence interval. The meta‐analysis included only nine events. </p> <p><sup>2</sup>Low due to imprecision and indirectness.The proportions of observed adverse events differ substantially across trials, and the direction of effect is heterogeneous. However, because the event rate is still relatively low across trials, all of the included trials may be subject to considerable random error, thus explaining the apparent heterogeneity in the direction of estimates.<br/> <sup>3</sup>The observed treatment effects differ in both direction and magnitude, but most confidence intervals have considerable overlap. Low due to indirectness. </p> <p><sup>4</sup>Sustained virological response does not seem to be a valid surrogate marker for assessing hepatitis C virus treatment efficacy of interferon treatment. Very low due to high risk of bias in all trials and imprecision and indirectness due to surrogate<br/> <sup>5</sup>Only randomised clinical trials were included. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin for chronic hepatitis C</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/full#CD005441-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005441-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Liver‐related morbidity plus all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.38, 3.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events leading to treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.66, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.25, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005441-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Haematological effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.98, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [1.76, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.63 [1.68, 4.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fatigue and flu‐like symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 General fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.93, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Rigours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.88, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2934</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.05, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.90, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.99, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.98, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.88, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Psychiatric symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.82, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.91, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.86, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Dermatological symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Alopecia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.88, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3027</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.96, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.93, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Injection site reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1817</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.50, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Thyroid malfunction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.73, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Gastrointestinal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3023</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.01, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.93, 1.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005441-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup and sensitivity analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Sustanied virological response according to trial methodological quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Lower risk of bias trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.17, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 High risk of bias trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.23, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Sustanied virological response according to baseline treatment history <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Naive participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.25, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Non‐responders and relapsers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.96, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.67, 2.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Sustained virological response according to genotype <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Genotype one</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.27, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Genotypes two and three</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [1.03, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Genotype four</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.30, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Sustained virological response according to baseline viral load <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 High viral load</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.01, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Low viral Load</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1027</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.05, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Predominantly high viral load (more than 65% of total participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.87, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Predominantly low viral load (more than 65% of total participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.22, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Similar proportions of high and low baseline viral loads</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.01, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Unknown baseline viral load</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.11, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Sustained virological response according to the type of peginterferon <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Peginterferon alpha‐2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.46, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Peginterferon alpha‐2b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.06, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Sustained virological response according to the type of peginterferon and the type of interferon <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Peginterferon alpha‐2a versus interferon alpha‐2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.63, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Peginterferon alpha‐2a versus interferon alpha‐2b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.11, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Peginterferon alpha‐2b versus interferon alpha‐2b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.06, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Peginterferon alpha‐2b versus consensus interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>671</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.92, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Peginterferon alpha‐2b versus leucocyte interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.05, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Sustained virological response in trials with or without amantadine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Trial without amantadine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.22, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Trial with amantadine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [1.26, 2.23]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup and sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005441.pub3/references#CD005441-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005441.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005441-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005441-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005441-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD005441-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD005441-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD005441-note-0003">Polski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005441\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005441\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005441\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005441\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005441\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005441.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005441.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005441.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005441.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005441.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718854344"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005441.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718854348"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005441.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dda7c59ef935f',t:'MTc0MDcxODg1NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 